TABLE 14.2__2000.4.1.1.14.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=BIRDSHOT CHOROIDOPATHY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
DEPENDENCY									
BSL VALUE	PLO	14	85.12	16.724	50.0	75.00	91.67	100.00	100.0
	ADA	15	87.22	15.387	58.3	75.00	100.00	100.00	100.0
	TOT	29	86.21	15.792	50.0	75.00	91.67	100.00	100.0
FINAL/ET VALUE	PLO	14	85.71	19.997	50.0	75.00	100.00	100.00	100.0
	ADA	15	90.56	11.298	75.0	75.00	100.00	100.00	100.0
	TOT	29	88.22	15.986	50.0	75.00	100.00	100.00	100.0
CHG FROM BSL	PLO	14	0.60	8.930	-16.7	0.00	0.00	0.00	25.0
	ADA	15	3.33	10.351	-16.7	0.00	0.00	8.33	25.0
	TOT	29	2.01	9.620	-16.7	0.00	0.00	0.00	25.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.14.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=BIRDSHOT CHOROIDOPATHY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
DRIVING									
BSL VALUE	PLO	13	75.96	25.354	16.7	62.50	83.33	91.67	100.0
	ADA	13	66.35	25.027	0.0	58.33	66.67	79.17	100.0
	TOT	26	71.15	25.164	0.0	58.33	75.00	91.67	100.0
FINAL/ET VALUE	PLO	13	80.13	17.526	50.0	66.67	83.33	91.67	100.0
	ADA	13	73.08	26.604	0.0	66.67	83.33	83.33	100.0
	TOT	26	76.60	22.363	0.0	66.67	83.33	91.67	100.0
CHG FROM BSL	PLO	13	4.17	21.246	-25.0	0.00	0.00	0.00	66.7
	ADA	13	6.73	11.224	-8.3	0.00	4.17	16.67	25.0
	TOT	26	5.45	16.699	-25.0	0.00	0.00	12.50	66.7

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.14.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=BIRDSHOT CHOROIDOPATHY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
COLOR VISION									
BSL VALUE	PLO	14	85.71	18.898	50.0	75.00	100.00	100.00	100.0
	ADA	15	90.00	18.420	50.0	75.00	100.00	100.00	100.0
	TOT	29	87.93	18.445	50.0	75.00	100.00	100.00	100.0
FINAL/ET VALUE	PLO	14	89.29	16.155	50.0	75.00	100.00	100.00	100.0
	ADA	15	90.00	18.420	50.0	75.00	100.00	100.00	100.0
	TOT	29	89.66	17.057	50.0	75.00	100.00	100.00	100.0
CHG FROM BSL	PLO	14	3.57	13.363	-25.0	0.00	0.00	0.00	25.0
	ADA	15	0.00	9.449	-25.0	0.00	0.00	0.00	25.0
	TOT	29	1.72	11.439	-25.0	0.00	0.00	0.00	25.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.14.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=BIRDSHOT CHOROIDOPATHY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
PERIPHERAL VISION									
BSL VALUE	PLO	14	73.21	26.790	25.0	50.00	75.00	100.00	100.0
	ADA	15	73.33	27.495	25.0	50.00	75.00	100.00	100.0
	TOT	29	73.28	26.668	25.0	50.00	75.00	100.00	100.0
FINAL/ET VALUE	PLO	14	82.14	24.862	25.0	75.00	100.00	100.00	100.0
	ADA	15	80.00	27.058	25.0	75.00	100.00	100.00	100.0
	TOT	29	81.03	25.578	25.0	75.00	100.00	100.00	100.0
CHG FROM BSL	PLO	14	8.93	18.624	-25.0	0.00	0.00	25.00	50.0
	ADA	15	6.67	27.495	-75.0	0.00	0.00	25.00	50.0
	TOT	29	7.76	23.245	-75.0	0.00	0.00	25.00	50.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.14.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=BIRDSHOT CHOROIDOPATHY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
TOTAL SCORE									
BSL VALUE	PLO	14	76.56	17.273	43.6	62.65	79.66	93.33	94.2
	ADA	15	75.83	14.162	50.0	67.88	73.83	87.77	95.9
	TOT	29	76.18	15.458	43.6	64.36	73.83	88.64	95.9
FINAL/ET VALUE	PLO	14	80.95	16.948	58.4	65.30	90.55	96.86	97.6
	ADA	15	81.23	14.418	53.0	67.01	87.20	92.50	100.0
	TOT	29	81.10	15.405	53.0	65.30	87.65	94.58	100.0
CHG FROM BSL	PLO	14	4.40	8.976	-12.6	0.95	3.62	6.25	25.0
	ADA	15	5.41	10.968	-21.5	3.30	6.82	12.99	17.3
	TOT	29	4.92	9.890	-21.5	2.65	4.36	10.91	25.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.15.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=MULTIFOCAL CHOROIDITIS AND PANUVEITIS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
GENERAL HEALTH									
BSL VALUE	PLO	2	62.50	17.678	50.0	50.00	62.50	75.00	75.0
	ADA	5	60.00	13.693	50.0	50.00	50.00	75.00	75.0
	TOT	7	60.71	13.363	50.0	50.00	50.00	75.00	75.0
FINAL/ET VALUE	PLO	2	50.00	0.000	50.0	50.00	50.00	50.00	50.0
	ADA	5	60.00	22.361	50.0	50.00	50.00	50.00	100.0
	TOT	7	57.14	18.898	50.0	50.00	50.00	50.00	100.0
CHG FROM BSL	PLO	2	-12.50	17.678	-25.0	-25.00	-12.50	0.00	0.0
	ADA	5	0.00	17.678	-25.0	0.00	0.00	0.00	25.0
	TOT	7	-3.57	17.252	-25.0	-25.00	0.00	0.00	25.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.15.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=MULTIFOCAL CHOROIDITIS AND PANUVEITIS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
GENERAL VISION									
BSL VALUE	PLO	2	70.00	14.142	60.0	60.00	70.00	80.00	80.0
	ADA	5	76.00	21.909	40.0	80.00	80.00	80.00	100.0
	TOT	7	74.29	19.024	40.0	60.00	80.00	80.00	100.0
FINAL/ET VALUE	PLO	2	70.00	14.142	60.0	60.00	70.00	80.00	80.0
	ADA	5	68.00	26.833	40.0	40.00	80.00	80.00	100.0
	TOT	7	68.57	22.678	40.0	40.00	80.00	80.00	100.0
CHG FROM BSL	PLO	2	0.00	0.000	0.0	0.00	0.00	0.00	0.0
	ADA	5	-8.00	17.889	-40.0	0.00	0.00	0.00	0.0
	TOT	7	-5.71	15.119	-40.0	0.00	0.00	0.00	0.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.15.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=MULTIFOCAL CHOROIDITIS AND PANUVEITIS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
OCULAR PAIN									
BSL VALUE	PLO	2	93.75	8.839	87.5	87.50	93.75	100.00	100.0
	ADA	5	90.00	10.458	75.0	87.50	87.50	100.00	100.0
	TOT	7	91.07	9.449	75.0	87.50	87.50	100.00	100.0
FINAL/ET VALUE	PLO	2	100.00	0.000	100.0	100.00	100.00	100.00	100.0
	ADA	5	80.00	22.707	50.0	62.50	87.50	100.00	100.0
	TOT	7	85.71	20.952	50.0	62.50	100.00	100.00	100.0
CHG FROM BSL	PLO	2	6.25	8.839	0.0	0.00	6.25	12.50	12.5
	ADA	5	-10.00	13.693	-25.0	-25.00	0.00	0.00	0.0
	TOT	7	-5.36	14.174	-25.0	-25.00	0.00	0.00	12.5

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.15.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=MULTIFOCAL CHOROIDITIS AND PANUVEITIS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
NEAR VISION									
BSL VALUE	PLO	2	62.50	5.893	58.3	58.33	62.50	66.67	66.7
	ADA	5	80.00	16.245	58.3	66.67	91.67	91.67	91.7
	TOT	7	75.00	15.957	58.3	58.33	66.67	91.67	91.7
FINAL/ET VALUE	PLO	2	70.83	17.678	58.3	58.33	70.83	83.33	83.3
	ADA	5	85.00	20.750	58.3	66.67	100.00	100.00	100.0
	TOT	7	80.95	19.670	58.3	58.33	83.33	100.00	100.0
CHG FROM BSL	PLO	2	8.33	11.785	0.0	0.00	8.33	16.67	16.7
	ADA	5	5.00	26.745	-33.3	0.00	8.33	8.33	41.7
	TOT	7	5.95	22.420	-33.3	0.00	8.33	16.67	41.7

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.15.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=MULTIFOCAL CHOROIDITIS AND PANUVEITIS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
DISTANCE VISION									
BSL VALUE	PLO	2	70.83	17.678	58.3	58.33	70.83	83.33	83.3
	ADA	5	88.33	9.501	75.0	83.33	91.67	91.67	100.0
	TOT	7	83.33	13.608	58.3	75.00	83.33	91.67	100.0
FINAL/ET VALUE	PLO	2	62.50	5.893	58.3	58.33	62.50	66.67	66.7
	ADA	5	83.33	22.822	58.3	58.33	100.00	100.00	100.0
	TOT	7	77.38	21.362	58.3	58.33	66.67	100.00	100.0
CHG FROM BSL	PLO	2	-8.33	11.785	-16.7	-16.67	-8.33	0.00	0.0
	ADA	5	-5.00	15.138	-25.0	-16.67	0.00	8.33	8.3
	TOT	7	-5.95	13.363	-25.0	-16.67	0.00	8.33	8.3

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.15.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=MULTIFOCAL CHOROIDITIS AND PANUVEITIS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
SOCIAL FUNCTIONING									
BSL VALUE	PLO	2	100.00	0.000	100.0	100.00	100.00	100.00	100.0
	ADA	5	97.50	5.590	87.5	100.00	100.00	100.00	100.0
	TOT	7	98.21	4.725	87.5	100.00	100.00	100.00	100.0
FINAL/ET VALUE	PLO	2	93.75	8.839	87.5	87.50	93.75	100.00	100.0
	ADA	5	95.00	6.847	87.5	87.50	100.00	100.00	100.0
	TOT	7	94.64	6.682	87.5	87.50	100.00	100.00	100.0
CHG FROM BSL	PLO	2	-6.25	8.839	-12.5	-12.50	-6.25	0.00	0.0
	ADA	5	-2.50	5.590	-12.5	0.00	0.00	0.00	0.0
	TOT	7	-3.57	6.099	-12.5	-12.50	0.00	0.00	0.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.15.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=MULTIFOCAL CHOROIDITIS AND PANUVEITIS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
MENTAL HEALTH									
BSL VALUE	PLO	2	87.50	8.839	81.3	81.25	87.50	93.75	93.8
	ADA	5	73.75	24.367	37.5	62.50	81.25	87.50	100.0
	TOT	7	77.68	21.304	37.5	62.50	81.25	93.75	100.0
FINAL/ET VALUE	PLO	2	78.13	4.419	75.0	75.00	78.13	81.25	81.3
	ADA	5	77.50	28.845	37.5	56.25	93.75	100.00	100.0
	TOT	7	77.68	23.623	37.5	56.25	81.25	100.00	100.0
CHG FROM BSL	PLO	2	-9.38	13.258	-18.8	-18.75	-9.38	0.00	0.0
	ADA	5	3.75	18.006	-25.0	0.00	6.25	18.75	18.8
	TOT	7	0.00	16.925	-25.0	-18.75	0.00	18.75	18.8

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.15.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=MULTIFOCAL CHOROIDITIS AND PANUVEITIS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
ROLE DIFFICULTIES									
BSL VALUE	PLO	2	75.00	0.000	75.0	75.00	75.00	75.00	75.0
	ADA	5	72.50	28.504	25.0	75.00	75.00	87.50	100.0
	TOT	7	73.21	23.306	25.0	75.00	75.00	87.50	100.0
FINAL/ET VALUE	PLO	2	81.25	8.839	75.0	75.00	81.25	87.50	87.5
	ADA	5	75.00	30.619	25.0	75.00	75.00	100.00	100.0
	TOT	7	76.79	25.443	25.0	75.00	75.00	100.00	100.0
CHG FROM BSL	PLO	2	6.25	8.839	0.0	0.00	6.25	12.50	12.5
	ADA	5	2.50	5.590	0.0	0.00	0.00	0.00	12.5
	TOT	7	3.57	6.099	0.0	0.00	0.00	12.50	12.5

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.15.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=MULTIFOCAL CHOROIDITIS AND PANUVEITIS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
DEPENDENCY									
BSL VALUE	PLO	2	95.83	5.893	91.7	91.67	95.83	100.00	100.0
	ADA	5	95.00	11.180	75.0	100.00	100.00	100.00	100.0
	TOT	7	95.24	9.449	75.0	91.67	100.00	100.00	100.0
FINAL/ET VALUE	PLO	2	83.33	0.000	83.3	83.33	83.33	83.33	83.3
	ADA	5	85.00	25.276	41.7	83.33	100.00	100.00	100.0
	TOT	7	84.52	20.654	41.7	83.33	83.33	100.00	100.0
CHG FROM BSL	PLO	2	-12.50	5.893	-16.7	-16.67	-12.50	-8.33	-8.3
	ADA	5	-10.00	14.907	-33.3	-16.67	0.00	0.00	0.0
	TOT	7	-10.71	12.467	-33.3	-16.67	-8.33	0.00	0.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.15.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=MULTIFOCAL CHOROIDITIS AND PANUVEITIS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
DRIVING									
BSL VALUE	PLO	2	70.83	17.678	58.3	58.33	70.83	83.33	83.3
	ADA	5	96.67	4.564	91.7	91.67	100.00	100.00	100.0
	TOT	7	89.29	14.996	58.3	83.33	91.67	100.00	100.0
FINAL/ET VALUE	PLO	2	58.33	11.785	50.0	50.00	58.33	66.67	66.7
	ADA	5	90.83	12.638	75.0	79.17	100.00	100.00	100.0
	TOT	7	81.55	19.522	50.0	66.67	79.17	100.00	100.0
CHG FROM BSL	PLO	2	-12.50	5.893	-16.7	-16.67	-12.50	-8.33	-8.3
	ADA	5	-5.83	13.044	-25.0	-12.50	0.00	0.00	8.3
	TOT	7	-7.74	11.393	-25.0	-16.67	-8.33	0.00	8.3

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.15.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=MULTIFOCAL CHOROIDITIS AND PANUVEITIS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
COLOR VISION									
BSL VALUE	PLO	2	100.00	0.000	100.0	100.00	100.00	100.00	100.0
	ADA	5	100.00	0.000	100.0	100.00	100.00	100.00	100.0
	TOT	7	100.00	0.000	100.0	100.00	100.00	100.00	100.0
FINAL/ET VALUE	PLO	2	100.00	0.000	100.0	100.00	100.00	100.00	100.0
	ADA	5	100.00	0.000	100.0	100.00	100.00	100.00	100.0
	TOT	7	100.00	0.000	100.0	100.00	100.00	100.00	100.0
CHG FROM BSL	PLO	2	0.00	0.000	0.0	0.00	0.00	0.00	0.0
	ADA	5	0.00	0.000	0.0	0.00	0.00	0.00	0.0
	TOT	7	0.00	0.000	0.0	0.00	0.00	0.00	0.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.15.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=MULTIFOCAL CHOROIDITIS AND PANUVEITIS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
PERIPHERAL VISION									
BSL VALUE	PLO	2	100.00	0.000	100.0	100.00	100.00	100.00	100.0
	ADA	5	100.00	0.000	100.0	100.00	100.00	100.00	100.0
	TOT	7	100.00	0.000	100.0	100.00	100.00	100.00	100.0
FINAL/ET VALUE	PLO	2	87.50	17.678	75.0	75.00	87.50	100.00	100.0
	ADA	5	95.00	11.180	75.0	100.00	100.00	100.00	100.0
	TOT	7	92.86	12.199	75.0	75.00	100.00	100.00	100.0
CHG FROM BSL	PLO	2	-12.50	17.678	-25.0	-25.00	-12.50	0.00	0.0
	ADA	5	-5.00	11.180	-25.0	0.00	0.00	0.00	0.0
	TOT	7	-7.14	12.199	-25.0	-25.00	0.00	0.00	0.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.15.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=MULTIFOCAL CHOROIDITIS AND PANUVEITIS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
TOTAL SCORE									
BSL VALUE	PLO	2	84.20	0.857	83.6	83.60	84.20	84.81	84.8
	ADA	5	88.16	8.464	78.3	81.14	88.52	95.45	97.4
	TOT	7	87.03	7.184	78.3	81.14	84.81	95.45	97.4
FINAL/ET VALUE	PLO	2	80.51	2.491	78.8	78.75	80.51	82.27	82.3
	ADA	5	84.97	17.336	58.9	75.80	92.50	98.18	99.4
	TOT	7	83.70	14.357	58.9	75.80	82.27	98.18	99.4
CHG FROM BSL	PLO	2	-3.69	3.348	-6.1	-6.06	-3.69	-1.33	-1.3
	ADA	5	-3.19	10.956	-22.2	-2.46	0.76	3.98	4.0
	TOT	7	-3.33	9.053	-22.2	-6.06	-1.33	3.98	4.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.16.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=VOGT KOYANAGI HARADA)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL HEALTH												
BSL VALUE	PLO	29	50.00	18.898	25.0	25.00	50.00	75.00	75.0			
	ADA	34	53.68	22.303	0.0	50.00	50.00	75.00	100.0			
	TOT	63	51.98	20.724	0.0	50.00	50.00	75.00	100.0			
FINAL/ET VALUE	PLO	29	50.00	27.549	0.0	25.00	50.00	75.00	100.0			
	ADA	34	50.00	26.112	0.0	25.00	50.00	75.00	100.0			
	TOT	63	50.00	26.564	0.0	25.00	50.00	75.00	100.0			
CHG FROM BSL	PLO	29	0.00	23.146	-75.0	0.00	0.00	25.00	25.0			
	ADA	34	-3.68	21.437	-50.0	0.00	0.00	0.00	50.0			
	TOT	63	-1.98	22.135	-75.0	0.00	0.00	0.00	50.0			
										-3.68	(-14.92, 7.56)	0.516A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.16.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=VOGT KOYANAGI HARADA)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL VISION												
BSL VALUE	PLO	29	69.66	13.754	40.0	60.00	80.00	80.00	100.0			
	ADA	33	65.45	16.026	40.0	60.00	60.00	80.00	100.0			
	TOT	62	67.42	15.034	40.0	60.00	60.00	80.00	100.0			
FINAL/ET VALUE	PLO	29	68.28	21.056	20.0	60.00	80.00	80.00	100.0			
	ADA	33	64.24	21.070	20.0	60.00	60.00	80.00	100.0			
	TOT	62	66.13	20.988	20.0	60.00	70.00	80.00	100.0			
CHG FROM BSL	PLO	29	-1.38	16.845	-40.0	-20.00	0.00	0.00	40.0			
	ADA	33	-1.21	16.537	-40.0	0.00	0.00	0.00	20.0			
	TOT	62	-1.29	16.544	-40.0	-20.00	0.00	0.00	40.0			
										0.17	(-8.33, 8.66)	0.969A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.16.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=VOGT KOYANAGI HARADA)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
OCULAR PAIN												
BSL VALUE	PLO	29	66.81	25.721	12.5	50.00	62.50	87.50	100.0			
	ADA	34	70.22	23.236	25.0	50.00	75.00	87.50	100.0			
	TOT	63	68.65	24.271	12.5	50.00	75.00	87.50	100.0			
FINAL/ET VALUE	PLO	29	70.26	23.720	25.0	50.00	62.50	100.00	100.0			
	ADA	34	73.90	23.104	12.5	62.50	75.00	100.00	100.0			
	TOT	63	72.22	23.271	12.5	50.00	75.00	100.00	100.0			
CHG FROM BSL	PLO	29	3.45	21.102	-25.0	-12.50	0.00	12.50	62.5			
	ADA	34	3.68	22.724	-50.0	-12.50	0.00	12.50	62.5			
	TOT	63	3.57	21.816	-50.0	-12.50	0.00	12.50	62.5			
										0.23	(-10.89, 11.35)	0.967A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.16.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=VOGT KOYANAGI HARADA)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
NEAR VISION												
BSL VALUE	PLO	29	67.82	26.232	0.0	58.33	75.00	91.67	100.0			
	ADA	34	71.45	22.802	12.5	58.33	75.00	91.67	100.0			
	TOT	63	69.78	24.307	0.0	58.33	75.00	91.67	100.0			
FINAL/ET VALUE	PLO	29	75.29	22.325	33.3	58.33	83.33	91.67	100.0			
	ADA	34	70.34	33.219	0.0	50.00	83.33	100.00	100.0			
	TOT	63	72.62	28.611	0.0	58.33	83.33	100.00	100.0			
CHG FROM BSL	PLO	29	7.47	18.141	-16.7	0.00	0.00	16.67	75.0			
	ADA	34	-1.10	27.280	-75.0	-8.33	0.00	16.67	41.7			
	TOT	63	2.84	23.734	-75.0	-8.33	0.00	16.67	75.0			
										-8.57	(-20.47, 3.32)	0.155A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.16.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=VOGT KOYANAGI HARADA)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DISTANCE VISION												
BSL VALUE	PLO	29	64.94	26.854	25.0	41.67	66.67	91.67	100.0			
	ADA	34	70.34	23.565	8.3	58.33	70.83	91.67	100.0			
	TOT	63	67.86	25.072	8.3	41.67	66.67	91.67	100.0			
FINAL/ET VALUE	PLO	29	71.41	25.678	16.7	58.33	75.00	91.67	100.0			
	ADA	34	71.81	29.872	0.0	50.00	83.33	100.00	100.0			
	TOT	63	71.63	27.799	0.0	50.00	83.33	100.00	100.0			
CHG FROM BSL	PLO	29	6.47	17.873	-33.3	0.00	0.00	16.67	50.0			
	ADA	34	1.47	21.538	-50.0	-8.33	0.00	16.67	41.7			
	TOT	63	3.77	19.937	-50.0	-8.33	0.00	16.67	50.0			
										-4.99	(-15.07, 5.08)	0.326A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.16.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=VOGT KOYANAGI HARADA)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
SOCIAL FUNCTIONING												
BSL VALUE	PLO	29	82.33	20.188	37.5	62.50	87.50	100.00	100.0			
	ADA	34	80.15	27.024	0.0	75.00	87.50	100.00	100.0			
	TOT	63	81.15	23.957	0.0	62.50	87.50	100.00	100.0			
FINAL/ET VALUE	PLO	29	78.66	26.909	6.3	62.50	87.50	100.00	100.0			
	ADA	34	82.35	25.584	12.5	62.50	100.00	100.00	100.0			
	TOT	63	80.65	26.054	6.3	62.50	100.00	100.00	100.0			
CHG FROM BSL	PLO	29	-3.66	15.447	-43.8	-12.50	0.00	0.00	25.0			
	ADA	34	2.21	13.225	-25.0	0.00	0.00	12.50	25.0			
	TOT	63	-0.50	14.476	-43.8	-12.50	0.00	12.50	25.0			
										5.87	(-1.35, 13.09)	0.109A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.16.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=VOGT KOYANAGI HARADA)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
MENTAL HEALTH												
BSL VALUE	PLO	29	55.82	28.880	0.0	37.50	56.25	81.25	100.0			
	ADA	34	67.10	24.967	0.0	56.25	78.13	87.50	100.0			
	TOT	63	61.90	27.213	0.0	43.75	68.75	87.50	100.0			
FINAL/ET VALUE	PLO	29	61.42	32.350	0.0	37.50	68.75	87.50	100.0			
	ADA	34	69.67	28.125	0.0	56.25	75.00	93.75	100.0			
	TOT	63	65.87	30.180	0.0	50.00	75.00	93.75	100.0			
CHG FROM BSL	PLO	29	5.60	20.276	-56.3	0.00	6.25	12.50	43.8			
	ADA	34	2.57	16.933	-37.5	-12.50	6.25	12.50	37.5			
	TOT	63	3.97	18.455	-56.3	-6.25	6.25	12.50	43.8			
										-3.03	(-12.40, 6.34)	0.520A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.16.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=VOGT KOYANAGI HARADA)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
ROLE DIFFICULTIES												
BSL VALUE	PLO	29	61.21	31.222	0.0	37.50	62.50	87.50	100.0			
	ADA	34	67.65	29.213	0.0	50.00	75.00	100.00	100.0			
	TOT	63	64.68	30.082	0.0	37.50	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	29	65.09	33.471	0.0	37.50	75.00	100.00	100.0			
	ADA	34	76.47	29.479	0.0	50.00	87.50	100.00	100.0			
	TOT	63	71.23	31.641	0.0	50.00	87.50	100.00	100.0			
CHG FROM BSL	PLO	29	3.88	28.368	-62.5	0.00	0.00	12.50	62.5			
	ADA	34	8.82	22.303	-25.0	0.00	0.00	12.50	62.5			
	TOT	63	6.55	25.187	-62.5	0.00	0.00	12.50	62.5			
										4.94	(-7.83, 17.72)	0.442A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.16.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=VOGT KOYANAGI HARADA)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DEPENDENCY												
BSL VALUE	PLO	29	73.99	31.882	0.0	50.00	91.67	100.00	100.0			
	ADA	34	79.90	27.686	8.3	75.00	91.67	100.00	100.0			
	TOT	63	77.18	29.594	0.0	58.33	91.67	100.00	100.0			
FINAL/ET VALUE	PLO	29	75.29	31.298	8.3	58.33	91.67	100.00	100.0			
	ADA	34	81.13	29.180	8.3	66.67	100.00	100.00	100.0			
	TOT	63	78.44	30.070	8.3	58.33	100.00	100.00	100.0			
CHG FROM BSL	PLO	29	1.29	20.807	-83.3	0.00	0.00	8.33	41.7			
	ADA	34	1.23	22.108	-50.0	0.00	0.00	8.33	58.3			
	TOT	63	1.26	21.346	-83.3	0.00	0.00	8.33	58.3			
										-0.07	(-10.95, 10.81)	0.990A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.16.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=VOGT KOYANAGI HARADA)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DRIVING												
BSL VALUE	PLO	18	56.48	31.643	0.0	41.67	58.33	75.00	100.0			
	ADA	16	64.84	40.339	0.0	29.17	83.33	95.83	100.0			
	TOT	34	60.42	35.685	0.0	41.67	75.00	83.33	100.0			
FINAL/ET VALUE	PLO	18	49.54	34.445	0.0	8.33	58.33	75.00	100.0			
	ADA	16	55.73	42.243	0.0	0.00	79.17	87.50	100.0			
	TOT	34	52.45	37.844	0.0	8.33	62.50	83.33	100.0			
CHG FROM BSL	PLO	18	-6.94	14.292	-41.7	-16.67	0.00	0.00	8.3			
	ADA	16	-9.11	17.626	-58.3	-14.58	0.00	0.00	8.3			
	TOT	34	-7.97	15.737	-58.3	-16.67	0.00	0.00	8.3			
										-2.17	(-13.33, 8.99)	0.695A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.16.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=VOGT KOYANAGI HARADA)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
COLOR VISION												
BSL VALUE	PLO	28	88.39	15.931	50.0	75.00	100.00	100.00	100.0			
	ADA	33	87.88	20.843	25.0	75.00	100.00	100.00	100.0			
	TOT	61	88.11	18.600	25.0	75.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	28	89.29	17.252	50.0	75.00	100.00	100.00	100.0			
	ADA	33	87.88	26.606	0.0	100.00	100.00	100.00	100.0			
	TOT	61	88.52	22.626	0.0	75.00	100.00	100.00	100.0			
CHG FROM BSL	PLO	28	0.89	15.931	-25.0	0.00	0.00	0.00	50.0			
	ADA	33	0.00	16.536	-50.0	0.00	0.00	0.00	50.0			
	TOT	61	0.41	16.132	-50.0	0.00	0.00	0.00	50.0			
										-0.89	(-9.25, 7.47)	0.832A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.16.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=VOGT KOYANAGI HARADA)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
PERIPHERAL VISION												
BSL VALUE	PLO	29	68.97	23.769	25.0	50.00	75.00	100.00	100.0			
	ADA	33	75.00	26.517	0.0	50.00	75.00	100.00	100.0			
	TOT	62	72.18	25.247	0.0	50.00	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	29	78.02	22.573	25.0	75.00	75.00	100.00	100.0			
	ADA	33	77.27	29.556	0.0	75.00	100.00	100.00	100.0			
	TOT	62	77.62	26.312	0.0	75.00	75.00	100.00	100.0			
CHG FROM BSL	PLO	29	9.05	19.735	-25.0	0.00	0.00	25.00	50.0			
	ADA	33	2.27	19.125	-25.0	0.00	0.00	25.00	25.0			
	TOT	62	5.44	19.552	-25.0	0.00	0.00	25.00	50.0			
										-6.78	(-16.66, 3.10)	0.175A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.16.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=VOGT KOYANAGI HARADA)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
TOTAL SCORE												
BSL VALUE	PLO	29	69.06	19.001	41.6	49.28	67.25	85.87	95.9			
	ADA	34	73.07	19.579	15.4	66.63	78.04	87.58	95.9			
	TOT	63	71.22	19.265	15.4	53.30	75.25	87.58	95.9			
FINAL/ET VALUE	PLO	29	71.42	21.656	28.7	53.33	76.78	89.79	100.0			
	ADA	34	74.34	24.668	12.4	57.42	86.61	92.77	99.4			
	TOT	63	73.00	23.191	12.4	56.70	84.33	90.80	100.0			
CHG FROM BSL	PLO	29	2.36	12.514	-25.7	-3.52	3.03	8.33	29.4			
	ADA	34	1.27	13.126	-33.6	-6.44	6.00	11.17	24.4			
	TOT	63	1.77	12.757	-33.6	-6.44	4.08	10.23	29.4			
										-1.09	(-7.58, 5.41)	0.739A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.17.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=SARCOID)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL HEALTH												
BSL VALUE	PLO	20	37.50	26.283	0.0	25.00	25.00	50.00	100.0			
	ADA	22	53.41	22.221	25.0	50.00	50.00	75.00	100.0			
	TOT	42	45.83	25.253	0.0	25.00	50.00	50.00	100.0			
FINAL/ET VALUE	PLO	20	43.13	23.464	0.0	25.00	37.50	68.75	75.0			
	ADA	22	54.55	26.034	0.0	50.00	56.25	75.00	100.0			
	TOT	42	49.11	25.211	0.0	25.00	50.00	75.00	100.0			
CHG FROM BSL	PLO	20	5.63	15.430	-25.0	0.00	0.00	25.00	25.0			
	ADA	22	1.14	19.253	-25.0	-25.00	0.00	25.00	25.0			
	TOT	42	3.27	17.474	-25.0	0.00	0.00	25.00	25.0			
										-4.49	(-15.44, 6.46)	0.412A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.17.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=SARCOID)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL VISION												
BSL VALUE	PLO	20	60.00	15.894	40.0	50.00	60.00	60.00	100.0			
	ADA	22	67.27	16.954	40.0	60.00	60.00	80.00	100.0			
	TOT	42	63.81	16.668	40.0	60.00	60.00	80.00	100.0			
FINAL/ET VALUE	PLO	20	62.00	20.417	20.0	60.00	60.00	80.00	100.0			
	ADA	22	67.73	23.489	20.0	60.00	80.00	80.00	100.0			
	TOT	42	65.00	22.003	20.0	60.00	60.00	80.00	100.0			
CHG FROM BSL	PLO	20	2.00	17.045	-40.0	0.00	0.00	20.00	20.0			
	ADA	22	0.45	19.634	-40.0	0.00	0.00	20.00	40.0			
	TOT	42	1.19	18.240	-40.0	0.00	0.00	20.00	40.0			
										-1.55	(-13.07, 9.97)	0.788A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.17.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=SARCOID)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
OCULAR PAIN												
BSL VALUE	PLO	20	77.50	21.306	25.0	68.75	81.25	93.75	100.0			
	ADA	22	78.98	20.188	25.0	75.00	75.00	100.00	100.0			
	TOT	42	78.27	20.486	25.0	75.00	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	20	76.88	25.090	25.0	50.00	87.50	100.00	100.0			
	ADA	22	77.27	19.532	37.5	62.50	81.25	87.50	100.0			
	TOT	42	77.08	22.072	25.0	62.50	87.50	100.00	100.0			
CHG FROM BSL	PLO	20	-0.63	20.867	-50.0	0.00	0.00	12.50	37.5			
	ADA	22	-1.70	24.182	-37.5	-12.50	0.00	12.50	62.5			
	TOT	42	-1.19	22.396	-50.0	-12.50	0.00	12.50	62.5			
										-1.08	(-15.23, 13.07)	0.878A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.17.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=SARCOID)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
NEAR VISION												
BSL VALUE	PLO	20	70.42	21.877	16.7	58.33	75.00	87.50	100.0			
	ADA	22	78.79	15.796	33.3	75.00	75.00	91.67	100.0			
	TOT	42	74.80	19.170	16.7	66.67	75.00	91.67	100.0			
FINAL/ET VALUE	PLO	20	76.46	18.500	41.7	66.67	75.00	91.67	100.0			
	ADA	22	79.36	21.915	33.3	75.00	83.33	100.00	100.0			
	TOT	42	77.98	20.168	33.3	66.67	83.33	91.67	100.0			
CHG FROM BSL	PLO	20	6.04	15.618	-25.0	-2.08	0.00	20.83	33.3			
	ADA	22	0.57	16.076	-41.7	-4.17	0.00	16.67	25.0			
	TOT	42	3.17	15.908	-41.7	-4.17	0.00	16.67	33.3			
										-5.47	(-15.38, 4.43)	0.271A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.17.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=SARCOID)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DISTANCE VISION												
BSL VALUE	PLO	20	72.50	21.815	41.7	50.00	75.00	91.67	100.0			
	ADA	22	78.41	15.357	41.7	66.67	75.00	91.67	100.0			
	TOT	42	75.60	18.715	41.7	66.67	75.00	91.67	100.0			
FINAL/ET VALUE	PLO	20	76.04	20.045	33.3	64.58	75.00	95.83	100.0			
	ADA	22	81.06	20.279	33.3	75.00	87.50	100.00	100.0			
	TOT	42	78.67	20.082	33.3	66.67	83.33	100.00	100.0			
CHG FROM BSL	PLO	20	3.54	20.290	-41.7	-4.17	0.00	16.67	50.0			
	ADA	22	2.65	13.458	-25.0	0.00	0.00	8.33	25.0			
	TOT	42	3.08	16.845	-41.7	0.00	0.00	16.67	50.0			
										-0.89	(-11.54, 9.76)	0.867A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.17.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=SARCOID)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
SOCIAL FUNCTIONING												
BSL VALUE	PLO	20	85.00	19.702	37.5	75.00	93.75	100.00	100.0			
	ADA	22	92.05	13.108	50.0	87.50	100.00	100.00	100.0			
	TOT	42	88.69	16.750	37.5	75.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	20	85.94	16.458	50.0	75.00	90.63	100.00	100.0			
	ADA	22	91.76	15.597	50.0	87.50	100.00	100.00	100.0			
	TOT	42	88.99	16.087	50.0	75.00	100.00	100.00	100.0			
CHG FROM BSL	PLO	20	0.94	17.710	-37.5	-3.13	0.00	12.50	37.5			
	ADA	22	-0.28	15.726	-50.0	0.00	0.00	6.25	25.0			
	TOT	42	0.30	16.504	-50.0	0.00	0.00	12.50	37.5			
										-1.22	(-11.65, 9.20)	0.814A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.17.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=SARCOID)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
MENTAL HEALTH												
BSL VALUE	PLO	20	67.50	24.719	12.5	50.00	71.88	90.63	93.8			
	ADA	22	67.14	19.669	25.0	56.25	71.88	81.25	93.8			
	TOT	42	67.31	21.940	12.5	50.00	71.88	83.33	93.8			
FINAL/ET VALUE	PLO	20	74.69	23.948	18.8	65.63	78.13	93.75	100.0			
	ADA	22	77.56	22.875	25.0	62.50	87.50	93.75	100.0			
	TOT	42	76.19	23.149	18.8	62.50	84.38	93.75	100.0			
CHG FROM BSL	PLO	20	7.19	27.302	-43.8	-3.13	3.13	21.88	68.8			
	ADA	22	10.42	14.519	-37.5	6.25	12.50	18.75	31.3			
	TOT	42	8.88	21.356	-43.8	0.00	12.50	18.75	68.8			
										3.23	(-10.23, 16.69)	0.630A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.17.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=SARCOID)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
ROLE DIFFICULTIES												
BSL VALUE	PLO	20	76.25	22.544	37.5	56.25	75.00	100.00	100.0			
	ADA	22	72.16	23.443	25.0	62.50	75.00	87.50	100.0			
	TOT	42	74.11	22.832	25.0	62.50	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	20	80.00	20.838	37.5	68.75	81.25	100.00	100.0			
	ADA	22	76.70	25.383	25.0	75.00	75.00	100.00	100.0			
	TOT	42	78.27	23.108	25.0	75.00	75.00	100.00	100.0			
CHG FROM BSL	PLO	20	3.75	17.724	-12.5	-6.25	0.00	6.25	62.5			
	ADA	22	4.55	24.563	-50.0	0.00	0.00	12.50	75.0			
	TOT	42	4.17	21.325	-50.0	0.00	0.00	12.50	75.0			
										0.80	(-12.68, 14.27)	0.906A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.17.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=SARCOID)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DEPENDENCY												
BSL VALUE	PLO	20	87.08	23.798	16.7	83.33	100.00	100.00	100.0			
	ADA	22	91.29	12.723	58.3	83.33	100.00	100.00	100.0			
	TOT	42	89.29	18.705	16.7	83.33	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	20	83.33	23.258	25.0	79.17	91.67	100.00	100.0			
	ADA	22	92.05	14.198	50.0	83.33	100.00	100.00	100.0			
	TOT	42	87.90	19.321	25.0	83.33	100.00	100.00	100.0			
CHG FROM BSL	PLO	20	-3.75	27.236	-58.3	-12.50	0.00	0.00	75.0			
	ADA	22	0.76	8.494	-25.0	0.00	0.00	0.00	16.7			
	TOT	42	-1.39	19.644	-58.3	0.00	0.00	0.00	75.0			
										4.51	(-7.83, 16.84)	0.464A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.17.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=SARCOID)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DRIVING												
BSL VALUE	PLO	16	76.56	24.948	25.0	62.50	83.33	100.00	100.0			
	ADA	21	67.06	36.370	0.0	58.33	83.33	91.67	100.0			
	TOT	37	71.17	31.890	0.0	58.33	83.33	100.00	100.0			
FINAL/ET VALUE	PLO	16	73.70	22.138	25.0	58.33	79.17	89.58	100.0			
	ADA	21	70.83	32.005	0.0	66.67	75.00	100.00	100.0			
	TOT	37	72.07	27.845	0.0	58.33	75.00	100.00	100.0			
CHG FROM BSL	PLO	16	-2.86	17.659	-33.3	-16.67	-2.08	16.67	25.0			
	ADA	21	3.77	25.066	-33.3	0.00	0.00	0.00	100.0			
	TOT	37	0.90	22.138	-33.3	-8.33	0.00	0.00	100.0			
										6.63	(-8.32, 21.59)	0.374A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.17.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=SARCOID)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
COLOR VISION												
BSL VALUE	PLO	20	91.25	18.629	50.0	100.00	100.00	100.00	100.0			
	ADA	22	97.73	10.660	50.0	100.00	100.00	100.00	100.0			
	TOT	42	94.64	15.157	50.0	100.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	20	91.88	11.666	75.0	75.00	100.00	100.00	100.0			
	ADA	22	98.30	5.845	75.0	100.00	100.00	100.00	100.0			
	TOT	42	95.24	9.545	75.0	100.00	100.00	100.00	100.0			
CHG FROM BSL	PLO	20	0.63	13.126	-25.0	0.00	0.00	0.00	25.0			
	ADA	22	0.57	12.486	-25.0	0.00	0.00	0.00	50.0			
	TOT	42	0.60	12.637	-25.0	0.00	0.00	0.00	50.0			
										-0.06	(-8.05, 7.93)	0.989A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.17.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=SARCOID)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
PERIPHERAL VISION												
BSL VALUE	PLO	20	76.25	23.613	25.0	50.00	75.00	100.00	100.0			
	ADA	21	80.95	20.774	50.0	75.00	75.00	100.00	100.0			
	TOT	41	78.66	22.052	25.0	50.00	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	20	79.38	20.389	50.0	62.50	75.00	100.00	100.0			
	ADA	21	82.14	21.129	50.0	75.00	100.00	100.00	100.0			
	TOT	41	80.79	20.558	50.0	75.00	75.00	100.00	100.0			
CHG FROM BSL	PLO	20	3.13	23.604	-50.0	-6.25	0.00	25.00	50.0			
	ADA	21	1.19	14.740	-25.0	0.00	0.00	0.00	25.0			
	TOT	41	2.13	19.345	-50.0	0.00	0.00	25.00	50.0			
										-1.93	(-14.30, 10.43)	0.753A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.17.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=SARCOID)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
TOTAL SCORE												
BSL VALUE	PLO	20	76.34	15.539	44.2	66.99	81.12	87.71	95.5			
	ADA	22	79.31	11.901	48.1	73.45	80.17	87.39	98.9			
	TOT	42	77.90	13.664	44.2	70.87	80.17	87.46	98.9			
FINAL/ET VALUE	PLO	20	77.82	15.933	42.4	68.29	85.09	87.80	98.2			
	ADA	22	81.39	16.832	45.9	74.70	85.76	92.31	100.0			
	TOT	42	79.69	16.310	42.4	72.04	85.76	91.63	100.0			
CHG FROM BSL	PLO	20	1.48	13.129	-30.9	-4.13	3.76	8.26	19.3			
	ADA	22	2.08	10.392	-24.9	-0.45	2.97	8.07	22.2			
	TOT	42	1.80	11.631	-30.9	-1.78	3.37	8.07	22.2			
										0.60	(-6.75, 7.95)	0.869A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.18.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=BEHCET'S)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
GENERAL HEALTH									
BSL VALUE	PLO	7	53.57	33.630	0.0	25.00	50.00	75.00	100.0
	ADA	10	60.00	24.152	25.0	50.00	50.00	75.00	100.0
	TOT	17	57.35	27.620	0.0	50.00	50.00	75.00	100.0
FINAL/ET VALUE	PLO	7	50.00	32.275	0.0	25.00	50.00	75.00	100.0
	ADA	10	65.00	21.082	25.0	50.00	75.00	75.00	100.0
	TOT	17	58.82	26.430	0.0	50.00	50.00	75.00	100.0
CHG FROM BSL	PLO	7	-3.57	9.449	-25.0	0.00	0.00	0.00	0.0
	ADA	10	5.00	22.973	-25.0	0.00	0.00	25.00	50.0
	TOT	17	1.47	18.689	-25.0	0.00	0.00	0.00	50.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.18.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=BEHCET'S)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
GENERAL VISION									
BSL VALUE	PLO	7	68.57	19.518	40.0	40.00	80.00	80.00	80.0
	ADA	10	62.00	14.757	40.0	60.00	60.00	80.00	80.0
	TOT	17	64.71	16.627	40.0	60.00	60.00	80.00	80.0
FINAL/ET VALUE	PLO	7	62.86	17.995	40.0	40.00	60.00	80.00	80.0
	ADA	10	82.00	11.353	60.0	80.00	80.00	80.00	100.0
	TOT	17	74.12	16.977	40.0	60.00	80.00	80.00	100.0
CHG FROM BSL	PLO	7	-5.71	9.759	-20.0	-20.00	0.00	0.00	0.0
	ADA	10	20.00	13.333	0.0	20.00	20.00	20.00	40.0
	TOT	17	9.41	17.489	-20.0	0.00	0.00	20.00	40.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.18.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=BEHCET'S)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
OCULAR PAIN									
BSL VALUE	PLO	7	66.07	21.304	25.0	62.50	62.50	87.50	87.5
	ADA	10	78.75	19.588	50.0	62.50	75.00	100.00	100.0
	TOT	17	73.53	20.673	25.0	62.50	75.00	87.50	100.0
FINAL/ET VALUE	PLO	7	66.07	17.252	50.0	50.00	62.50	75.00	100.0
	ADA	10	92.50	10.541	75.0	87.50	100.00	100.00	100.0
	TOT	17	81.62	18.811	50.0	62.50	87.50	100.00	100.0
CHG FROM BSL	PLO	7	0.00	16.137	-25.0	-12.50	0.00	12.50	25.0
	ADA	10	13.75	17.129	0.0	0.00	6.25	25.00	50.0
	TOT	17	8.09	17.645	-25.0	0.00	0.00	25.00	50.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.18.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=BEHCET'S)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
NEAR VISION									
BSL VALUE	PLO	7	71.43	24.465	33.3	50.00	66.67	91.67	100.0
	ADA	10	75.83	20.953	33.3	66.67	79.17	91.67	100.0
	TOT	17	74.02	21.827	33.3	66.67	75.00	91.67	100.0
FINAL/ET VALUE	PLO	7	69.05	21.897	50.0	50.00	58.33	100.00	100.0
	ADA	10	92.50	10.722	75.0	83.33	100.00	100.00	100.0
	TOT	17	82.84	19.648	50.0	66.67	91.67	100.00	100.0
CHG FROM BSL	PLO	7	-2.38	18.456	-33.3	-16.67	0.00	16.67	16.7
	ADA	10	16.67	17.123	0.0	8.33	8.33	25.00	50.0
	TOT	17	8.82	19.648	-33.3	0.00	8.33	16.67	50.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.18.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=BEHCET'S)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
DISTANCE VISION									
BSL VALUE	PLO	7	78.57	17.910	50.0	58.33	83.33	91.67	100.0
	ADA	10	74.58	21.557	37.5	50.00	83.33	83.33	100.0
	TOT	17	76.23	19.641	37.5	58.33	83.33	83.33	100.0
FINAL/ET VALUE	PLO	7	75.00	18.634	50.0	66.67	66.67	100.00	100.0
	ADA	10	86.67	16.292	50.0	75.00	91.67	100.00	100.0
	TOT	17	81.86	17.735	50.0	66.67	83.33	100.00	100.0
CHG FROM BSL	PLO	7	-3.57	13.486	-16.7	-16.67	0.00	8.33	16.7
	ADA	10	12.08	18.050	-25.0	0.00	14.58	25.00	41.7
	TOT	17	5.64	17.735	-25.0	0.00	8.33	16.67	41.7

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.18.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=BEHCET'S)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
SOCIAL FUNCTIONING									
BSL VALUE	PLO	7	85.71	19.670	50.0	75.00	100.00	100.00	100.0
	ADA	10	87.50	14.434	62.5	75.00	93.75	100.00	100.0
	TOT	17	86.76	16.220	50.0	75.00	100.00	100.00	100.0
FINAL/ET VALUE	PLO	7	83.93	20.045	50.0	62.50	87.50	100.00	100.0
	ADA	10	90.00	11.487	75.0	75.00	93.75	100.00	100.0
	TOT	17	87.50	15.309	50.0	75.00	87.50	100.00	100.0
CHG FROM BSL	PLO	7	-1.79	13.363	-12.5	-12.50	0.00	0.00	25.0
	ADA	10	2.50	19.365	-25.0	0.00	0.00	12.50	37.5
	TOT	17	0.74	16.812	-25.0	-12.50	0.00	0.00	37.5

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.18.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=BEHCET'S)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
MENTAL HEALTH									
BSL VALUE	PLO	7	59.82	25.222	25.0	31.25	62.50	81.25	87.5
	ADA	10	53.33	30.162	0.0	37.50	56.25	81.25	87.5
	TOT	17	56.00	27.588	0.0	37.50	62.50	81.25	87.5
FINAL/ET VALUE	PLO	7	66.07	28.380	25.0	31.25	75.00	87.50	100.0
	ADA	10	77.50	25.550	25.0	68.75	84.38	100.00	100.0
	TOT	17	72.79	26.511	25.0	62.50	81.25	93.75	100.0
CHG FROM BSL	PLO	7	6.25	11.411	-6.3	0.00	0.00	18.75	25.0
	ADA	10	24.17	19.049	-6.3	12.50	25.00	37.50	62.5
	TOT	17	16.79	18.318	-6.3	0.00	16.67	25.00	62.5

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.18.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=BEHCET'S)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
ROLE DIFFICULTIES									
BSL VALUE	PLO	7	66.07	22.493	37.5	37.50	75.00	75.00	100.0
	ADA	10	66.25	25.035	25.0	37.50	75.00	87.50	100.0
	TOT	17	66.18	23.287	25.0	37.50	75.00	75.00	100.0
FINAL/ET VALUE	PLO	7	71.43	27.683	25.0	50.00	75.00	100.00	100.0
	ADA	10	83.75	25.035	25.0	75.00	100.00	100.00	100.0
	TOT	17	78.68	26.058	25.0	62.50	87.50	100.00	100.0
CHG FROM BSL	PLO	7	5.36	24.851	-37.5	-12.50	12.50	25.00	37.5
	ADA	10	17.50	21.409	-12.5	0.00	12.50	25.00	62.5
	TOT	17	12.50	22.964	-37.5	0.00	12.50	25.00	62.5

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.18.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=BEHCET'S)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
DEPENDENCY									
BSL VALUE	PLO	7	84.52	20.654	41.7	83.33	83.33	100.00	100.0
	ADA	10	80.83	29.672	8.3	66.67	95.83	100.00	100.0
	TOT	17	82.35	25.665	8.3	83.33	91.67	100.00	100.0
FINAL/ET VALUE	PLO	7	85.71	21.362	41.7	75.00	91.67	100.00	100.0
	ADA	10	86.67	15.811	58.3	75.00	91.67	100.00	100.0
	TOT	17	86.27	17.663	41.7	75.00	91.67	100.00	100.0
CHG FROM BSL	PLO	7	1.19	8.909	-8.3	-8.33	0.00	8.33	16.7
	ADA	10	5.83	25.474	-25.0	-8.33	0.00	8.33	58.3
	TOT	17	3.92	20.008	-25.0	-8.33	0.00	8.33	58.3

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.18.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=BEHCET'S)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
DRIVING									
BSL VALUE	PLO	6	83.33	13.944	58.3	83.33	83.33	91.67	100.0
	ADA	10	58.33	34.247	0.0	50.00	62.50	83.33	100.0
	TOT	16	67.71	30.410	0.0	58.33	83.33	83.33	100.0
FINAL/ET VALUE	PLO	6	74.31	16.753	50.0	66.67	72.92	83.33	100.0
	ADA	10	78.33	30.732	0.0	75.00	83.33	100.00	100.0
	TOT	16	76.82	25.774	0.0	68.75	83.33	100.00	100.0
CHG FROM BSL	PLO	6	-9.03	15.460	-33.3	-20.83	-4.17	0.00	8.3
	ADA	10	20.00	31.720	-8.3	0.00	12.50	25.00	100.0
	TOT	16	9.11	29.900	-33.3	-4.17	0.00	16.67	100.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.18.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=BEHCET'S)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
COLOR VISION									
BSL VALUE	PLO	7	92.86	18.898	50.0	100.00	100.00	100.00	100.0
	ADA	10	97.50	7.906	75.0	100.00	100.00	100.00	100.0
	TOT	17	95.59	13.215	50.0	100.00	100.00	100.00	100.0
FINAL/ET VALUE	PLO	7	85.71	19.670	50.0	75.00	100.00	100.00	100.0
	ADA	10	100.00	0.000	100.0	100.00	100.00	100.00	100.0
	TOT	17	94.12	14.057	50.0	100.00	100.00	100.00	100.0
CHG FROM BSL	PLO	7	-7.14	12.199	-25.0	-25.00	0.00	0.00	0.0
	ADA	10	2.50	7.906	0.0	0.00	0.00	0.00	25.0
	TOT	17	-1.47	10.719	-25.0	0.00	0.00	0.00	25.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.18.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=BEHCET'S)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
PERIPHERAL VISION									
BSL VALUE	PLO	7	71.43	22.493	50.0	50.00	75.00	100.00	100.0
	ADA	10	72.50	18.447	50.0	50.00	75.00	75.00	100.0
	TOT	17	72.06	19.530	50.0	50.00	75.00	75.00	100.0
FINAL/ET VALUE	PLO	7	67.86	23.780	50.0	50.00	50.00	100.00	100.0
	ADA	10	87.50	13.176	75.0	75.00	87.50	100.00	100.0
	TOT	17	79.41	20.224	50.0	75.00	75.00	100.00	100.0
CHG FROM BSL	PLO	7	-3.57	17.252	-25.0	-25.00	0.00	0.00	25.0
	ADA	10	15.00	24.152	-25.0	0.00	12.50	25.00	50.0
	TOT	17	7.35	22.989	-25.0	0.00	0.00	25.00	50.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.18.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=BEHCET'S)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
TOTAL SCORE									
BSL VALUE	PLO	7	74.75	16.676	40.3	72.39	75.83	85.87	91.4
	ADA	10	73.40	13.748	52.2	57.05	76.53	81.40	89.6
	TOT	17	73.96	14.528	40.3	72.39	75.91	83.22	91.4
FINAL/ET VALUE	PLO	7	73.09	16.920	46.3	62.73	71.67	90.68	96.7
	ADA	10	87.04	12.911	65.8	77.54	89.94	98.18	100.0
	TOT	17	81.29	15.849	46.3	68.52	85.68	96.67	100.0
CHG FROM BSL	PLO	7	-1.66	8.671	-14.7	-9.66	-0.76	6.04	10.8
	ADA	10	13.64	12.647	-11.6	8.56	12.05	20.45	37.0
	TOT	17	7.34	13.355	-14.7	-0.76	8.56	13.56	37.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.19.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS=0-1)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL HEALTH												
BSL VALUE	PLO	50	50.00	23.690	0.0	25.00	50.00	75.00	100.0			
	ADA	57	53.95	23.044	0.0	50.00	50.00	75.00	100.0			
	TOT	107	52.10	23.321	0.0	25.00	50.00	75.00	100.0			
FINAL/ET VALUE	PLO	50	54.25	21.667	0.0	50.00	50.00	75.00	100.0			
	ADA	57	53.07	26.335	0.0	25.00	50.00	75.00	100.0			
	TOT	107	53.62	24.161	0.0	50.00	50.00	75.00	100.0			
CHG FROM BSL	PLO	50	4.25	18.491	-25.0	0.00	0.00	25.00	50.0			
	ADA	57	-0.88	22.641	-50.0	-25.00	0.00	25.00	50.0			
	TOT	107	1.52	20.868	-50.0	0.00	0.00	25.00	50.0			
										-5.13	(-13.12, 2.87)	0.206A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.19.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS=0-1)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL VISION												
BSL VALUE	PLO	50	66.00	14.708	20.0	60.00	60.00	80.00	100.0			
	ADA	57	64.91	16.596	40.0	60.00	60.00	80.00	100.0			
	TOT	107	65.42	15.678	20.0	60.00	60.00	80.00	100.0			
FINAL/ET VALUE	PLO	50	68.40	15.167	20.0	60.00	80.00	80.00	100.0			
	ADA	57	71.58	17.707	20.0	60.00	80.00	80.00	100.0			
	TOT	107	70.09	16.569	20.0	60.00	80.00	80.00	100.0			
CHG FROM BSL	PLO	50	2.40	13.786	-20.0	0.00	0.00	20.00	20.0			
	ADA	57	6.67	14.310	-40.0	0.00	0.00	20.00	40.0			
	TOT	107	4.67	14.163	-40.0	0.00	0.00	20.00	40.0			
										4.27	(-1.14, 9.67)	0.121A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.19.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS=0-1)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#		P-VALUE@
OCULAR PAIN													
BSL VALUE	PLO	50	75.50	23.685	25.0	62.50	87.50	100.00	100.0				
	ADA	57	78.73	20.316	25.0	75.00	75.00	100.00	100.0				
	TOT	107	77.22	21.909	25.0	62.50	75.00	100.00	100.0				
FINAL/ET VALUE	PLO	50	82.00	20.385	37.5	62.50	87.50	100.00	100.0				
	ADA	57	80.04	22.016	12.5	75.00	87.50	100.00	100.0				
	TOT	107	80.96	21.193	12.5	62.50	87.50	100.00	100.0				
CHG FROM BSL	PLO	50	6.50	16.413	-25.0	0.00	0.00	12.50	62.5				
	ADA	57	1.32	20.140	-62.5	-12.50	0.00	12.50	62.5				
	TOT	107	3.74	18.589	-62.5	0.00	0.00	12.50	62.5				
										-5.18	(-12.29,	1.92)	0.151A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.19.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS=0-1)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
NEAR VISION												
BSL VALUE	PLO	50	73.00	21.858	16.7	58.33	75.00	91.67	100.0			
	ADA	57	76.17	19.760	25.0	58.33	75.00	91.67	100.0			
	TOT	107	74.69	20.729	16.7	58.33	75.00	91.67	100.0			
FINAL/ET VALUE	PLO	50	81.33	19.311	33.3	66.67	83.33	100.00	100.0			
	ADA	57	81.73	20.317	0.0	75.00	83.33	100.00	100.0			
	TOT	107	81.54	19.761	0.0	66.67	83.33	100.00	100.0			
CHG FROM BSL	PLO	50	8.33	16.410	-25.0	0.00	8.33	16.67	75.0			
	ADA	57	5.56	19.628	-75.0	0.00	0.00	16.67	41.7			
	TOT	107	6.85	18.164	-75.0	0.00	8.33	16.67	75.0			
										-2.78	(-9.77, 4.21)	0.433A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.19.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS=0-1)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DISTANCE VISION												
BSL VALUE	PLO	50	74.50	23.715	16.7	58.33	83.33	91.67	100.0			
	ADA	57	75.15	20.548	25.0	58.33	83.33	91.67	100.0			
	TOT	107	74.84	21.980	16.7	58.33	83.33	91.67	100.0			
FINAL/ET VALUE	PLO	50	79.17	21.773	25.0	66.67	83.33	100.00	100.0			
	ADA	57	79.90	21.145	0.0	75.00	83.33	100.00	100.0			
	TOT	107	79.56	21.342	0.0	66.67	83.33	100.00	100.0			
CHG FROM BSL	PLO	50	4.67	17.265	-33.3	0.00	0.00	16.67	50.0			
	ADA	57	4.75	18.708	-50.0	0.00	8.33	16.67	75.0			
	TOT	107	4.71	17.963	-50.0	0.00	0.00	16.67	75.0			
										0.08	(-6.85, 7.02)	0.981A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.19.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS=0-1)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
SOCIAL FUNCTIONING												
BSL VALUE	PLO	50	89.50	18.274	25.0	75.00	100.00	100.00	100.0			
	ADA	57	88.82	15.967	25.0	75.00	100.00	100.00	100.0			
	TOT	107	89.14	17.005	25.0	75.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	50	88.50	16.529	50.0	75.00	100.00	100.00	100.0			
	ADA	57	89.47	15.985	25.0	75.00	100.00	100.00	100.0			
	TOT	107	89.02	16.172	25.0	75.00	100.00	100.00	100.0			
CHG FROM BSL	PLO	50	-1.00	12.069	-37.5	0.00	0.00	0.00	37.5			
	ADA	57	0.66	14.832	-25.0	0.00	0.00	12.50	50.0			
	TOT	107	-0.12	13.574	-37.5	0.00	0.00	0.00	50.0			
										1.66	(-3.57, 6.89)	0.531A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.19.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS=0-1)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
MENTAL HEALTH												
BSL VALUE	PLO	50	67.00	23.455	6.3	50.00	75.00	87.50	100.0			
	ADA	57	64.00	24.634	0.0	50.00	68.75	81.25	93.8			
	TOT	107	65.40	24.024	0.0	50.00	75.00	83.33	100.0			
FINAL/ET VALUE	PLO	50	75.38	23.838	12.5	68.75	81.25	93.75	100.0			
	ADA	57	75.22	21.938	12.5	62.50	81.25	93.75	100.0			
	TOT	107	75.29	22.736	12.5	62.50	81.25	93.75	100.0			
CHG FROM BSL	PLO	50	8.38	13.280	-37.5	0.00	6.25	18.75	43.8			
	ADA	57	11.22	18.654	-25.0	0.00	12.50	18.75	62.5			
	TOT	107	9.89	16.352	-37.5	0.00	6.25	18.75	62.5			
										2.85	(-3.44, 9.13)	0.372A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.19.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS=0-1)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
ROLE DIFFICULTIES												
BSL VALUE	PLO	50	69.50	27.567	12.5	50.00	75.00	100.00	100.0			
	ADA	57	71.05	25.678	12.5	50.00	75.00	87.50	100.0			
	TOT	107	70.33	26.462	12.5	50.00	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	50	77.25	25.716	12.5	50.00	87.50	100.00	100.0			
	ADA	57	76.97	24.412	25.0	62.50	75.00	100.00	100.0			
	TOT	107	77.10	24.911	12.5	62.50	87.50	100.00	100.0			
CHG FROM BSL	PLO	50	7.75	21.708	-37.5	0.00	0.00	25.00	62.5			
	ADA	57	5.92	18.314	-37.5	0.00	0.00	12.50	62.5			
	TOT	107	6.78	19.897	-37.5	0.00	0.00	12.50	62.5			
										-1.83	(-9.50, 5.84)	0.637A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.19.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS=0-1)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DEPENDENCY												
BSL VALUE	PLO	50	85.00	23.268	16.7	75.00	100.00	100.00	100.0			
	ADA	57	85.82	22.601	8.3	75.00	100.00	100.00	100.0			
	TOT	107	85.44	22.810	8.3	75.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	50	87.50	22.541	0.0	83.33	100.00	100.00	100.0			
	ADA	57	86.70	20.159	8.3	75.00	100.00	100.00	100.0			
	TOT	107	87.07	21.207	0.0	83.33	100.00	100.00	100.0			
CHG FROM BSL	PLO	50	2.50	11.934	-41.7	0.00	0.00	8.33	41.7			
	ADA	57	0.88	16.493	-41.7	0.00	0.00	0.00	58.3			
	TOT	107	1.64	14.499	-41.7	0.00	0.00	0.00	58.3			
										-1.62	(-7.21, 3.97)	0.566A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.19.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS=0-1)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DRIVING												
BSL VALUE	PLO	39	72.22	27.462	0.0	66.67	83.33	91.67	100.0			
	ADA	39	61.75	35.289	0.0	41.67	66.67	91.67	100.0			
	TOT	78	66.99	31.851	0.0	50.00	83.33	91.67	100.0			
FINAL/ET VALUE	PLO	39	70.41	28.498	0.0	58.33	83.33	91.67	100.0			
	ADA	39	67.74	32.957	0.0	58.33	83.33	91.67	100.0			
	TOT	78	69.07	30.637	0.0	58.33	83.33	91.67	100.0			
CHG FROM BSL	PLO	39	-1.82	12.710	-33.3	-8.33	0.00	8.33	25.0			
	ADA	39	5.98	19.955	-41.7	0.00	0.00	16.67	100.0			
	TOT	78	2.08	17.078	-41.7	0.00	0.00	8.33	100.0			
										7.80	(0.25, 15.34)	0.043A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.19.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS=0-1)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
COLOR VISION												
BSL VALUE	PLO	50	93.50	14.115	50.0	100.00	100.00	100.00	100.0			
	ADA	56	96.43	10.032	50.0	100.00	100.00	100.00	100.0			
	TOT	106	95.05	12.160	50.0	100.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	50	94.50	12.667	50.0	100.00	100.00	100.00	100.0			
	ADA	56	95.09	12.079	50.0	100.00	100.00	100.00	100.0			
	TOT	106	94.81	12.304	50.0	100.00	100.00	100.00	100.0			
CHG FROM BSL	PLO	50	1.00	13.325	-25.0	0.00	0.00	0.00	50.0			
	ADA	56	-1.34	10.022	-50.0	0.00	0.00	0.00	25.0			
	TOT	106	-0.24	11.698	-50.0	0.00	0.00	0.00	50.0			
										-2.34	(-6.85, 2.17)	0.306A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.19.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS=0-1)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
PERIPHERAL VISION												
BSL VALUE	PLO	50	77.50	25.877	0.0	50.00	75.00	100.00	100.0			
	ADA	57	78.95	21.542	25.0	75.00	75.00	100.00	100.0			
	TOT	107	78.27	23.563	0.0	75.00	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	50	82.00	22.610	25.0	75.00	100.00	100.00	100.0			
	ADA	57	83.77	20.858	0.0	75.00	75.00	100.00	100.0			
	TOT	107	82.94	21.609	0.0	75.00	100.00	100.00	100.0			
CHG FROM BSL	PLO	50	4.50	18.688	-50.0	0.00	0.00	25.00	50.0			
	ADA	57	4.82	16.663	-25.0	0.00	0.00	25.00	50.0			
	TOT	107	4.67	17.554	-50.0	0.00	0.00	25.00	50.0			
										0.32	(-6.45, 7.10)	0.925A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.19.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS=0-1)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
TOTAL SCORE												
BSL VALUE	PLO	50	76.60	17.504	26.6	67.25	83.83	88.52	97.6			
	ADA	57	76.80	13.935	43.7	70.42	78.86	87.77	97.6			
	TOT	107	76.71	15.628	26.6	67.88	81.70	88.21	97.6			
FINAL/ET VALUE	PLO	50	80.63	16.994	31.7	70.53	86.48	94.96	100.0			
	ADA	57	80.73	16.686	12.4	71.67	84.43	92.77	100.0			
	TOT	107	80.68	16.751	12.4	70.80	85.49	93.64	100.0			
CHG FROM BSL	PLO	50	4.03	9.225	-28.0	-0.68	4.56	9.28	21.5			
	ADA	57	3.92	11.540	-31.3	-0.57	4.36	10.15	42.0			
	TOT	107	3.98	10.474	-31.3	-0.68	4.55	10.15	42.0			
										-0.11	(-4.15, 3.93)	0.957A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.20.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS=2)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL HEALTH												
BSL VALUE	PLO	44	56.82	27.154	0.0	37.50	50.00	75.00	100.0			
	ADA	46	57.61	20.323	25.0	50.00	50.00	75.00	100.0			
	TOT	90	57.22	23.775	0.0	50.00	50.00	75.00	100.0			
FINAL/ET VALUE	PLO	44	48.86	24.085	0.0	25.00	50.00	75.00	100.0			
	ADA	46	57.61	19.450	25.0	50.00	50.00	75.00	100.0			
	TOT	90	53.33	22.156	0.0	50.00	50.00	75.00	100.0			
CHG FROM BSL	PLO	44	-7.95	21.413	-75.0	-25.00	0.00	0.00	25.0			
	ADA	46	0.00	17.280	-25.0	0.00	0.00	0.00	50.0			
	TOT	90	-3.89	19.710	-75.0	-25.00	0.00	0.00	50.0			
										7.95	(-0.18, 16.09)	0.055A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.20.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS=2)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL VISION												
BSL VALUE	PLO	44	71.14	15.434	40.0	60.00	80.00	80.00	100.0			
	ADA	45	70.22	13.897	40.0	60.00	80.00	80.00	100.0			
	TOT	89	70.67	14.601	40.0	60.00	80.00	80.00	100.0			
FINAL/ET VALUE	PLO	44	63.18	18.773	20.0	40.00	60.00	80.00	100.0			
	ADA	45	71.33	16.733	20.0	60.00	80.00	80.00	100.0			
	TOT	89	67.30	18.139	20.0	60.00	70.00	80.00	100.0			
CHG FROM BSL	PLO	44	-7.95	18.118	-40.0	-20.00	0.00	0.00	40.0			
	ADA	45	1.11	14.805	-40.0	0.00	0.00	0.00	40.0			
	TOT	89	-3.37	17.052	-40.0	-20.00	0.00	0.00	40.0			
										9.07	(2.10, 16.03)	0.011A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.20.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS=2)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
OCULAR PAIN												
BSL VALUE	PLO	44	77.84	21.544	25.0	62.50	75.00	100.00	100.0			
	ADA	46	74.32	21.978	25.0	62.50	75.00	87.50	100.0			
	TOT	90	76.04	21.716	25.0	62.50	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	44	77.27	20.579	25.0	62.50	75.00	100.00	100.0			
	ADA	46	80.43	18.569	37.5	62.50	75.00	100.00	100.0			
	TOT	90	78.89	19.531	25.0	62.50	75.00	100.00	100.0			
CHG FROM BSL	PLO	44	-0.57	18.862	-50.0	0.00	0.00	6.25	62.5			
	ADA	46	6.11	23.881	-50.0	0.00	0.00	12.50	62.5			
	TOT	90	2.85	21.715	-50.0	0.00	0.00	12.50	62.5			
										6.68	(-2.36, 15.72)	0.145A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.20.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS=2)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
NEAR VISION												
BSL VALUE	PLO	44	72.06	23.597	12.5	62.50	75.00	91.67	100.0			
	ADA	46	75.00	22.754	8.3	58.33	75.00	91.67	100.0			
	TOT	90	73.56	23.087	8.3	58.33	75.00	91.67	100.0			
FINAL/ET VALUE	PLO	44	72.92	23.024	16.7	58.33	75.00	91.67	100.0			
	ADA	46	76.72	27.026	0.0	75.00	83.33	100.00	100.0			
	TOT	90	74.86	25.081	0.0	58.33	81.25	100.00	100.0			
CHG FROM BSL	PLO	44	0.85	19.053	-33.3	-8.33	0.00	8.33	62.5			
	ADA	46	1.72	21.545	-66.7	-8.33	0.00	16.67	41.7			
	TOT	90	1.30	20.256	-66.7	-8.33	0.00	8.33	62.5			
										0.87	(-7.67, 9.40)	0.840A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.20.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS=2)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DISTANCE VISION												
BSL VALUE	PLO	44	77.65	21.248	8.3	66.67	83.33	91.67	100.0			
	ADA	46	76.45	21.770	8.3	66.67	83.33	91.67	100.0			
	TOT	90	77.04	21.404	8.3	66.67	83.33	91.67	100.0			
FINAL/ET VALUE	PLO	44	74.43	23.666	8.3	58.33	75.00	95.83	100.0			
	ADA	46	77.72	25.823	0.0	66.67	87.50	100.00	100.0			
	TOT	90	76.11	24.708	0.0	58.33	83.33	100.00	100.0			
CHG FROM BSL	PLO	44	-3.22	14.624	-41.7	-8.33	0.00	8.33	25.0			
	ADA	46	1.27	15.438	-41.7	-8.33	0.00	8.33	41.7			
	TOT	90	-0.93	15.130	-41.7	-8.33	0.00	8.33	41.7			
										4.49	(-1.82, 10.79)	0.161A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.20.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS=2)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
SOCIAL FUNCTIONING												
BSL VALUE	PLO	44	90.63	15.748	37.5	87.50	100.00	100.00	100.0			
	ADA	46	87.23	21.326	0.0	75.00	100.00	100.00	100.0			
	TOT	90	88.89	18.780	0.0	87.50	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	44	89.91	14.840	50.0	75.00	100.00	100.00	100.0			
	ADA	46	88.18	20.079	25.0	87.50	100.00	100.00	100.0			
	TOT	90	89.03	17.636	25.0	75.00	100.00	100.00	100.0			
CHG FROM BSL	PLO	44	-0.71	13.494	-37.5	0.00	0.00	0.00	25.0			
	ADA	46	0.95	15.477	-50.0	0.00	0.00	6.25	25.0			
	TOT	90	0.14	14.484	-50.0	0.00	0.00	0.00	25.0			
										1.66	(-4.43, 7.76)	0.589A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.20.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS=2)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
MENTAL HEALTH												
BSL VALUE	PLO	44	68.13	19.955	12.5	50.00	71.88	87.50	100.0			
	ADA	46	68.48	20.154	12.5	56.25	71.88	81.25	100.0			
	TOT	90	68.31	19.945	12.5	56.25	71.88	81.25	100.0			
FINAL/ET VALUE	PLO	44	66.90	23.793	18.8	50.00	75.00	87.50	100.0			
	ADA	46	75.54	25.407	12.5	62.50	84.38	93.75	100.0			
	TOT	90	71.32	24.875	12.5	50.00	75.00	93.75	100.0			
CHG FROM BSL	PLO	44	-1.23	20.399	-43.8	-15.63	0.00	12.50	37.5			
	ADA	46	7.07	16.224	-37.5	0.00	6.25	12.50	37.5			
	TOT	90	3.01	18.749	-43.8	-6.25	6.25	12.50	37.5			
										8.30	(0.59, 16.00)	0.035A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.20.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS=2)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
ROLE DIFFICULTIES												
BSL VALUE	PLO	44	70.45	23.205	12.5	50.00	75.00	100.00	100.0			
	ADA	46	68.48	27.606	12.5	50.00	75.00	100.00	100.0			
	TOT	90	69.44	25.426	12.5	50.00	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	44	67.33	26.028	25.0	50.00	75.00	93.75	100.0			
	ADA	46	78.26	23.487	25.0	62.50	87.50	100.00	100.0			
	TOT	90	72.92	25.227	25.0	50.00	75.00	100.00	100.0			
CHG FROM BSL	PLO	44	-3.13	19.276	-50.0	-12.50	0.00	12.50	50.0			
	ADA	46	9.78	22.656	-37.5	0.00	0.00	25.00	75.0			
	TOT	90	3.47	21.935	-50.0	0.00	0.00	12.50	75.0			
										12.91	(4.08, 21.74)	0.005A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.20.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS=2)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DEPENDENCY												
BSL VALUE	PLO	43	85.95	22.420	0.0	83.33	91.67	100.00	100.0			
	ADA	46	84.42	23.935	8.3	83.33	91.67	100.00	100.0			
	TOT	89	85.16	23.096	0.0	83.33	91.67	100.00	100.0			
FINAL/ET VALUE	PLO	43	82.75	25.678	0.0	75.00	100.00	100.00	100.0			
	ADA	46	86.59	23.797	16.7	83.33	100.00	100.00	100.0			
	TOT	89	84.74	24.658	0.0	83.33	100.00	100.00	100.0			
CHG FROM BSL	PLO	43	-3.20	17.627	-58.3	-8.33	0.00	0.00	33.3			
	ADA	46	2.17	15.559	-50.0	0.00	0.00	8.33	50.0			
	TOT	89	-0.42	16.714	-58.3	0.00	0.00	8.33	50.0			
										5.37	(-1.62, 12.37)	0.131A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.20.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS=2)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DRIVING												
BSL VALUE	PLO	39	70.09	30.090	0.0	50.00	83.33	91.67	100.0			
	ADA	34	72.06	33.279	0.0	66.67	83.33	91.67	100.0			
	TOT	73	71.00	31.407	0.0	58.33	83.33	91.67	100.0			
FINAL/ET VALUE	PLO	39	64.53	29.180	0.0	50.00	70.83	83.33	100.0			
	ADA	34	73.90	30.624	0.0	66.67	83.33	100.00	100.0			
	TOT	73	68.89	30.023	0.0	58.33	75.00	91.67	100.0			
CHG FROM BSL	PLO	39	-5.56	17.841	-41.7	-8.33	0.00	0.00	66.7			
	ADA	34	1.84	22.711	-33.3	-8.33	0.00	8.33	100.0			
	TOT	73	-2.11	20.449	-41.7	-8.33	0.00	0.00	100.0			
										7.39	(-2.08, 16.87)	0.124A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.20.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS=2)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
COLOR VISION												
BSL VALUE	PLO	43	86.05	22.693	25.0	75.00	100.00	100.00	100.0			
	ADA	46	94.02	15.973	25.0	100.00	100.00	100.00	100.0			
	TOT	89	90.17	19.807	25.0	100.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	43	87.79	19.189	25.0	75.00	100.00	100.00	100.0			
	ADA	46	92.66	20.846	0.0	100.00	100.00	100.00	100.0			
	TOT	89	90.31	20.099	0.0	100.00	100.00	100.00	100.0			
CHG FROM BSL	PLO	43	1.74	14.836	-50.0	0.00	0.00	0.00	25.0			
	ADA	46	-1.36	14.001	-50.0	0.00	0.00	0.00	50.0			
	TOT	89	0.14	14.413	-50.0	0.00	0.00	0.00	50.0			
										-3.10	(-9.18, 2.97)	0.313A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.20.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS=2)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
PERIPHERAL VISION												
BSL VALUE	PLO	42	78.57	22.477	25.0	75.00	75.00	100.00	100.0			
	ADA	44	80.11	25.046	0.0	62.50	100.00	100.00	100.0			
	TOT	86	79.36	23.699	0.0	75.00	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	42	82.44	20.854	25.0	75.00	81.25	100.00	100.0			
	ADA	44	82.95	22.081	25.0	75.00	100.00	100.00	100.0			
	TOT	86	82.70	21.366	25.0	75.00	100.00	100.00	100.0			
CHG FROM BSL	PLO	42	3.87	19.224	-25.0	0.00	0.00	25.00	50.0			
	ADA	44	2.84	20.329	-50.0	0.00	0.00	25.00	50.0			
	TOT	86	3.34	19.687	-50.0	0.00	0.00	25.00	50.0			
										-1.03	(-9.52, 7.46)	0.810A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.20.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS=2)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
TOTAL SCORE												
BSL VALUE	PLO	44	77.01	16.742	25.3	67.01	82.69	90.45	95.5			
	ADA	46	77.27	16.690	15.4	70.87	80.65	88.52	99.4			
	TOT	90	77.15	16.622	15.4	70.87	81.73	90.23	99.4			
FINAL/ET VALUE	PLO	44	75.43	17.196	27.9	63.64	77.71	89.00	99.6			
	ADA	46	80.30	18.960	25.0	73.83	87.67	92.50	100.0			
	TOT	90	77.92	18.184	25.0	66.42	85.02	90.98	100.0			
CHG FROM BSL	PLO	44	-1.59	11.931	-30.9	-7.50	0.24	3.09	29.4			
	ADA	46	3.03	11.461	-30.8	-0.83	3.73	9.58	24.4			
	TOT	90	0.77	11.857	-30.9	-4.19	1.86	6.17	29.4			
										4.62	(-0.28, 9.52)	0.064A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.21.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS>=3)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL HEALTH												
BSL VALUE	PLO	31	50.81	25.400	0.0	25.00	50.00	75.00	100.0			
	ADA	28	60.71	19.754	25.0	50.00	50.00	75.00	100.0			
	TOT	59	55.51	23.243	0.0	50.00	50.00	75.00	100.0			
FINAL/ET VALUE	PLO	31	50.81	25.400	0.0	50.00	50.00	75.00	100.0			
	ADA	28	59.82	25.765	0.0	50.00	62.50	75.00	100.0			
	TOT	59	55.08	25.756	0.0	50.00	50.00	75.00	100.0			
CHG FROM BSL	PLO	31	0.00	12.910	-25.0	0.00	0.00	0.00	25.0			
	ADA	28	-0.89	20.952	-50.0	-25.00	0.00	25.00	25.0			
	TOT	59	-0.42	17.052	-50.0	0.00	0.00	0.00	25.0			
										-0.89	(-9.87, 8.08)	0.843A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.21.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS>=3)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL VISION												
BSL VALUE	PLO	31	66.45	20.904	40.0	40.00	60.00	80.00	100.0			
	ADA	28	68.57	15.803	40.0	60.00	60.00	80.00	100.0			
	TOT	59	67.46	18.532	40.0	60.00	60.00	80.00	100.0			
FINAL/ET VALUE	PLO	31	58.71	22.471	20.0	40.00	60.00	80.00	100.0			
	ADA	28	63.57	24.376	20.0	40.00	60.00	80.00	100.0			
	TOT	59	61.02	23.319	20.0	40.00	60.00	80.00	100.0			
CHG FROM BSL	PLO	31	-7.74	12.304	-40.0	-20.00	0.00	0.00	20.0			
	ADA	28	-5.00	18.559	-40.0	-20.00	0.00	0.00	40.0			
	TOT	59	-6.44	15.510	-40.0	-20.00	0.00	0.00	40.0			
										2.74	(-5.39, 10.88)	0.502A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.21.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS>=3)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
OCULAR PAIN												
BSL VALUE	PLO	31	74.19	23.259	12.5	50.00	75.00	100.00	100.0			
	ADA	28	85.27	17.365	50.0	75.00	87.50	100.00	100.0			
	TOT	59	79.45	21.244	12.5	62.50	87.50	100.00	100.0			
FINAL/ET VALUE	PLO	31	75.00	21.164	25.0	50.00	75.00	100.00	100.0			
	ADA	28	82.59	20.224	37.5	68.75	87.50	100.00	100.0			
	TOT	59	78.60	20.897	25.0	62.50	75.00	100.00	100.0			
CHG FROM BSL	PLO	31	0.81	15.790	-25.0	-12.50	0.00	0.00	50.0			
	ADA	28	-2.68	20.513	-50.0	-12.50	0.00	6.25	50.0			
	TOT	59	-0.85	18.109	-50.0	-12.50	0.00	0.00	50.0			
										-3.49	(-12.98, 6.01)	0.465A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.21.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS>=3)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
NEAR VISION												
BSL VALUE	PLO	31	68.28	29.924	0.0	50.00	75.00	91.67	100.0			
	ADA	28	75.89	21.676	25.0	66.67	79.17	95.83	100.0			
	TOT	59	71.89	26.393	0.0	50.00	75.00	91.67	100.0			
FINAL/ET VALUE	PLO	31	68.68	23.542	25.0	50.00	66.67	91.67	100.0			
	ADA	28	75.30	28.007	0.0	62.50	83.33	100.00	100.0			
	TOT	59	71.82	25.747	0.0	50.00	75.00	100.00	100.0			
CHG FROM BSL	PLO	31	0.40	14.124	-33.3	-8.33	0.00	8.33	33.3			
	ADA	28	-0.60	20.529	-58.3	-8.33	0.00	8.33	50.0			
	TOT	59	-0.07	17.310	-58.3	-8.33	0.00	8.33	50.0			
										-1.00	(-10.11, 8.11)	0.827A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.21.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS>=3)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DISTANCE VISION												
BSL VALUE	PLO	31	68.28	25.587	25.0	41.67	66.67	91.67	100.0			
	ADA	28	75.30	19.964	33.3	62.50	75.00	95.83	100.0			
	TOT	59	71.61	23.166	25.0	50.00	75.00	91.67	100.0			
FINAL/ET VALUE	PLO	31	67.74	22.100	16.7	50.00	66.67	83.33	100.0			
	ADA	28	77.38	24.934	16.7	58.33	83.33	100.00	100.0			
	TOT	59	72.32	23.782	16.7	58.33	75.00	91.67	100.0			
CHG FROM BSL	PLO	31	-0.54	14.543	-25.0	-8.33	0.00	4.17	41.7			
	ADA	28	2.08	16.609	-25.0	-12.50	0.00	12.50	41.7			
	TOT	59	0.71	15.478	-25.0	-8.33	0.00	8.33	41.7			
										2.62	(-5.50, 10.74)	0.521A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.21.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS>=3)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
SOCIAL FUNCTIONING												
BSL VALUE	PLO	31	79.84	21.573	37.5	62.50	75.00	100.00	100.0			
	ADA	28	87.05	19.977	25.0	81.25	100.00	100.00	100.0			
	TOT	59	83.26	20.969	25.0	75.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	31	78.63	25.909	6.3	62.50	87.50	100.00	100.0			
	ADA	28	87.50	21.784	12.5	81.25	100.00	100.00	100.0			
	TOT	59	82.84	24.250	6.3	75.00	100.00	100.00	100.0			
CHG FROM BSL	PLO	31	-1.21	14.650	-43.8	-12.50	0.00	0.00	37.5			
	ADA	28	0.45	12.492	-25.0	0.00	0.00	0.00	37.5			
	TOT	59	-0.42	13.578	-43.8	-6.25	0.00	0.00	37.5			
										1.66	(-5.48, 8.79)	0.644A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.21.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS>=3)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
MENTAL HEALTH												
BSL VALUE	PLO	31	53.83	28.717	0.0	31.25	56.25	81.25	93.8			
	ADA	28	64.58	24.395	0.0	53.13	68.75	84.38	93.8			
	TOT	59	58.93	27.072	0.0	37.50	62.50	81.25	93.8			
FINAL/ET VALUE	PLO	31	59.68	31.243	0.0	37.50	62.50	93.75	100.0			
	ADA	28	74.11	26.282	0.0	59.38	81.25	93.75	100.0			
	TOT	59	66.53	29.652	0.0	50.00	68.75	93.75	100.0			
CHG FROM BSL	PLO	31	5.85	19.891	-56.3	-6.25	6.25	12.50	68.8			
	ADA	28	9.52	19.373	-37.5	0.00	12.50	18.75	43.8			
	TOT	59	7.59	19.565	-56.3	0.00	6.25	12.50	68.8			
										3.68	(-6.58, 13.93)	0.476A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.21.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS>=3)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
ROLE DIFFICULTIES												
BSL VALUE	PLO	31	62.10	28.226	0.0	37.50	50.00	87.50	100.0			
	ADA	28	70.54	25.733	0.0	50.00	75.00	87.50	100.0			
	TOT	59	66.10	27.174	0.0	50.00	75.00	87.50	100.0			
FINAL/ET VALUE	PLO	31	62.90	32.353	0.0	37.50	50.00	100.00	100.0			
	ADA	28	75.00	29.067	0.0	56.25	75.00	100.00	100.0			
	TOT	59	68.64	31.174	0.0	50.00	75.00	100.00	100.0			
CHG FROM BSL	PLO	31	0.81	21.875	-62.5	0.00	0.00	12.50	62.5			
	ADA	28	4.46	23.866	-50.0	-6.25	0.00	12.50	62.5			
	TOT	59	2.54	22.717	-62.5	0.00	0.00	12.50	62.5			
										3.66	(-8.27, 15.58)	0.541A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.21.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS>=3)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DEPENDENCY												
BSL VALUE	PLO	31	72.04	33.163	0.0	50.00	91.67	100.00	100.0			
	ADA	28	86.90	19.698	25.0	75.00	100.00	100.00	100.0			
	TOT	59	79.10	28.381	0.0	58.33	91.67	100.00	100.0			
FINAL/ET VALUE	PLO	31	74.19	31.502	8.3	50.00	91.67	100.00	100.0			
	ADA	28	87.80	23.294	8.3	83.33	100.00	100.00	100.0			
	TOT	59	80.65	28.510	8.3	58.33	100.00	100.00	100.0			
CHG FROM BSL	PLO	31	2.15	22.768	-83.3	0.00	0.00	8.33	75.0			
	ADA	28	0.89	19.423	-50.0	0.00	0.00	4.17	50.0			
	TOT	59	1.55	21.075	-83.3	0.00	0.00	8.33	75.0			
										-1.26	(-12.35, 9.84)	0.821A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.21.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS>=3)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DRIVING												
BSL VALUE	PLO	26	65.71	27.037	0.0	58.33	64.58	91.67	100.0			
	ADA	27	75.31	27.685	0.0	66.67	83.33	100.00	100.0			
	TOT	53	70.60	27.535	0.0	58.33	75.00	91.67	100.0			
FINAL/ET VALUE	PLO	26	63.78	25.570	0.0	50.00	72.92	83.33	100.0			
	ADA	27	68.67	32.179	0.0	58.33	79.17	100.00	100.0			
	TOT	53	66.27	28.951	0.0	50.00	75.00	83.33	100.0			
CHG FROM BSL	PLO	26	-1.92	15.331	-33.3	-12.50	0.00	8.33	25.0			
	ADA	27	-6.64	19.415	-58.3	-16.67	0.00	0.00	41.7			
	TOT	53	-4.32	17.525	-58.3	-16.67	0.00	0.00	41.7			
										-4.71	(-14.38, 4.96)	0.333A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.21.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS>=3)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
COLOR VISION												
BSL VALUE	PLO	30	89.17	16.973	50.0	75.00	100.00	100.00	100.0			
	ADA	28	91.07	18.276	50.0	100.00	100.00	100.00	100.0			
	TOT	58	90.09	17.484	50.0	75.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	30	87.92	16.893	50.0	75.00	100.00	100.00	100.0			
	ADA	28	92.86	19.072	25.0	100.00	100.00	100.00	100.0			
	TOT	58	90.30	17.992	25.0	75.00	100.00	100.00	100.0			
CHG FROM BSL	PLO	30	-1.25	10.561	-25.0	0.00	0.00	0.00	25.0			
	ADA	28	1.79	13.486	-25.0	0.00	0.00	0.00	50.0			
	TOT	58	0.22	12.051	-25.0	0.00	0.00	0.00	50.0			
										3.04	(-3.31, 9.38)	0.342A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.21.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS>=3)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
PERIPHERAL VISION												
BSL VALUE	PLO	31	69.35	25.585	25.0	50.00	50.00	100.00	100.0			
	ADA	28	79.46	22.622	25.0	62.50	75.00	100.00	100.0			
	TOT	59	74.15	24.550	25.0	50.00	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	31	74.19	21.635	25.0	50.00	75.00	100.00	100.0			
	ADA	28	78.57	29.435	25.0	50.00	100.00	100.00	100.0			
	TOT	59	76.27	25.501	25.0	50.00	75.00	100.00	100.0			
CHG FROM BSL	PLO	31	4.84	19.546	-25.0	0.00	0.00	25.00	50.0			
	ADA	28	-0.89	24.039	-75.0	-12.50	0.00	12.50	50.0			
	TOT	59	2.12	21.794	-75.0	0.00	0.00	25.00	50.0			
										-5.73	(-17.11, 5.64)	0.317A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.21.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS>=3)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
TOTAL SCORE												
BSL VALUE	PLO	31	69.71	20.086	40.3	49.28	70.87	89.36	96.0			
	ADA	28	78.19	16.463	35.5	71.14	81.36	89.94	98.9			
	TOT	59	73.74	18.790	35.5	55.27	78.92	89.36	98.9			
FINAL/ET VALUE	PLO	31	69.48	20.301	28.7	46.75	70.98	87.46	97.7			
	ADA	28	78.26	21.504	20.4	64.64	86.61	93.30	100.0			
	TOT	59	73.65	21.166	20.4	54.51	81.63	91.93	100.0			
CHG FROM BSL	PLO	31	-0.23	7.897	-20.6	-6.74	0.00	4.55	19.3			
	ADA	28	0.07	13.778	-33.6	-3.56	1.99	7.45	37.0			
	TOT	59	-0.09	10.984	-33.6	-5.98	0.57	5.19	37.0			
										0.31	(-5.48, 6.09)	0.916A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.22.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TIME SINCE LAST FLARE < 6 MONTHS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL HEALTH												
BSL VALUE	PLO	88	50.00	23.973	0.0	25.00	50.00	75.00	100.0			
	ADA	84	56.55	19.833	0.0	50.00	50.00	75.00	100.0			
	TOT	172	53.20	22.228	0.0	50.00	50.00	75.00	100.0			
FINAL/ET VALUE	PLO	88	49.72	23.518	0.0	25.00	50.00	75.00	100.0			
	ADA	84	57.14	22.735	0.0	50.00	50.00	75.00	100.0			
	TOT	172	53.34	23.370	0.0	50.00	50.00	75.00	100.0			
CHG FROM BSL	PLO	88	-0.28	17.978	-50.0	0.00	0.00	0.00	50.0			
	ADA	84	0.60	20.062	-50.0	-12.50	0.00	25.00	50.0			
	TOT	172	0.15	18.973	-50.0	0.00	0.00	6.25	50.0			
										0.88	(-4.85, 6.61)	0.762A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.22.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TIME SINCE LAST FLARE < 6 MONTHS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL VISION												
BSL VALUE	PLO	88	67.61	18.131	20.0	60.00	80.00	80.00	100.0			
	ADA	84	67.62	15.493	40.0	60.00	60.00	80.00	100.0			
	TOT	172	67.62	16.845	20.0	60.00	60.00	80.00	100.0			
FINAL/ET VALUE	PLO	88	61.82	20.031	20.0	40.00	60.00	80.00	100.0			
	ADA	84	67.98	20.107	20.0	60.00	80.00	80.00	100.0			
	TOT	172	64.83	20.246	20.0	60.00	60.00	80.00	100.0			
CHG FROM BSL	PLO	88	-5.80	16.451	-40.0	-20.00	0.00	0.00	40.0			
	ADA	84	0.36	17.177	-40.0	0.00	0.00	5.00	40.0			
	TOT	172	-2.79	17.041	-40.0	-20.00	0.00	0.00	40.0			
										6.15	(1.09, 11.21)	0.017A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.22.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TIME SINCE LAST FLARE < 6 MONTHS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
OCULAR PAIN												
BSL VALUE	PLO	88	73.44	23.959	12.5	62.50	75.00	100.00	100.0			
	ADA	84	78.65	21.393	25.0	62.50	87.50	100.00	100.0			
	TOT	172	75.98	22.826	12.5	62.50	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	88	76.42	21.395	25.0	62.50	75.00	100.00	100.0			
	ADA	84	80.65	20.572	12.5	62.50	87.50	100.00	100.0			
	TOT	172	78.49	21.043	12.5	62.50	75.00	100.00	100.0			
CHG FROM BSL	PLO	88	2.98	18.178	-50.0	0.00	0.00	12.50	62.5			
	ADA	84	2.01	21.956	-50.0	-12.50	0.00	12.50	62.5			
	TOT	172	2.51	20.059	-50.0	0.00	0.00	12.50	62.5			
										-0.97	(-7.03, 5.08)	0.751A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.22.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TIME SINCE LAST FLARE < 6 MONTHS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
NEAR VISION												
BSL VALUE	PLO	88	69.37	25.771	0.0	58.33	75.00	91.67	100.0			
	ADA	84	76.39	21.435	8.3	62.50	79.17	91.67	100.0			
	TOT	172	72.80	23.944	0.0	58.33	75.00	91.67	100.0			
FINAL/ET VALUE	PLO	88	72.11	22.982	16.7	58.33	75.00	91.67	100.0			
	ADA	84	78.22	24.877	0.0	70.83	83.33	100.00	100.0			
	TOT	172	75.10	24.052	0.0	58.33	83.33	100.00	100.0			
CHG FROM BSL	PLO	88	2.75	17.800	-33.3	-8.33	0.00	8.33	75.0			
	ADA	84	1.84	22.733	-75.0	-8.33	0.00	16.67	50.0			
	TOT	172	2.30	20.304	-75.0	-8.33	0.00	8.33	75.0			
										-0.91	(-7.04, 5.22)	0.770A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.22.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TIME SINCE LAST FLARE < 6 MONTHS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DISTANCE VISION												
BSL VALUE	PLO	88	72.63	23.670	8.3	50.00	83.33	91.67	100.0			
	ADA	84	75.15	21.388	8.3	66.67	75.00	91.67	100.0			
	TOT	172	73.86	22.554	8.3	58.33	79.17	91.67	100.0			
FINAL/ET VALUE	PLO	88	72.25	23.382	8.3	58.33	75.00	91.67	100.0			
	ADA	84	77.28	24.109	0.0	62.50	83.33	100.00	100.0			
	TOT	172	74.71	23.804	0.0	58.33	83.33	91.67	100.0			
CHG FROM BSL	PLO	88	-0.38	16.650	-41.7	-8.33	0.00	8.33	50.0			
	ADA	84	2.13	17.766	-50.0	-6.25	0.00	8.33	75.0			
	TOT	172	0.85	17.200	-50.0	-8.33	0.00	8.33	75.0			
										2.51	(-2.67, 7.69)	0.340A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.22.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TIME SINCE LAST FLARE < 6 MONTHS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
SOCIAL FUNCTIONING												
BSL VALUE	PLO	88	85.65	19.562	37.5	75.00	100.00	100.00	100.0			
	ADA	84	87.20	19.108	0.0	75.00	100.00	100.00	100.0			
	TOT	172	86.41	19.301	0.0	75.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	88	84.16	20.608	6.3	75.00	93.75	100.00	100.0			
	ADA	84	88.17	18.713	25.0	75.00	100.00	100.00	100.0			
	TOT	172	86.12	19.750	6.3	75.00	100.00	100.00	100.0			
CHG FROM BSL	PLO	88	-1.49	14.023	-43.8	-12.50	0.00	0.00	37.5			
	ADA	84	0.97	14.633	-50.0	0.00	0.00	3.13	50.0			
	TOT	172	-0.29	14.336	-50.0	0.00	0.00	0.00	50.0			
										2.46	(-1.85, 6.77)	0.262A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.22.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TIME SINCE LAST FLARE < 6 MONTHS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
MENTAL HEALTH												
BSL VALUE	PLO	88	61.62	25.642	0.0	43.75	68.75	81.25	93.8			
	ADA	84	66.47	22.130	0.0	53.13	71.88	81.25	100.0			
	TOT	172	63.99	24.044	0.0	43.75	68.75	81.25	100.0			
FINAL/ET VALUE	PLO	88	64.20	27.866	0.0	43.75	71.88	87.50	100.0			
	ADA	84	75.74	23.394	12.5	62.50	81.25	93.75	100.0			
	TOT	172	69.84	26.347	0.0	50.00	75.00	93.75	100.0			
CHG FROM BSL	PLO	88	2.58	18.926	-56.3	-6.25	6.25	12.50	50.0			
	ADA	84	9.28	17.987	-37.5	0.00	12.50	18.75	62.5			
	TOT	172	5.85	18.723	-56.3	-3.13	6.25	18.75	62.5			
										6.70	(1.13, 12.26)	0.019A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.22.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TIME SINCE LAST FLARE < 6 MONTHS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
ROLE DIFFICULTIES												
BSL VALUE	PLO	88	67.05	27.280	0.0	50.00	75.00	100.00	100.0			
	ADA	84	70.09	25.375	12.5	50.00	75.00	87.50	100.0			
	TOT	172	68.53	26.334	0.0	50.00	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	88	66.34	29.505	0.0	43.75	68.75	100.00	100.0			
	ADA	84	77.38	23.242	25.0	62.50	75.00	100.00	100.0			
	TOT	172	71.73	27.125	0.0	50.00	75.00	100.00	100.0			
CHG FROM BSL	PLO	88	-0.71	19.454	-62.5	-12.50	0.00	12.50	50.0			
	ADA	84	7.29	21.885	-50.0	0.00	0.00	25.00	75.0			
	TOT	172	3.20	21.002	-62.5	0.00	0.00	12.50	75.0			
										8.00	(1.78, 14.23)	0.012A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.22.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TIME SINCE LAST FLARE < 6 MONTHS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DEPENDENCY												
BSL VALUE	PLO	87	79.84	27.211	0.0	66.67	91.67	100.00	100.0			
	ADA	84	85.42	21.564	8.3	79.17	100.00	100.00	100.0			
	TOT	171	82.58	24.686	0.0	75.00	91.67	100.00	100.0			
FINAL/ET VALUE	PLO	87	78.93	28.326	0.0	58.33	91.67	100.00	100.0			
	ADA	84	87.70	19.850	16.7	83.33	100.00	100.00	100.0			
	TOT	171	83.24	24.852	0.0	75.00	100.00	100.00	100.0			
CHG FROM BSL	PLO	87	-0.91	17.705	-83.3	0.00	0.00	8.33	33.3			
	ADA	84	2.28	17.276	-50.0	0.00	0.00	8.33	58.3			
	TOT	171	0.66	17.517	-83.3	0.00	0.00	8.33	58.3			
										3.19	(-2.09, 8.47)	0.235A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.22.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TIME SINCE LAST FLARE < 6 MONTHS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DRIVING												
BSL VALUE	PLO	73	70.21	27.679	0.0	58.33	83.33	91.67	100.0			
	ADA	66	73.42	29.902	0.0	66.67	83.33	91.67	100.0			
	TOT	139	71.73	28.696	0.0	58.33	83.33	91.67	100.0			
FINAL/ET VALUE	PLO	73	64.90	27.180	0.0	50.00	75.00	83.33	100.0			
	ADA	66	72.98	28.953	0.0	66.67	83.33	100.00	100.0			
	TOT	139	68.74	28.226	0.0	58.33	75.00	91.67	100.0			
CHG FROM BSL	PLO	73	-5.31	14.571	-41.7	-16.67	0.00	0.00	25.0			
	ADA	66	-0.44	19.600	-58.3	-8.33	0.00	0.00	100.0			
	TOT	139	-3.00	17.253	-58.3	-8.33	0.00	0.00	100.0			
										4.87	(-0.89, 10.62)	0.097A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.22.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TIME SINCE LAST FLARE < 6 MONTHS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
COLOR VISION												
BSL VALUE	PLO	86	87.50	20.201	25.0	75.00	100.00	100.00	100.0			
	ADA	83	93.98	15.416	25.0	100.00	100.00	100.00	100.0			
	TOT	169	90.68	18.249	25.0	100.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	86	87.94	18.235	25.0	75.00	100.00	100.00	100.0			
	ADA	83	93.83	17.282	0.0	100.00	100.00	100.00	100.0			
	TOT	169	90.83	17.965	0.0	87.50	100.00	100.00	100.0			
CHG FROM BSL	PLO	86	0.44	13.346	-50.0	0.00	0.00	0.00	25.0			
	ADA	83	-0.15	11.793	-50.0	0.00	0.00	0.00	50.0			
	TOT	169	0.15	12.573	-50.0	0.00	0.00	0.00	50.0			
										-0.59	(-4.42, 3.24)	0.763A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.22.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TIME SINCE LAST FLARE < 6 MONTHS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
PERIPHERAL VISION												
BSL VALUE	PLO	86	74.42	23.632	25.0	50.00	75.00	100.00	100.0			
	ADA	82	78.96	24.046	0.0	50.00	75.00	100.00	100.0			
	TOT	168	76.64	23.873	0.0	50.00	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	86	78.05	22.107	25.0	75.00	75.00	100.00	100.0			
	ADA	82	82.32	23.402	0.0	75.00	100.00	100.00	100.0			
	TOT	168	80.13	22.781	0.0	75.00	75.00	100.00	100.0			
CHG FROM BSL	PLO	86	3.63	19.352	-50.0	0.00	0.00	25.00	50.0			
	ADA	82	3.35	20.322	-75.0	0.00	0.00	25.00	50.0			
	TOT	168	3.50	19.773	-75.0	0.00	0.00	25.00	50.0			
										-0.28	(-6.32, 5.76)	0.927A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.22.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TIME SINCE LAST FLARE < 6 MONTHS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
TOTAL SCORE												
BSL VALUE	PLO	88	73.41	19.061	25.3	57.95	78.75	89.47	97.6			
	ADA	84	77.44	15.524	15.4	70.63	80.17	88.81	99.4			
	TOT	172	75.38	17.490	15.4	66.11	80.12	88.90	99.4			
FINAL/ET VALUE	PLO	88	73.25	19.432	27.9	59.19	74.55	90.74	100.0			
	ADA	84	79.97	18.180	12.4	71.02	85.87	92.41	100.0			
	TOT	172	76.53	19.076	12.4	64.02	81.88	92.13	100.0			
CHG FROM BSL	PLO	88	-0.17	10.657	-30.9	-6.40	1.43	5.33	29.4			
	ADA	84	2.53	12.615	-33.6	-2.08	3.66	9.43	42.0			
	TOT	172	1.15	11.698	-33.6	-3.22	2.41	7.32	42.0			
										2.69	(-0.81, 6.20)	0.131A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.23.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TIME SINCE LAST FLARE >= 6 MONTHS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL HEALTH												
BSL VALUE	PLO	37	58.78	27.774	0.0	25.00	50.00	75.00	100.0			
	ADA	47	56.91	24.284	25.0	50.00	50.00	75.00	100.0			
	TOT	84	57.74	25.735	0.0	37.50	50.00	75.00	100.0			
FINAL/ET VALUE	PLO	37	55.74	22.935	0.0	50.00	50.00	75.00	100.0			
	ADA	47	54.26	26.230	0.0	25.00	50.00	75.00	100.0			
	TOT	84	54.91	24.698	0.0	50.00	50.00	75.00	100.0			
CHG FROM BSL	PLO	37	-3.04	21.531	-75.0	-25.00	0.00	0.00	25.0			
	ADA	47	-2.66	21.003	-50.0	-25.00	0.00	0.00	50.0			
	TOT	84	-2.83	21.109	-75.0	-25.00	0.00	0.00	50.0			
										0.38	(-8.90, 9.67)	0.935A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.23.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TIME SINCE LAST FLARE >= 6 MONTHS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL VISION												
BSL VALUE	PLO	37	68.65	12.945	40.0	60.00	60.00	80.00	100.0			
	ADA	46	67.39	15.977	40.0	60.00	60.00	80.00	100.0			
	TOT	83	67.95	14.630	40.0	60.00	60.00	80.00	100.0			
FINAL/ET VALUE	PLO	37	69.73	13.842	40.0	60.00	80.00	80.00	100.0			
	ADA	46	73.04	16.980	20.0	60.00	80.00	80.00	100.0			
	TOT	83	71.57	15.655	20.0	60.00	80.00	80.00	100.0			
CHG FROM BSL	PLO	37	1.08	13.288	-20.0	0.00	0.00	0.00	20.0			
	ADA	46	5.65	13.107	-20.0	0.00	0.00	20.00	40.0			
	TOT	83	3.61	13.305	-20.0	0.00	0.00	20.00	40.0			
										4.57	(-1.22, 10.37)	0.120A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.23.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TIME SINCE LAST FLARE >= 6 MONTHS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
OCULAR PAIN												
BSL VALUE	PLO	37	82.09	18.291	50.0	62.50	87.50	100.00	100.0			
	ADA	47	78.46	19.277	25.0	62.50	75.00	100.00	100.0			
	TOT	84	80.06	18.825	25.0	62.50	87.50	100.00	100.0			
FINAL/ET VALUE	PLO	37	83.78	18.130	50.0	75.00	87.50	100.00	100.0			
	ADA	47	80.85	20.164	37.5	75.00	75.00	100.00	100.0			
	TOT	84	82.14	19.237	37.5	75.00	81.25	100.00	100.0			
CHG FROM BSL	PLO	37	1.69	15.355	-50.0	0.00	0.00	12.50	37.5			
	ADA	47	2.39	21.436	-62.5	-12.50	0.00	12.50	50.0			
	TOT	84	2.08	18.896	-62.5	0.00	0.00	12.50	50.0			
										0.70	(-7.61, 9.01)	0.867A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.23.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TIME SINCE LAST FLARE >= 6 MONTHS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
NEAR VISION												
BSL VALUE	PLO	37	76.58	20.772	16.7	66.67	75.00	91.67	100.0			
	ADA	47	74.47	20.663	25.0	58.33	75.00	91.67	100.0			
	TOT	84	75.40	20.612	16.7	62.50	75.00	91.67	100.0			
FINAL/ET VALUE	PLO	37	82.66	18.465	33.3	75.00	83.33	100.00	100.0			
	ADA	47	79.26	24.132	8.3	75.00	83.33	100.00	100.0			
	TOT	84	80.75	21.761	8.3	75.00	83.33	100.00	100.0			
CHG FROM BSL	PLO	37	6.08	15.547	-33.3	0.00	8.33	16.67	50.0			
	ADA	47	4.79	15.806	-41.7	-8.33	0.00	16.67	41.7			
	TOT	84	5.36	15.611	-41.7	0.00	0.00	16.67	50.0			
										-1.29	(-8.15, 5.57)	0.709A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.23.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TIME SINCE LAST FLARE >= 6 MONTHS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DISTANCE VISION												
BSL VALUE	PLO	37	77.48	22.895	16.7	66.67	83.33	100.00	100.0			
	ADA	47	76.51	19.648	33.3	58.33	83.33	91.67	100.0			
	TOT	84	76.93	21.013	16.7	62.50	83.33	91.67	100.0			
FINAL/ET VALUE	PLO	37	80.41	20.527	33.3	66.67	83.33	100.00	100.0			
	ADA	47	80.94	22.535	16.7	75.00	91.67	100.00	100.0			
	TOT	84	80.70	21.547	16.7	66.67	91.67	100.00	100.0			
CHG FROM BSL	PLO	37	2.93	14.193	-25.0	0.00	0.00	8.33	50.0			
	ADA	47	4.43	15.982	-41.7	-4.17	0.00	16.67	41.7			
	TOT	84	3.77	15.150	-41.7	0.00	0.00	8.33	50.0			
										1.50	(-5.15, 8.16)	0.654A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.23.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TIME SINCE LAST FLARE >= 6 MONTHS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
SOCIAL FUNCTIONING												
BSL VALUE	PLO	37	91.89	15.925	25.0	87.50	100.00	100.00	100.0			
	ADA	47	89.10	18.174	25.0	87.50	100.00	100.00	100.0			
	TOT	84	90.33	17.175	25.0	87.50	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	37	92.23	13.929	50.0	87.50	100.00	100.00	100.0			
	ADA	47	89.36	18.791	12.5	75.00	100.00	100.00	100.0			
	TOT	84	90.63	16.790	12.5	87.50	100.00	100.00	100.0			
CHG FROM BSL	PLO	37	0.34	10.820	-25.0	0.00	0.00	0.00	37.5			
	ADA	47	0.27	14.392	-50.0	0.00	0.00	12.50	25.0			
	TOT	84	0.30	12.868	-50.0	0.00	0.00	0.00	37.5			
										-0.07	(-5.73, 5.59)	0.980A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.23.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TIME SINCE LAST FLARE >= 6 MONTHS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
MENTAL HEALTH												
BSL VALUE	PLO	37	70.10	19.826	25.0	56.25	75.00	81.25	100.0			
	ADA	47	64.32	24.714	0.0	50.00	68.75	81.25	100.0			
	TOT	84	66.87	22.745	0.0	56.25	68.75	81.25	100.0			
FINAL/ET VALUE	PLO	37	78.72	19.233	18.8	68.75	81.25	93.75	100.0			
	ADA	47	73.94	25.180	0.0	56.25	81.25	93.75	100.0			
	TOT	84	76.04	22.749	0.0	65.63	81.25	93.75	100.0			
CHG FROM BSL	PLO	37	8.61	15.405	-18.8	0.00	6.25	18.75	68.8			
	ADA	47	9.62	18.087	-31.3	0.00	6.25	18.75	62.5			
	TOT	84	9.18	16.867	-31.3	0.00	6.25	18.75	68.8			
										1.00	(-6.41, 8.42)	0.788A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.23.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TIME SINCE LAST FLARE >= 6 MONTHS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
ROLE DIFFICULTIES												
BSL VALUE	PLO	37	70.27	23.999	25.0	50.00	75.00	87.50	100.0			
	ADA	47	69.95	27.909	0.0	50.00	75.00	87.50	100.0			
	TOT	84	70.09	26.106	0.0	50.00	75.00	87.50	100.0			
FINAL/ET VALUE	PLO	37	79.39	21.893	25.0	75.00	87.50	100.00	100.0			
	ADA	47	76.33	28.100	0.0	50.00	87.50	100.00	100.0			
	TOT	84	77.68	25.453	0.0	62.50	87.50	100.00	100.0			
CHG FROM BSL	PLO	37	9.12	24.053	-25.0	0.00	0.00	25.00	62.5			
	ADA	47	6.38	19.828	-37.5	0.00	0.00	12.50	62.5			
	TOT	84	7.59	21.696	-37.5	0.00	0.00	12.50	62.5			
										-2.74	(-12.26, 6.79)	0.569A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.23.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TIME SINCE LAST FLARE >= 6 MONTHS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#		P-VALUE@
DEPENDENCY													
BSL VALUE	PLO	37	87.39	23.375	16.7	91.67	100.00	100.00	100.0				
	ADA	47	85.82	23.946	8.3	75.00	100.00	100.00	100.0				
	TOT	84	86.51	23.567	8.3	79.17	100.00	100.00	100.0				
FINAL/ET VALUE	PLO	37	90.99	18.980	0.0	91.67	100.00	100.00	100.0				
	ADA	47	85.46	25.565	8.3	75.00	100.00	100.00	100.0				
	TOT	84	87.90	22.937	0.0	83.33	100.00	100.00	100.0				
CHG FROM BSL	PLO	37	3.60	15.780	-16.7	0.00	0.00	0.00	75.0				
	ADA	47	-0.35	15.731	-50.0	0.00	0.00	0.00	58.3				
	TOT	84	1.39	15.781	-50.0	0.00	0.00	0.00	75.0				
										-3.96	(-10.85,	2.93)	0.256A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.23.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TIME SINCE LAST FLARE >= 6 MONTHS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DRIVING												
BSL VALUE	PLO	31	68.82	29.889	0.0	58.33	75.00	91.67	100.0			
	ADA	34	60.17	37.001	0.0	33.33	66.67	91.67	100.0			
	TOT	65	64.29	33.818	0.0	50.00	75.00	91.67	100.0			
FINAL/ET VALUE	PLO	31	70.43	29.802	0.0	50.00	83.33	91.67	100.0			
	ADA	34	64.46	36.429	0.0	33.33	83.33	91.67	100.0			
	TOT	65	67.31	33.311	0.0	50.00	83.33	91.67	100.0			
CHG FROM BSL	PLO	31	1.61	16.446	-33.3	0.00	0.00	8.33	66.7			
	ADA	34	4.29	24.023	-41.7	0.00	0.00	16.67	100.0			
	TOT	65	3.01	20.644	-41.7	0.00	0.00	8.33	100.0			
										2.68	(-7.63, 12.98)	0.606A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.23.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TIME SINCE LAST FLARE >= 6 MONTHS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
COLOR VISION												
BSL VALUE	PLO	37	95.27	11.544	50.0	100.00	100.00	100.00	100.0			
	ADA	47	95.21	12.378	50.0	100.00	100.00	100.00	100.0			
	TOT	84	95.24	11.946	50.0	100.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	37	96.62	8.665	75.0	100.00	100.00	100.00	100.0			
	ADA	47	93.62	16.866	25.0	100.00	100.00	100.00	100.0			
	TOT	84	94.94	13.873	25.0	100.00	100.00	100.00	100.0			
CHG FROM BSL	PLO	37	1.35	13.105	-25.0	0.00	0.00	0.00	50.0			
	ADA	47	-1.60	13.192	-50.0	0.00	0.00	0.00	50.0			
	TOT	84	-0.30	13.157	-50.0	0.00	0.00	0.00	50.0			
										-2.95	(-8.70, 2.80)	0.311A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.23.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TIME SINCE LAST FLARE >= 6 MONTHS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
PERIPHERAL VISION												
BSL VALUE	PLO	37	79.05	27.331	0.0	75.00	100.00	100.00	100.0			
	ADA	47	80.32	20.810	25.0	75.00	75.00	100.00	100.0			
	TOT	84	79.76	23.757	0.0	75.00	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	37	85.14	20.800	25.0	75.00	100.00	100.00	100.0			
	ADA	47	82.45	23.263	25.0	75.00	100.00	100.00	100.0			
	TOT	84	83.63	22.122	25.0	75.00	100.00	100.00	100.0			
CHG FROM BSL	PLO	37	6.08	18.071	-25.0	0.00	0.00	25.00	50.0			
	ADA	47	2.13	18.672	-50.0	0.00	0.00	0.00	50.0			
	TOT	84	3.87	18.406	-50.0	0.00	0.00	12.50	50.0			
										-3.95	(-12.00, 4.10)	0.331A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.23.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TIME SINCE LAST FLARE >= 6 MONTHS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
TOTAL SCORE												
BSL VALUE	PLO	37	78.90	14.856	35.2	68.90	83.86	89.39	95.2			
	ADA	47	76.94	15.290	35.5	71.36	81.14	87.77	97.6			
	TOT	84	77.81	15.041	35.2	70.13	83.20	89.09	97.6			
FINAL/ET VALUE	PLO	37	82.67	13.408	40.6	75.61	86.63	92.88	97.4			
	ADA	47	80.19	19.190	20.4	70.80	86.82	95.53	100.0			
	TOT	84	81.28	16.840	20.4	71.85	86.82	94.20	100.0			
CHG FROM BSL	PLO	37	3.77	8.630	-7.0	-4.17	2.84	7.12	25.0			
	ADA	47	3.25	10.987	-30.8	-2.08	4.36	10.04	22.7			
	TOT	84	3.48	9.963	-30.8	-2.66	3.31	9.38	25.0			
										-0.51	(-4.89, 3.87)	0.816A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.24.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE < 15 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL HEALTH												
BSL VALUE	PLO	94	52.39	25.942	0.0	25.00	50.00	75.00	100.0			
	ADA	103	56.31	21.213	0.0	50.00	50.00	75.00	100.0			
	TOT	197	54.44	23.608	0.0	50.00	50.00	75.00	100.0			
FINAL/ET VALUE	PLO	94	51.73	24.566	0.0	25.00	50.00	75.00	100.0			
	ADA	103	55.34	23.846	0.0	50.00	50.00	75.00	100.0			
	TOT	197	53.62	24.198	0.0	50.00	50.00	75.00	100.0			
CHG FROM BSL	PLO	94	-0.66	18.547	-50.0	0.00	0.00	0.00	50.0			
	ADA	103	-0.97	20.314	-50.0	-25.00	0.00	0.00	50.0			
	TOT	197	-0.82	19.442	-50.0	-25.00	0.00	0.00	50.0			
										-0.31	(-5.79, 5.18)	0.912A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.24.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE < 15 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL VISION												
BSL VALUE	PLO	94	69.26	16.607	20.0	60.00	80.00	80.00	100.0			
	ADA	103	68.16	14.400	40.0	60.00	60.00	80.00	100.0			
	TOT	197	68.68	15.462	20.0	60.00	60.00	80.00	100.0			
FINAL/ET VALUE	PLO	94	65.96	18.510	20.0	60.00	60.00	80.00	100.0			
	ADA	103	70.58	18.934	20.0	60.00	80.00	80.00	100.0			
	TOT	197	68.38	18.828	20.0	60.00	80.00	80.00	100.0			
CHG FROM BSL	PLO	94	-3.30	16.552	-40.0	-20.00	0.00	0.00	40.0			
	ADA	103	2.43	16.177	-40.0	0.00	0.00	20.00	40.0			
	TOT	197	-0.30	16.565	-40.0	0.00	0.00	0.00	40.0			
										5.73	(1.12, 10.33)	0.015A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.24.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE < 15 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
OCULAR PAIN												
BSL VALUE	PLO	94	76.86	22.965	25.0	62.50	75.00	100.00	100.0			
	ADA	103	76.40	20.857	25.0	62.50	75.00	100.00	100.0			
	TOT	197	76.62	21.833	25.0	62.50	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	94	78.99	20.837	25.0	62.50	75.00	100.00	100.0			
	ADA	103	79.85	20.355	12.5	62.50	75.00	100.00	100.0			
	TOT	197	79.44	20.538	12.5	62.50	75.00	100.00	100.0			
CHG FROM BSL	PLO	94	2.13	18.206	-50.0	0.00	0.00	12.50	62.5			
	ADA	103	3.46	22.256	-50.0	-12.50	0.00	12.50	62.5			
	TOT	197	2.82	20.384	-50.0	-12.50	0.00	12.50	62.5			
										1.33	(-4.41, 7.08)	0.648A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.24.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE < 15 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
NEAR VISION												
BSL VALUE	PLO	94	72.92	23.828	0.0	58.33	75.00	91.67	100.0			
	ADA	103	74.64	20.891	8.3	58.33	75.00	91.67	100.0			
	TOT	197	73.82	22.300	0.0	58.33	75.00	91.67	100.0			
FINAL/ET VALUE	PLO	94	76.82	21.391	25.0	58.33	83.33	100.00	100.0			
	ADA	103	77.79	25.361	0.0	66.67	83.33	100.00	100.0			
	TOT	197	77.33	23.496	0.0	66.67	83.33	100.00	100.0			
CHG FROM BSL	PLO	94	3.90	18.309	-33.3	-8.33	0.00	8.33	75.0			
	ADA	103	3.16	21.306	-75.0	-8.33	0.00	16.67	50.0			
	TOT	197	3.51	19.885	-75.0	-8.33	0.00	16.67	75.0			
										-0.75	(-6.35, 4.86)	0.793A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.24.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE < 15 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DISTANCE VISION												
BSL VALUE	PLO	94	76.06	21.033	33.3	58.33	83.33	91.67	100.0			
	ADA	103	74.92	19.923	25.0	58.33	75.00	91.67	100.0			
	TOT	197	75.47	20.416	25.0	58.33	83.33	91.67	100.0			
FINAL/ET VALUE	PLO	94	76.82	21.373	16.7	66.67	83.33	100.00	100.0			
	ADA	103	78.03	23.550	0.0	66.67	83.33	100.00	100.0			
	TOT	197	77.45	22.489	0.0	66.67	83.33	100.00	100.0			
CHG FROM BSL	PLO	94	0.75	15.968	-41.7	-8.33	0.00	8.33	50.0			
	ADA	103	3.11	18.281	-50.0	-4.17	0.00	12.50	75.0			
	TOT	197	1.99	17.213	-50.0	-8.33	0.00	8.33	75.0			
										2.36	(-2.48, 7.20)	0.337A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.24.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE < 15 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
SOCIAL FUNCTIONING												
BSL VALUE	PLO	94	88.83	17.911	37.5	75.00	100.00	100.00	100.0			
	ADA	103	87.14	18.312	25.0	75.00	100.00	100.00	100.0			
	TOT	197	87.94	18.096	25.0	75.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	94	87.77	18.029	25.0	75.00	100.00	100.00	100.0			
	ADA	103	88.77	18.737	12.5	75.00	100.00	100.00	100.0			
	TOT	197	88.29	18.362	12.5	75.00	100.00	100.00	100.0			
CHG FROM BSL	PLO	94	-1.06	13.015	-37.5	0.00	0.00	0.00	37.5			
	ADA	103	1.64	15.031	-50.0	0.00	0.00	12.50	50.0			
	TOT	197	0.35	14.134	-50.0	0.00	0.00	0.00	50.0			
										2.70	(-1.27, 6.67)	0.181A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.24.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE < 15 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
MENTAL HEALTH												
BSL VALUE	PLO	94	65.74	22.431	6.3	50.00	71.88	81.25	93.8			
	ADA	103	63.83	23.532	0.0	50.00	68.75	81.25	100.0			
	TOT	197	64.74	22.975	0.0	50.00	68.75	81.25	100.0			
FINAL/ET VALUE	PLO	94	71.01	24.574	0.0	50.00	78.13	93.75	100.0			
	ADA	103	73.97	24.894	0.0	62.50	81.25	93.75	100.0			
	TOT	197	72.56	24.723	0.0	56.25	81.25	93.75	100.0			
CHG FROM BSL	PLO	94	5.27	20.068	-56.3	0.00	6.25	18.75	68.8			
	ADA	103	10.13	19.036	-37.5	0.00	12.50	18.75	62.5			
	TOT	197	7.82	19.637	-56.3	0.00	6.25	18.75	68.8			
										4.86	(-0.64, 10.35)	0.083A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.24.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE < 15 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
ROLE DIFFICULTIES												
BSL VALUE	PLO	94	69.41	26.349	0.0	50.00	75.00	100.00	100.0			
	ADA	103	69.05	26.709	0.0	50.00	75.00	87.50	100.0			
	TOT	197	69.23	26.471	0.0	50.00	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	94	71.01	27.934	0.0	50.00	75.00	100.00	100.0			
	ADA	103	75.61	25.688	0.0	50.00	75.00	100.00	100.0			
	TOT	197	73.41	26.813	0.0	50.00	75.00	100.00	100.0			
CHG FROM BSL	PLO	94	1.60	20.758	-50.0	-12.50	0.00	12.50	62.5			
	ADA	103	6.55	20.846	-50.0	0.00	0.00	12.50	75.0			
	TOT	197	4.19	20.899	-50.0	0.00	0.00	12.50	75.0			
										4.96	(-0.90, 10.81)	0.096A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.24.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE < 15 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DEPENDENCY												
BSL VALUE	PLO	93	85.17	21.820	8.3	75.00	100.00	100.00	100.0			
	ADA	103	84.71	22.690	8.3	75.00	100.00	100.00	100.0			
	TOT	196	84.93	22.225	8.3	75.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	93	85.39	22.942	0.0	83.33	100.00	100.00	100.0			
	ADA	103	86.17	22.704	8.3	75.00	100.00	100.00	100.0			
	TOT	196	85.80	22.762	0.0	79.17	100.00	100.00	100.0			
CHG FROM BSL	PLO	93	0.22	17.957	-83.3	0.00	0.00	0.00	75.0			
	ADA	103	1.46	16.561	-50.0	0.00	0.00	8.33	58.3			
	TOT	196	0.87	17.204	-83.3	0.00	0.00	8.33	75.0			
										1.23	(-3.63, 6.10)	0.618A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.24.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE < 15 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DRIVING												
BSL VALUE	PLO	77	74.89	23.792	0.0	58.33	83.33	91.67	100.0			
	ADA	77	67.69	32.233	0.0	58.33	83.33	91.67	100.0			
	TOT	154	71.29	28.466	0.0	58.33	83.33	91.67	100.0			
FINAL/ET VALUE	PLO	77	70.35	24.890	0.0	58.33	75.00	91.67	100.0			
	ADA	77	70.29	31.684	0.0	58.33	83.33	100.00	100.0			
	TOT	154	70.32	28.397	0.0	58.33	75.00	91.67	100.0			
CHG FROM BSL	PLO	77	-4.55	16.012	-41.7	-8.33	0.00	0.00	66.7			
	ADA	77	2.60	23.298	-58.3	0.00	0.00	8.33	100.0			
	TOT	154	-0.97	20.244	-58.3	-8.33	0.00	4.17	100.0			
										7.14	(0.78, 13.51)	0.028A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.24.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE < 15 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
COLOR VISION												
BSL VALUE	PLO	93	91.13	17.149	25.0	100.00	100.00	100.00	100.0			
	ADA	102	94.36	14.031	50.0	100.00	100.00	100.00	100.0			
	TOT	195	92.82	15.639	25.0	100.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	93	90.99	15.893	50.0	75.00	100.00	100.00	100.0			
	ADA	102	93.50	17.478	0.0	100.00	100.00	100.00	100.0			
	TOT	195	92.31	16.745	0.0	100.00	100.00	100.00	100.0			
CHG FROM BSL	PLO	93	-0.13	12.294	-50.0	0.00	0.00	0.00	25.0			
	ADA	102	-0.86	13.426	-50.0	0.00	0.00	0.00	50.0			
	TOT	195	-0.51	12.871	-50.0	0.00	0.00	0.00	50.0			
										-0.72	(-4.37, 2.92)	0.696A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.24.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE < 15 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
PERIPHERAL VISION												
BSL VALUE	PLO	92	76.90	23.799	25.0	50.00	75.00	100.00	100.0			
	ADA	101	78.47	22.647	25.0	50.00	75.00	100.00	100.0			
	TOT	193	77.72	23.156	25.0	50.00	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	92	82.61	20.798	25.0	75.00	87.50	100.00	100.0			
	ADA	101	82.43	23.597	0.0	75.00	100.00	100.00	100.0			
	TOT	193	82.51	22.249	0.0	75.00	100.00	100.00	100.0			
CHG FROM BSL	PLO	92	5.71	20.587	-50.0	0.00	0.00	25.00	50.0			
	ADA	101	3.96	18.951	-50.0	0.00	0.00	25.00	50.0			
	TOT	193	4.79	19.715	-50.0	0.00	0.00	25.00	50.0			
										-1.75	(-7.36, 3.87)	0.540A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.24.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE < 15 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
TOTAL SCORE												
BSL VALUE	PLO	94	76.81	16.802	26.6	65.71	83.16	90.23	97.6			
	ADA	103	76.32	15.003	35.5	69.13	79.58	87.77	98.9			
	TOT	197	76.55	15.848	26.6	67.46	80.45	88.52	98.9			
FINAL/ET VALUE	PLO	94	77.84	17.363	28.7	66.44	82.22	92.88	100.0			
	ADA	103	79.56	19.062	12.4	70.80	86.40	92.77	100.0			
	TOT	197	78.74	18.245	12.4	68.52	85.08	92.88	100.0			
CHG FROM BSL	PLO	94	1.03	11.118	-30.9	-4.47	2.37	6.67	29.4			
	ADA	103	3.24	12.586	-33.6	-0.83	3.90	10.15	42.0			
	TOT	197	2.19	11.930	-33.6	-3.04	2.95	9.02	42.0			
										2.21	(-1.14, 5.56)	0.195A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.25.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE >= 15 to < 30 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL HEALTH												
BSL VALUE	PLO	28	54.46	24.583	25.0	25.00	50.00	75.00	100.0			
	ADA	22	55.68	23.058	25.0	50.00	50.00	75.00	100.0			
	TOT	50	55.00	23.690	25.0	50.00	50.00	75.00	100.0			
FINAL/ET VALUE	PLO	28	50.89	19.816	0.0	50.00	50.00	50.00	100.0			
	ADA	22	56.82	26.928	0.0	25.00	62.50	75.00	100.0			
	TOT	50	53.50	23.151	0.0	50.00	50.00	75.00	100.0			
CHG FROM BSL	PLO	28	-3.57	21.207	-75.0	-12.50	0.00	0.00	25.0			
	ADA	22	1.14	22.463	-50.0	0.00	0.00	25.00	25.0			
	TOT	50	-1.50	21.671	-75.0	0.00	0.00	0.00	25.0			
										4.71	(-7.76, 17.18)	0.451A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.25.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE >= 15 to < 30 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL VISION												
BSL VALUE	PLO	28	62.14	15.719	40.0	50.00	60.00	80.00	80.0			
	ADA	21	60.00	18.974	40.0	40.00	60.00	80.00	100.0			
	TOT	49	61.22	17.033	40.0	40.00	60.00	80.00	100.0			
FINAL/ET VALUE	PLO	28	58.57	18.800	20.0	40.00	60.00	80.00	80.0			
	ADA	21	63.81	20.610	40.0	40.00	60.00	80.00	100.0			
	TOT	49	60.82	19.562	20.0	40.00	60.00	80.00	100.0			
CHG FROM BSL	PLO	28	-3.57	12.237	-20.0	-20.00	0.00	0.00	20.0			
	ADA	21	3.81	16.272	-40.0	0.00	0.00	20.00	40.0			
	TOT	49	-0.41	14.428	-40.0	0.00	0.00	0.00	40.0			
										7.38	(-0.80, 15.57)	0.076A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.25.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE >= 15 to < 30 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
OCULAR PAIN												
BSL VALUE	PLO	28	74.11	22.804	12.5	50.00	75.00	93.75	100.0			
	ADA	22	85.80	19.402	25.0	75.00	93.75	100.00	100.0			
	TOT	50	79.25	21.959	12.5	62.50	87.50	100.00	100.0			
FINAL/ET VALUE	PLO	28	78.57	18.589	50.0	62.50	75.00	100.00	100.0			
	ADA	22	82.39	21.360	37.5	75.00	93.75	100.00	100.0			
	TOT	50	80.25	19.738	37.5	62.50	75.00	100.00	100.0			
CHG FROM BSL	PLO	28	4.46	13.699	-25.0	0.00	0.00	12.50	50.0			
	ADA	22	-3.41	20.479	-62.5	0.00	0.00	12.50	25.0			
	TOT	50	1.00	17.284	-62.5	0.00	0.00	12.50	50.0			
										-7.87	(-17.61, 1.87)	0.111A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.25.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE >= 15 to < 30 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
NEAR VISION												
BSL VALUE	PLO	28	66.07	27.304	16.7	50.00	75.00	91.67	100.0			
	ADA	22	75.57	22.651	12.5	66.67	79.17	91.67	100.0			
	TOT	50	70.25	25.561	12.5	50.00	75.00	91.67	100.0			
FINAL/ET VALUE	PLO	28	69.35	24.851	16.7	50.00	75.00	87.50	100.0			
	ADA	22	79.17	22.966	8.3	66.67	79.17	100.00	100.0			
	TOT	50	73.67	24.302	8.3	58.33	75.00	100.00	100.0			
CHG FROM BSL	PLO	28	3.27	12.493	-25.0	0.00	0.00	12.50	25.0			
	ADA	22	3.60	18.198	-33.3	-8.33	0.00	16.67	33.3			
	TOT	50	3.42	15.098	-33.3	0.00	0.00	16.67	33.3			
										0.32	(-8.41, 9.06)	0.941A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.25.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE >= 15 to < 30 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DISTANCE VISION												
BSL VALUE	PLO	28	66.96	29.352	8.3	50.00	66.67	100.00	100.0			
	ADA	22	75.00	25.066	8.3	58.33	83.33	91.67	100.0			
	TOT	50	70.50	27.572	8.3	58.33	79.17	91.67	100.0			
FINAL/ET VALUE	PLO	28	66.52	26.558	8.3	41.67	66.67	95.83	100.0			
	ADA	22	78.03	25.006	8.3	66.67	83.33	100.00	100.0			
	TOT	50	71.58	26.267	8.3	58.33	75.00	100.00	100.0			
CHG FROM BSL	PLO	28	-0.45	15.059	-33.3	-8.33	0.00	6.25	41.7			
	ADA	22	3.03	11.937	-25.0	0.00	0.00	8.33	25.0			
	TOT	50	1.08	13.750	-33.3	-8.33	0.00	8.33	41.7			
										3.48	(-4.42, 11.37)	0.380A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.25.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE >= 15 to < 30 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
SOCIAL FUNCTIONING												
BSL VALUE	PLO	28	82.59	21.338	25.0	68.75	93.75	100.00	100.0			
	ADA	22	88.64	22.463	0.0	87.50	100.00	100.00	100.0			
	TOT	50	85.25	21.825	0.0	75.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	28	81.92	22.907	6.3	62.50	87.50	100.00	100.0			
	ADA	22	86.36	19.635	25.0	75.00	93.75	100.00	100.0			
	TOT	50	83.88	21.432	6.3	75.00	87.50	100.00	100.0			
CHG FROM BSL	PLO	28	-0.67	14.468	-43.8	-12.50	0.00	0.00	37.5			
	ADA	22	-2.27	12.581	-25.0	-12.50	0.00	0.00	25.0			
	TOT	50	-1.38	13.558	-43.8	-12.50	0.00	0.00	37.5			
										-1.60	(-9.44, 6.23)	0.683A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.25.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE >= 15 to < 30 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
MENTAL HEALTH												
BSL VALUE	PLO	28	59.38	27.243	6.3	37.50	59.38	84.38	100.0			
	ADA	22	70.74	21.512	12.5	62.50	71.88	87.50	100.0			
	TOT	50	64.38	25.293	6.3	43.75	68.75	87.50	100.0			
FINAL/ET VALUE	PLO	28	60.71	29.110	0.0	40.63	62.50	87.50	100.0			
	ADA	22	78.13	21.107	18.8	75.00	81.25	93.75	100.0			
	TOT	50	68.38	27.094	0.0	50.00	75.00	93.75	100.0			
CHG FROM BSL	PLO	28	1.34	10.257	-18.8	-6.25	0.00	6.25	31.3			
	ADA	22	7.39	14.126	-25.0	0.00	9.38	12.50	31.3			
	TOT	50	4.00	12.356	-25.0	-6.25	6.25	12.50	31.3			
										6.05	(-0.89, 12.98)	0.086A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.25.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE >= 15 to < 30 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
ROLE DIFFICULTIES												
BSL VALUE	PLO	28	62.50	26.352	12.5	50.00	62.50	75.00	100.0			
	ADA	22	72.16	24.980	12.5	50.00	75.00	87.50	100.0			
	TOT	50	66.75	25.953	12.5	50.00	75.00	87.50	100.0			
FINAL/ET VALUE	PLO	28	67.41	26.861	25.0	50.00	75.00	87.50	100.0			
	ADA	22	80.68	23.694	25.0	75.00	87.50	100.00	100.0			
	TOT	50	73.25	26.124	25.0	50.00	75.00	100.00	100.0			
CHG FROM BSL	PLO	28	4.91	18.739	-25.0	0.00	0.00	12.50	50.0			
	ADA	22	8.52	22.289	-37.5	0.00	6.25	25.00	62.5			
	TOT	50	6.50	20.241	-37.5	0.00	0.00	12.50	62.5			
										3.61	(-8.06, 15.28)	0.537A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.25.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE >= 15 to < 30 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DEPENDENCY												
BSL VALUE	PLO	28	73.51	33.721	0.0	50.00	91.67	100.00	100.0			
	ADA	22	86.74	23.097	8.3	83.33	100.00	100.00	100.0			
	TOT	50	79.33	29.987	0.0	66.67	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	28	74.40	32.547	0.0	50.00	91.67	100.00	100.0			
	ADA	22	87.50	21.168	16.7	83.33	100.00	100.00	100.0			
	TOT	50	80.17	28.616	0.0	75.00	100.00	100.00	100.0			
CHG FROM BSL	PLO	28	0.89	15.769	-50.0	0.00	0.00	0.00	41.7			
	ADA	22	0.76	18.882	-33.3	-8.33	0.00	8.33	58.3			
	TOT	50	0.83	17.024	-50.0	0.00	0.00	0.00	58.3			
										-0.14	(-9.99, 9.72)	0.978A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.25.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE >= 15 to < 30 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DRIVING												
BSL VALUE	PLO	24	54.86	33.686	0.0	29.17	62.50	79.17	100.0			
	ADA	17	71.32	35.229	0.0	58.33	87.50	100.00	100.0			
	TOT	41	61.69	34.876	0.0	41.67	66.67	91.67	100.0			
FINAL/ET VALUE	PLO	24	55.03	31.922	0.0	37.50	60.42	79.17	100.0			
	ADA	17	68.38	32.108	0.0	66.67	75.00	83.33	100.0			
	TOT	41	60.57	32.290	0.0	41.67	75.00	83.33	100.0			
CHG FROM BSL	PLO	24	0.17	13.818	-25.0	-4.17	0.00	12.50	25.0			
	ADA	17	-2.94	12.037	-25.0	-12.50	0.00	0.00	25.0			
	TOT	41	-1.12	13.045	-25.0	-8.33	0.00	0.00	25.0			
										-3.11	(-11.53, 5.30)	0.458A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.25.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE >= 15 to < 30 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#		P-VALUE@
COLOR VISION													
BSL VALUE	PLO	27	85.19	22.209	25.0	75.00	100.00	100.00	100.0				
	ADA	22	93.18	17.563	25.0	100.00	100.00	100.00	100.0				
	TOT	49	88.78	20.451	25.0	75.00	100.00	100.00	100.0				
FINAL/ET VALUE	PLO	27	88.89	18.777	25.0	75.00	100.00	100.00	100.0				
	ADA	22	93.18	17.563	25.0	100.00	100.00	100.00	100.0				
	TOT	49	90.82	18.182	25.0	75.00	100.00	100.00	100.0				
CHG FROM BSL	PLO	27	3.70	16.559	-25.0	0.00	0.00	0.00	50.0				
	ADA	22	0.00	7.715	-25.0	0.00	0.00	0.00	25.0				
	TOT	49	2.04	13.343	-25.0	0.00	0.00	0.00	50.0				
										-3.70	(-11.42,	4.01)	0.339A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.25.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE >= 15 to < 30 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
PERIPHERAL VISION												
BSL VALUE	PLO	28	70.54	28.098	0.0	50.00	75.00	100.00	100.0			
	ADA	22	81.82	24.618	0.0	75.00	87.50	100.00	100.0			
	TOT	50	75.50	26.959	0.0	50.00	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	28	70.98	23.827	25.0	50.00	75.00	100.00	100.0			
	ADA	22	81.82	20.676	25.0	75.00	75.00	100.00	100.0			
	TOT	50	75.75	22.925	25.0	50.00	75.00	100.00	100.0			
CHG FROM BSL	PLO	28	0.45	12.947	-25.0	0.00	0.00	0.00	25.0			
	ADA	22	0.00	17.252	-25.0	0.00	0.00	0.00	50.0			
	TOT	50	0.25	14.831	-25.0	0.00	0.00	0.00	50.0			
										-0.45	(-9.03, 8.14)	0.917A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.25.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE >= 15 to < 30 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
TOTAL SCORE												
BSL VALUE	PLO	28	68.99	20.591	25.3	50.68	71.42	87.80	95.5			
	ADA	22	78.60	17.508	15.4	71.82	82.35	89.28	97.6			
	TOT	50	73.22	19.703	15.4	64.55	80.13	89.09	97.6			
FINAL/ET VALUE	PLO	28	70.04	19.950	27.9	53.93	72.52	87.42	96.0			
	ADA	22	80.30	17.228	25.0	70.49	83.40	92.88	100.0			
	TOT	50	74.55	19.313	25.0	62.73	80.52	88.98	100.0			
CHG FROM BSL	PLO	28	1.05	7.031	-9.7	-5.25	1.42	4.77	20.8			
	ADA	22	1.70	9.333	-22.2	-2.27	1.70	8.52	17.3			
	TOT	50	1.34	8.042	-22.2	-2.46	1.70	6.25	20.8			
										0.66	(-3.99, 5.31)	0.778A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.26.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE >= 30 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
GENERAL HEALTH									
BSL VALUE	PLO	3	41.67	14.434	25.0	25.00	50.00	50.00	50.0
	ADA	6	66.67	20.412	50.0	50.00	62.50	75.00	100.0
	TOT	9	58.33	21.651	25.0	50.00	50.00	75.00	100.0
FINAL/ET VALUE	PLO	3	50.00	25.000	25.0	25.00	50.00	75.00	75.0
	ADA	6	66.67	12.910	50.0	50.00	75.00	75.00	75.0
	TOT	9	61.11	18.162	25.0	50.00	75.00	75.00	75.0
CHG FROM BSL	PLO	3	8.33	14.434	0.0	0.00	0.00	25.00	25.0
	ADA	6	0.00	15.811	-25.0	0.00	0.00	0.00	25.0
	TOT	9	2.78	15.023	-25.0	0.00	0.00	0.00	25.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.26.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE >= 30 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
GENERAL VISION									
BSL VALUE	PLO	3	80.00	20.000	60.0	60.00	80.00	100.00	100.0
	ADA	6	83.33	8.165	80.0	80.00	80.00	80.00	100.0
	TOT	9	82.22	12.019	60.0	80.00	80.00	80.00	100.0
FINAL/ET VALUE	PLO	3	60.00	20.000	40.0	40.00	60.00	80.00	80.0
	ADA	6	76.67	15.055	60.0	60.00	80.00	80.00	100.0
	TOT	9	71.11	17.638	40.0	60.00	80.00	80.00	100.0
CHG FROM BSL	PLO	3	-20.00	20.000	-40.0	-40.00	-20.00	0.00	0.0
	ADA	6	-6.67	10.328	-20.0	-20.00	0.00	0.00	0.0
	TOT	9	-11.11	14.530	-40.0	-20.00	0.00	0.00	0.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.26.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE >= 30 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
OCULAR PAIN									
BSL VALUE	PLO	3	66.67	14.434	50.0	50.00	75.00	75.00	75.0
	ADA	6	89.58	9.410	75.0	87.50	87.50	100.00	100.0
	TOT	9	81.94	15.450	50.0	75.00	87.50	87.50	100.0
FINAL/ET VALUE	PLO	3	66.67	38.188	25.0	25.00	75.00	100.00	100.0
	ADA	6	89.58	16.615	62.5	75.00	100.00	100.00	100.0
	TOT	9	81.94	25.853	25.0	75.00	100.00	100.00	100.0
CHG FROM BSL	PLO	3	0.00	25.000	-25.0	-25.00	0.00	25.00	25.0
	ADA	6	0.00	13.693	-25.0	0.00	0.00	12.50	12.5
	TOT	9	0.00	16.536	-25.0	0.00	0.00	12.50	25.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.26.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE >= 30 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
NEAR VISION									
BSL VALUE	PLO	3	77.78	17.347	58.3	58.33	83.33	91.67	91.7
	ADA	6	94.44	8.607	83.3	83.33	100.00	100.00	100.0
	TOT	9	88.89	13.819	58.3	83.33	91.67	100.00	100.0
FINAL/ET VALUE	PLO	3	80.56	17.347	66.7	66.67	75.00	100.00	100.0
	ADA	6	90.28	11.076	75.0	83.33	91.67	100.00	100.0
	TOT	9	87.04	13.249	66.7	75.00	83.33	100.00	100.0
CHG FROM BSL	PLO	3	2.78	24.056	-25.0	-25.00	16.67	16.67	16.7
	ADA	6	-4.17	14.672	-25.0	-16.67	0.00	0.00	16.7
	TOT	9	-1.85	17.067	-25.0	-16.67	0.00	16.67	16.7

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.26.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE >= 30 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
DISTANCE VISION									
BSL VALUE	PLO	3	77.78	31.549	41.7	41.67	91.67	100.00	100.0
	ADA	6	90.28	12.266	75.0	75.00	95.83	100.00	100.0
	TOT	9	86.11	19.543	41.7	75.00	91.67	100.00	100.0
FINAL/ET VALUE	PLO	3	83.33	14.434	75.0	75.00	75.00	100.00	100.0
	ADA	6	90.28	17.010	58.3	83.33	100.00	100.00	100.0
	TOT	9	87.96	15.652	58.3	75.00	100.00	100.00	100.0
CHG FROM BSL	PLO	3	5.56	29.266	-25.0	-25.00	8.33	33.33	33.3
	ADA	6	0.00	13.944	-16.7	-8.33	0.00	0.00	25.0
	TOT	9	1.85	18.530	-25.0	-8.33	0.00	8.33	33.3

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.26.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE >= 30 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
SOCIAL FUNCTIONING									
BSL VALUE	PLO	3	91.67	14.434	75.0	75.00	100.00	100.00	100.0
	ADA	6	97.92	5.103	87.5	100.00	100.00	100.00	100.0
	TOT	9	95.83	8.839	75.0	100.00	100.00	100.00	100.0
FINAL/ET VALUE	PLO	3	91.67	14.434	75.0	75.00	100.00	100.00	100.0
	ADA	6	93.75	15.309	62.5	100.00	100.00	100.00	100.0
	TOT	9	93.06	14.130	62.5	100.00	100.00	100.00	100.0
CHG FROM BSL	PLO	3	0.00	0.000	0.0	0.00	0.00	0.00	0.0
	ADA	6	-4.17	10.206	-25.0	0.00	0.00	0.00	0.0
	TOT	9	-2.78	8.333	-25.0	0.00	0.00	0.00	0.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.26.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE >= 30 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
MENTAL HEALTH									
BSL VALUE	PLO	3	58.33	52.042	0.0	0.00	75.00	100.00	100.0
	ADA	6	79.17	11.637	62.5	68.75	81.25	87.50	93.8
	TOT	9	72.22	29.500	0.0	68.75	81.25	87.50	100.0
FINAL/ET VALUE	PLO	3	62.50	49.608	6.3	6.25	81.25	100.00	100.0
	ADA	6	83.33	16.615	62.5	68.75	84.38	100.00	100.0
	TOT	9	76.39	29.938	6.3	68.75	81.25	100.00	100.0
CHG FROM BSL	PLO	3	4.17	3.608	0.0	0.00	6.25	6.25	6.3
	ADA	6	4.17	9.410	-12.5	0.00	6.25	12.50	12.5
	TOT	9	4.17	7.655	-12.5	0.00	6.25	6.25	12.5

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.26.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE >= 30 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
ROLE DIFFICULTIES									
BSL VALUE	PLO	3	75.00	25.000	50.0	50.00	75.00	100.00	100.0
	ADA	6	79.17	23.274	50.0	50.00	87.50	100.00	100.0
	TOT	9	77.78	22.341	50.0	50.00	87.50	100.00	100.0
FINAL/ET VALUE	PLO	3	70.83	50.518	12.5	12.50	100.00	100.00	100.0
	ADA	6	87.50	13.693	75.0	75.00	87.50	100.00	100.0
	TOT	9	81.94	28.717	12.5	75.00	100.00	100.00	100.0
CHG FROM BSL	PLO	3	-4.17	56.366	-62.5	-62.50	0.00	50.00	50.0
	ADA	6	8.33	24.580	-12.5	-12.50	0.00	25.00	50.0
	TOT	9	4.17	34.799	-62.5	-12.50	0.00	25.00	50.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.26.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE >= 30 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
DEPENDENCY									
BSL VALUE	PLO	3	66.67	57.735	0.0	0.00	100.00	100.00	100.0
	ADA	6	95.83	10.206	75.0	100.00	100.00	100.00	100.0
	TOT	9	86.11	33.333	0.0	100.00	100.00	100.00	100.0
FINAL/ET VALUE	PLO	3	69.44	52.924	8.3	8.33	100.00	100.00	100.0
	ADA	6	97.22	6.804	83.3	100.00	100.00	100.00	100.0
	TOT	9	87.96	30.366	8.3	100.00	100.00	100.00	100.0
CHG FROM BSL	PLO	3	2.78	4.811	0.0	0.00	0.00	8.33	8.3
	ADA	6	1.39	13.351	-16.7	0.00	0.00	0.00	25.0
	TOT	9	1.85	10.848	-16.7	0.00	0.00	0.00	25.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.26.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE >= 30 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
DRIVING									
BSL VALUE	PLO	3	58.33	50.690	0.0	0.00	83.33	91.67	91.7
	ADA	6	77.78	39.323	0.0	75.00	95.83	100.00	100.0
	TOT	9	71.30	41.271	0.0	75.00	91.67	100.00	100.0
FINAL/ET VALUE	PLO	3	61.11	52.924	0.0	0.00	91.67	91.67	91.7
	ADA	6	72.22	37.515	0.0	66.67	83.33	100.00	100.0
	TOT	9	68.52	40.134	0.0	66.67	83.33	91.67	100.0
CHG FROM BSL	PLO	3	2.78	4.811	0.0	0.00	0.00	8.33	8.3
	ADA	6	-5.56	6.804	-16.7	-8.33	-4.17	0.00	0.0
	TOT	9	-2.78	7.217	-16.7	-8.33	0.00	0.00	8.3

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.26.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE >= 30 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
COLOR VISION									
BSL VALUE	PLO	3	91.67	14.434	75.0	75.00	100.00	100.00	100.0
	ADA	6	100.00	0.000	100.0	100.00	100.00	100.00	100.0
	TOT	9	97.22	8.333	75.0	100.00	100.00	100.00	100.0
FINAL/ET VALUE	PLO	3	91.67	14.434	75.0	75.00	100.00	100.00	100.0
	ADA	6	100.00	0.000	100.0	100.00	100.00	100.00	100.0
	TOT	9	97.22	8.333	75.0	100.00	100.00	100.00	100.0
CHG FROM BSL	PLO	3	0.00	0.000	0.0	0.00	0.00	0.00	0.0
	ADA	6	0.00	0.000	0.0	0.00	0.00	0.00	0.0
	TOT	9	0.00	0.000	0.0	0.00	0.00	0.00	0.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.26.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE >= 30 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
PERIPHERAL VISION									
BSL VALUE	PLO	3	91.67	14.434	75.0	75.00	100.00	100.00	100.0
	ADA	6	87.50	20.917	50.0	75.00	100.00	100.00	100.0
	TOT	9	88.89	18.162	50.0	75.00	100.00	100.00	100.0
FINAL/ET VALUE	PLO	3	91.67	14.434	75.0	75.00	100.00	100.00	100.0
	ADA	6	83.33	30.277	25.0	75.00	100.00	100.00	100.0
	TOT	9	86.11	25.345	25.0	75.00	100.00	100.00	100.0
CHG FROM BSL	PLO	3	0.00	0.000	0.0	0.00	0.00	0.00	0.0
	ADA	6	-4.17	36.799	-75.0	0.00	0.00	25.00	25.0
	TOT	9	-2.78	29.167	-75.0	0.00	0.00	0.00	25.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.26.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE >= 30 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
TOTAL SCORE									
BSL VALUE	PLO	3	75.96	25.667	46.4	46.36	89.39	92.12	92.1
	ADA	6	88.64	9.595	73.4	82.08	90.51	95.91	99.4
	TOT	9	84.41	16.199	46.4	82.08	89.39	92.50	99.4
FINAL/ET VALUE	PLO	3	75.40	27.717	44.3	44.28	84.51	97.42	97.4
	ADA	6	87.65	11.865	67.0	84.43	88.14	98.18	100.0
	TOT	9	83.57	17.820	44.3	84.43	86.82	97.42	100.0
CHG FROM BSL	PLO	3	-0.56	7.933	-7.6	-7.61	-2.08	8.03	8.0
	ADA	6	-0.98	11.472	-21.5	-3.03	1.42	2.35	13.4
	TOT	9	-0.84	9.902	-21.5	-3.03	0.57	2.35	13.4

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.27.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, ONLY IN SUBJECTS WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: OCT EVIDENCE OF MACULAR EDEMA BASED ON CRT AT BASELINE=YES)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
GENERAL HEALTH									
BSL VALUE	PLO	13	55.77	32.522	25.0	25.00	50.00	100.00	100.0
	ADA	22	55.68	20.313	25.0	50.00	50.00	75.00	100.0
	TOT	35	55.71	25.063	25.0	50.00	50.00	75.00	100.0
FINAL/ET VALUE	PLO	13	50.00	20.412	25.0	25.00	50.00	75.00	75.0
	ADA	22	55.68	18.390	25.0	50.00	50.00	75.00	75.0
	TOT	35	53.57	19.071	25.0	50.00	50.00	75.00	75.0
CHG FROM BSL	PLO	13	-5.77	20.801	-50.0	-25.00	0.00	0.00	25.0
	ADA	22	0.00	16.815	-25.0	0.00	0.00	12.50	25.0
	TOT	35	-2.14	18.312	-50.0	-25.00	0.00	0.00	25.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.27.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, ONLY IN SUBJECTS WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: OCT EVIDENCE OF MACULAR EDEMA BASED ON CRT AT BASELINE=YES)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
GENERAL VISION									
BSL VALUE	PLO	13	61.54	20.755	40.0	40.00	60.00	80.00	100.0
	ADA	22	63.64	14.653	40.0	60.00	60.00	80.00	80.0
	TOT	35	62.86	16.903	40.0	40.00	60.00	80.00	100.0
FINAL/ET VALUE	PLO	13	60.00	18.257	40.0	40.00	60.00	80.00	80.0
	ADA	22	60.45	19.634	20.0	40.00	60.00	70.00	100.0
	TOT	35	60.29	18.863	20.0	40.00	60.00	80.00	100.0
CHG FROM BSL	PLO	13	-1.54	12.810	-20.0	0.00	0.00	0.00	20.0
	ADA	22	-3.18	20.327	-40.0	-20.00	0.00	20.00	20.0
	TOT	35	-2.57	17.714	-40.0	-20.00	0.00	10.00	20.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.27.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, ONLY IN SUBJECTS WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: OCT EVIDENCE OF MACULAR EDEMA BASED ON CRT AT BASELINE=YES)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
OCULAR PAIN									
BSL VALUE	PLO	13	74.04	21.926	37.5	62.50	75.00	100.00	100.0
	ADA	22	80.68	18.791	50.0	62.50	87.50	100.00	100.0
	TOT	35	78.21	19.959	37.5	62.50	75.00	100.00	100.0
FINAL/ET VALUE	PLO	13	74.04	18.014	50.0	62.50	75.00	75.00	100.0
	ADA	22	80.68	19.182	37.5	75.00	81.25	100.00	100.0
	TOT	35	78.21	18.773	37.5	62.50	75.00	100.00	100.0
CHG FROM BSL	PLO	13	0.00	11.411	-25.0	0.00	0.00	12.50	12.5
	ADA	22	0.00	18.898	-37.5	-12.50	0.00	12.50	50.0
	TOT	35	0.00	16.326	-37.5	-12.50	0.00	12.50	50.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.27.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, ONLY IN SUBJECTS WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: OCT EVIDENCE OF MACULAR EDEMA BASED ON CRT AT BASELINE=YES)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
NEAR VISION									
BSL VALUE	PLO	13	56.41	27.671	16.7	33.33	58.33	75.00	100.0
	ADA	22	67.61	21.126	12.5	58.33	66.67	83.33	100.0
	TOT	35	63.45	24.001	12.5	50.00	66.67	83.33	100.0
FINAL/ET VALUE	PLO	13	63.46	27.959	16.7	50.00	66.67	91.67	100.0
	ADA	22	68.56	26.344	8.3	50.00	75.00	83.33	100.0
	TOT	35	66.67	26.661	8.3	50.00	75.00	91.67	100.0
CHG FROM BSL	PLO	13	7.05	21.475	-25.0	-8.33	0.00	25.00	50.0
	ADA	22	0.95	18.983	-41.7	-8.33	0.00	16.67	33.3
	TOT	35	3.21	19.857	-41.7	-8.33	0.00	16.67	50.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.27.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, ONLY IN SUBJECTS WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: OCT EVIDENCE OF MACULAR EDEMA BASED ON CRT AT BASELINE=YES)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
DISTANCE VISION									
BSL VALUE	PLO	13	65.38	28.837	8.3	50.00	75.00	91.67	100.0
	ADA	22	72.73	22.884	8.3	66.67	75.00	91.67	100.0
	TOT	35	70.00	25.098	8.3	50.00	75.00	91.67	100.0
FINAL/ET VALUE	PLO	13	64.10	27.085	8.3	50.00	66.67	83.33	100.0
	ADA	22	72.35	27.384	8.3	50.00	79.17	100.00	100.0
	TOT	35	69.29	27.174	8.3	50.00	75.00	91.67	100.0
CHG FROM BSL	PLO	13	-1.28	14.372	-25.0	-8.33	0.00	8.33	25.0
	ADA	22	-0.38	18.807	-41.7	-8.33	0.00	8.33	41.7
	TOT	35	-0.71	17.075	-41.7	-8.33	0.00	8.33	41.7

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.27.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, ONLY IN SUBJECTS WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: OCT EVIDENCE OF MACULAR EDEMA BASED ON CRT AT BASELINE=YES)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
SOCIAL FUNCTIONING									
BSL VALUE	PLO	13	84.62	19.199	50.0	75.00	87.50	100.00	100.0
	ADA	22	82.95	24.258	0.0	75.00	87.50	100.00	100.0
	TOT	35	83.57	22.231	0.0	75.00	87.50	100.00	100.0
FINAL/ET VALUE	PLO	13	82.69	15.761	50.0	75.00	87.50	100.00	100.0
	ADA	22	83.24	23.096	25.0	75.00	96.88	100.00	100.0
	TOT	35	83.04	20.426	25.0	75.00	87.50	100.00	100.0
CHG FROM BSL	PLO	13	-1.92	17.564	-25.0	-12.50	0.00	12.50	25.0
	ADA	22	0.28	17.303	-50.0	0.00	0.00	12.50	25.0
	TOT	35	-0.54	17.175	-50.0	-12.50	0.00	12.50	25.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.27.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, ONLY IN SUBJECTS WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: OCT EVIDENCE OF MACULAR EDEMA BASED ON CRT AT BASELINE=YES)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
MENTAL HEALTH									
BSL VALUE	PLO	13	58.65	21.581	31.3	37.50	62.50	68.75	93.8
	ADA	22	57.95	25.383	12.5	37.50	59.38	81.25	93.8
	TOT	35	58.21	23.716	12.5	37.50	62.50	81.25	93.8
FINAL/ET VALUE	PLO	13	52.88	29.049	18.8	25.00	43.75	87.50	93.8
	ADA	22	68.18	30.185	12.5	50.00	75.00	93.75	100.0
	TOT	35	62.50	30.279	12.5	37.50	62.50	93.75	100.0
CHG FROM BSL	PLO	13	-5.77	20.326	-43.8	-12.50	-6.25	6.25	25.0
	ADA	22	10.23	16.875	-31.3	6.25	12.50	18.75	37.5
	TOT	35	4.29	19.576	-43.8	-6.25	6.25	18.75	37.5

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.27.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, ONLY IN SUBJECTS WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: OCT EVIDENCE OF MACULAR EDEMA BASED ON CRT AT BASELINE=YES)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
ROLE DIFFICULTIES									
BSL VALUE	PLO	13	59.62	30.257	12.5	37.50	50.00	87.50	100.0
	ADA	22	63.07	29.750	12.5	37.50	68.75	87.50	100.0
	TOT	35	61.79	29.540	12.5	37.50	62.50	87.50	100.0
FINAL/ET VALUE	PLO	13	56.73	29.587	25.0	25.00	50.00	75.00	100.0
	ADA	22	63.64	29.101	25.0	25.00	68.75	87.50	100.0
	TOT	35	61.07	29.043	25.0	25.00	62.50	87.50	100.0
CHG FROM BSL	PLO	13	-2.88	18.508	-37.5	-12.50	0.00	12.50	25.0
	ADA	22	0.57	24.844	-50.0	-12.50	0.00	0.00	75.0
	TOT	35	-0.71	22.472	-50.0	-12.50	0.00	12.50	75.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.27.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, ONLY IN SUBJECTS WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: OCT EVIDENCE OF MACULAR EDEMA BASED ON CRT AT BASELINE=YES)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
DEPENDENCY									
BSL VALUE	PLO	13	69.23	29.734	0.0	66.67	83.33	83.33	100.0
	ADA	22	80.68	27.263	8.3	58.33	100.00	100.00	100.0
	TOT	35	76.43	28.331	0.0	58.33	83.33	100.00	100.0
FINAL/ET VALUE	PLO	13	70.51	36.263	0.0	41.67	83.33	100.00	100.0
	ADA	22	78.79	31.363	8.3	66.67	100.00	100.00	100.0
	TOT	35	75.71	32.987	0.0	50.00	91.67	100.00	100.0
CHG FROM BSL	PLO	13	1.28	23.532	-58.3	0.00	0.00	16.67	25.0
	ADA	22	-1.89	13.833	-33.3	-8.33	0.00	8.33	25.0
	TOT	35	-0.71	17.778	-58.3	-8.33	0.00	8.33	25.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.27.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, ONLY IN SUBJECTS WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: OCT EVIDENCE OF MACULAR EDEMA BASED ON CRT AT BASELINE=YES)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
DRIVING									
BSL VALUE	PLO	13	53.85	38.432	0.0	16.67	83.33	83.33	91.7
	ADA	18	68.52	37.109	0.0	41.67	83.33	100.00	100.0
	TOT	31	62.37	37.754	0.0	33.33	83.33	91.67	100.0
FINAL/ET VALUE	PLO	13	55.45	35.084	0.0	33.33	75.00	83.33	91.7
	ADA	18	65.74	31.718	0.0	50.00	72.92	91.67	100.0
	TOT	31	61.42	33.001	0.0	33.33	75.00	83.33	100.0
CHG FROM BSL	PLO	13	1.60	20.521	-20.8	-8.33	0.00	0.00	66.7
	ADA	18	-2.78	28.973	-33.3	-12.50	0.00	0.00	100.0
	TOT	31	-0.94	25.475	-33.3	-8.33	0.00	0.00	100.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.27.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, ONLY IN SUBJECTS WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: OCT EVIDENCE OF MACULAR EDEMA BASED ON CRT AT BASELINE=YES)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
COLOR VISION									
BSL VALUE	PLO	13	80.77	25.318	25.0	75.00	100.00	100.00	100.0
	ADA	22	89.77	22.703	25.0	100.00	100.00	100.00	100.0
	TOT	35	86.43	23.750	25.0	75.00	100.00	100.00	100.0
FINAL/ET VALUE	PLO	13	86.54	24.185	25.0	75.00	100.00	100.00	100.0
	ADA	22	92.05	19.497	25.0	100.00	100.00	100.00	100.0
	TOT	35	90.00	21.179	25.0	100.00	100.00	100.00	100.0
CHG FROM BSL	PLO	13	5.77	10.963	0.0	0.00	0.00	0.00	25.0
	ADA	22	2.27	20.279	-50.0	0.00	0.00	0.00	50.0
	TOT	35	3.57	17.302	-50.0	0.00	0.00	0.00	50.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.27.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, ONLY IN SUBJECTS WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: OCT EVIDENCE OF MACULAR EDEMA BASED ON CRT AT BASELINE=YES)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
PERIPHERAL VISION									
BSL VALUE	PLO	13	65.38	33.132	0.0	50.00	75.00	100.00	100.0
	ADA	21	77.38	27.277	0.0	50.00	75.00	100.00	100.0
	TOT	34	72.79	29.751	0.0	50.00	75.00	100.00	100.0
FINAL/ET VALUE	PLO	13	75.00	28.868	25.0	50.00	75.00	100.00	100.0
	ADA	21	77.38	28.400	25.0	50.00	100.00	100.00	100.0
	TOT	34	76.47	28.164	25.0	50.00	87.50	100.00	100.0
CHG FROM BSL	PLO	13	9.62	21.743	-25.0	0.00	0.00	25.00	50.0
	ADA	21	0.00	20.917	-50.0	0.00	0.00	25.00	25.0
	TOT	34	3.68	21.437	-50.0	0.00	0.00	25.00	50.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.27.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, ONLY IN SUBJECTS WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: OCT EVIDENCE OF MACULAR EDEMA BASED ON CRT AT BASELINE=YES)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
TOTAL SCORE									
BSL VALUE	PLO	13	66.32	21.700	25.3	54.39	70.87	81.70	95.5
	ADA	22	73.27	19.209	15.4	63.08	79.99	85.08	97.6
	TOT	35	70.69	20.142	15.4	55.72	75.98	85.08	97.6
FINAL/ET VALUE	PLO	13	67.40	22.276	27.9	49.09	70.53	87.65	95.3
	ADA	22	73.98	22.333	25.0	57.16	80.29	91.93	100.0
	TOT	35	71.53	22.217	25.0	56.55	75.80	91.93	100.0
CHG FROM BSL	PLO	13	1.08	9.526	-9.8	-4.17	0.11	3.14	25.0
	ADA	22	0.71	13.343	-30.8	-2.46	2.92	9.58	22.2
	TOT	35	0.85	11.918	-30.8	-3.04	1.89	8.07	25.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.28.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, ONLY IN SUBJECTS WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: OCT EVIDENCE OF MACULAR EDEMA BASED ON CRT AT BASELINE=NO)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL HEALTH												
BSL VALUE	PLO	93	53.76	24.712	0.0	50.00	50.00	75.00	100.0			
	ADA	90	60.83	20.883	0.0	50.00	50.00	75.00	100.0			
	TOT	183	57.24	23.120	0.0	50.00	50.00	75.00	100.0			
FINAL/ET VALUE	PLO	93	53.90	22.115	0.0	50.00	50.00	75.00	100.0			
	ADA	90	61.11	22.521	0.0	50.00	75.00	75.00	100.0			
	TOT	183	57.45	22.546	0.0	50.00	50.00	75.00	100.0			
CHG FROM BSL	PLO	93	0.13	16.941	-25.0	0.00	0.00	0.00	50.0			
	ADA	90	0.28	19.651	-50.0	0.00	0.00	0.00	50.0			
	TOT	183	0.20	18.273	-50.0	0.00	0.00	0.00	50.0			
										0.14	(-5.20, 5.49)	0.958A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.28.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, ONLY IN SUBJECTS WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: OCT EVIDENCE OF MACULAR EDEMA BASED ON CRT AT BASELINE=NO)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL VISION												
BSL VALUE	PLO	93	70.65	15.590	20.0	60.00	80.00	80.00	100.0			
	ADA	89	72.13	14.019	40.0	60.00	80.00	80.00	100.0			
	TOT	182	71.37	14.821	20.0	60.00	80.00	80.00	100.0			
FINAL/ET VALUE	PLO	93	66.67	17.528	20.0	60.00	60.00	80.00	100.0			
	ADA	89	76.18	15.038	20.0	60.00	80.00	80.00	100.0			
	TOT	182	71.32	16.996	20.0	60.00	80.00	80.00	100.0			
CHG FROM BSL	PLO	93	-3.98	16.361	-40.0	-20.00	0.00	0.00	40.0			
	ADA	89	4.04	14.200	-40.0	0.00	0.00	20.00	40.0			
	TOT	182	-0.05	15.820	-40.0	0.00	0.00	0.00	40.0			
										8.02	(3.53, 12.51)	<0.001A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.28.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, ONLY IN SUBJECTS WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: OCT EVIDENCE OF MACULAR EDEMA BASED ON CRT AT BASELINE=NO)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
OCULAR PAIN												
BSL VALUE	PLO	93	75.27	23.165	12.5	62.50	75.00	100.00	100.0			
	ADA	90	78.40	21.100	25.0	75.00	84.38	100.00	100.0			
	TOT	183	76.81	22.168	12.5	62.50	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	93	78.63	21.618	25.0	62.50	75.00	100.00	100.0			
	ADA	90	82.22	20.439	12.5	75.00	87.50	100.00	100.0			
	TOT	183	80.40	21.066	12.5	62.50	87.50	100.00	100.0			
CHG FROM BSL	PLO	93	3.36	18.165	-50.0	0.00	0.00	12.50	62.5			
	ADA	90	3.82	22.086	-62.5	0.00	0.00	12.50	62.5			
	TOT	183	3.59	20.134	-62.5	0.00	0.00	12.50	62.5			
										0.46	(-5.43, 6.35)	0.878A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.28.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, ONLY IN SUBJECTS WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: OCT EVIDENCE OF MACULAR EDEMA BASED ON CRT AT BASELINE=NO)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
NEAR VISION												
BSL VALUE	PLO	93	74.51	22.621	12.5	58.33	75.00	91.67	100.0			
	ADA	90	79.03	21.204	8.3	66.67	83.33	100.00	100.0			
	TOT	183	76.73	21.993	8.3	66.67	83.33	91.67	100.0			
FINAL/ET VALUE	PLO	93	78.18	20.202	33.3	66.67	83.33	100.00	100.0			
	ADA	90	83.66	22.068	0.0	75.00	91.67	100.00	100.0			
	TOT	183	80.87	21.260	0.0	66.67	83.33	100.00	100.0			
CHG FROM BSL	PLO	93	3.67	17.123	-33.3	-8.33	0.00	16.67	75.0			
	ADA	90	4.63	18.290	-75.0	0.00	0.00	16.67	50.0			
	TOT	183	4.14	17.664	-75.0	-4.17	0.00	16.67	75.0			
										0.96	(-4.21, 6.12)	0.715A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.28.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, ONLY IN SUBJECTS WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: OCT EVIDENCE OF MACULAR EDEMA BASED ON CRT AT BASELINE=NO)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DISTANCE VISION												
BSL VALUE	PLO	93	75.27	22.604	16.7	58.33	83.33	91.67	100.0			
	ADA	90	79.58	19.343	25.0	66.67	83.33	91.67	100.0			
	TOT	183	77.39	21.117	16.7	66.67	83.33	91.67	100.0			
FINAL/ET VALUE	PLO	93	76.43	21.646	16.7	66.67	75.00	100.00	100.0			
	ADA	90	82.73	22.185	0.0	75.00	91.67	100.00	100.0			
	TOT	183	79.53	22.079	0.0	66.67	83.33	100.00	100.0			
CHG FROM BSL	PLO	93	1.16	16.772	-41.7	-8.33	0.00	8.33	50.0			
	ADA	90	3.15	16.833	-50.0	-4.17	0.00	8.33	75.0			
	TOT	183	2.14	16.786	-50.0	-8.33	0.00	8.33	75.0			
										1.98	(-2.92, 6.89)	0.426A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.28.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, ONLY IN SUBJECTS WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: OCT EVIDENCE OF MACULAR EDEMA BASED ON CRT AT BASELINE=NO)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
SOCIAL FUNCTIONING												
BSL VALUE	PLO	93	88.17	19.008	25.0	75.00	100.00	100.00	100.0			
	ADA	90	89.58	17.603	25.0	87.50	100.00	100.00	100.0			
	TOT	183	88.87	18.294	25.0	75.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	93	87.43	19.142	6.3	75.00	100.00	100.00	100.0			
	ADA	90	91.81	16.672	12.5	87.50	100.00	100.00	100.0			
	TOT	183	89.58	18.054	6.3	87.50	100.00	100.00	100.0			
CHG FROM BSL	PLO	93	-0.74	13.381	-43.8	0.00	0.00	0.00	37.5			
	ADA	90	2.22	12.511	-25.0	0.00	0.00	0.00	50.0			
	TOT	183	0.72	13.010	-43.8	0.00	0.00	0.00	50.0			
										2.96	(-0.82, 6.74)	0.124A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.28.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, ONLY IN SUBJECTS WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: OCT EVIDENCE OF MACULAR EDEMA BASED ON CRT AT BASELINE=NO)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
MENTAL HEALTH												
BSL VALUE	PLO	93	63.62	23.925	0.0	50.00	75.00	81.25	100.0			
	ADA	90	67.92	22.418	0.0	56.25	75.00	81.25	100.0			
	TOT	183	65.73	23.233	0.0	50.00	75.00	81.25	100.0			
FINAL/ET VALUE	PLO	93	70.09	25.368	0.0	56.25	75.00	87.50	100.0			
	ADA	90	77.99	22.839	0.0	68.75	81.25	93.75	100.0			
	TOT	183	73.98	24.414	0.0	62.50	81.25	93.75	100.0			
CHG FROM BSL	PLO	93	6.47	18.349	-56.3	0.00	6.25	18.75	68.8			
	ADA	90	10.07	17.794	-31.3	0.00	6.25	18.75	62.5			
	TOT	183	8.24	18.118	-56.3	0.00	6.25	18.75	68.8			
										3.60	(-1.68, 8.87)	0.180A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.28.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, ONLY IN SUBJECTS WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: OCT EVIDENCE OF MACULAR EDEMA BASED ON CRT AT BASELINE=NO)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
ROLE DIFFICULTIES												
BSL VALUE	PLO	93	67.34	25.672	0.0	50.00	75.00	87.50	100.0			
	ADA	90	70.83	25.761	0.0	50.00	75.00	87.50	100.0			
	TOT	183	69.06	25.705	0.0	50.00	75.00	87.50	100.0			
FINAL/ET VALUE	PLO	93	71.51	28.094	0.0	50.00	75.00	100.00	100.0			
	ADA	90	80.83	23.717	0.0	75.00	87.50	100.00	100.0			
	TOT	183	76.09	26.380	0.0	50.00	87.50	100.00	100.0			
CHG FROM BSL	PLO	93	4.17	22.447	-62.5	0.00	0.00	12.50	62.5			
	ADA	90	10.00	20.458	-25.0	0.00	0.00	25.00	62.5			
	TOT	183	7.04	21.631	-62.5	0.00	0.00	12.50	62.5			
										5.83	(-0.44, 12.10)	0.068A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.28.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, ONLY IN SUBJECTS WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: OCT EVIDENCE OF MACULAR EDEMA BASED ON CRT AT BASELINE=NO)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DEPENDENCY												
BSL VALUE	PLO	92	83.29	25.412	0.0	75.00	100.00	100.00	100.0			
	ADA	90	87.78	20.686	8.3	83.33	100.00	100.00	100.0			
	TOT	182	85.51	23.241	0.0	75.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	92	84.33	24.236	0.0	75.00	100.00	100.00	100.0			
	ADA	90	89.72	19.675	8.3	83.33	100.00	100.00	100.0			
	TOT	182	87.00	22.203	0.0	83.33	100.00	100.00	100.0			
CHG FROM BSL	PLO	92	1.04	17.181	-83.3	0.00	0.00	4.17	75.0			
	ADA	90	1.94	15.302	-50.0	0.00	0.00	0.00	50.0			
	TOT	182	1.49	16.240	-83.3	0.00	0.00	0.00	75.0			
										0.90	(-3.86, 5.67)	0.709A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.28.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, ONLY IN SUBJECTS WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: OCT EVIDENCE OF MACULAR EDEMA BASED ON CRT AT BASELINE=NO)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DRIVING												
BSL VALUE	PLO	77	73.05	23.884	0.0	58.33	83.33	91.67	100.0			
	ADA	68	73.77	28.922	0.0	62.50	83.33	95.83	100.0			
	TOT	145	73.39	26.275	0.0	58.33	83.33	91.67	100.0			
FINAL/ET VALUE	PLO	77	68.61	25.485	0.0	58.33	75.00	87.50	100.0			
	ADA	68	76.59	27.023	0.0	66.67	83.33	100.00	100.0			
	TOT	145	72.36	26.429	0.0	58.33	83.33	91.67	100.0			
CHG FROM BSL	PLO	77	-4.44	14.581	-41.7	-12.50	0.00	0.00	25.0			
	ADA	68	2.82	19.443	-41.7	-8.33	0.00	8.33	100.0			
	TOT	145	-1.03	17.358	-41.7	-8.33	0.00	8.33	100.0			
										7.26	(1.65, 12.86)	0.012A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.28.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, ONLY IN SUBJECTS WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: OCT EVIDENCE OF MACULAR EDEMA BASED ON CRT AT BASELINE=NO)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
COLOR VISION												
BSL VALUE	PLO	92	91.03	17.218	25.0	87.50	100.00	100.00	100.0			
	ADA	89	96.35	11.021	50.0	100.00	100.00	100.00	100.0			
	TOT	181	93.65	14.709	25.0	100.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	92	91.44	14.932	50.0	75.00	100.00	100.00	100.0			
	ADA	89	95.08	16.815	0.0	100.00	100.00	100.00	100.0			
	TOT	181	93.23	15.946	0.0	100.00	100.00	100.00	100.0			
CHG FROM BSL	PLO	92	0.41	13.923	-50.0	0.00	0.00	0.00	50.0			
	ADA	89	-1.26	9.241	-50.0	0.00	0.00	0.00	25.0			
	TOT	181	-0.41	11.851	-50.0	0.00	0.00	0.00	50.0			
										-1.67	(-5.15, 1.81)	0.344A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.28.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, ONLY IN SUBJECTS WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: OCT EVIDENCE OF MACULAR EDEMA BASED ON CRT AT BASELINE=NO)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
PERIPHERAL VISION												
BSL VALUE	PLO	91	76.92	23.638	25.0	50.00	75.00	100.00	100.0			
	ADA	89	82.02	22.293	25.0	75.00	100.00	100.00	100.0			
	TOT	180	79.44	23.061	25.0	75.00	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	91	81.18	21.439	25.0	75.00	75.00	100.00	100.0			
	ADA	89	85.39	21.914	0.0	75.00	100.00	100.00	100.0			
	TOT	180	83.26	21.718	0.0	75.00	100.00	100.00	100.0			
CHG FROM BSL	PLO	91	4.26	19.563	-50.0	0.00	0.00	25.00	50.0			
	ADA	89	3.37	19.653	-75.0	0.00	0.00	0.00	50.0			
	TOT	180	3.82	19.558	-75.0	0.00	0.00	25.00	50.0			
										-0.89	(-6.66, 4.88)	0.762A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.28.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, ONLY IN SUBJECTS WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: OCT EVIDENCE OF MACULAR EDEMA BASED ON CRT AT BASELINE=NO)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
TOTAL SCORE												
BSL VALUE	PLO	93	76.09	17.043	26.6	65.11	83.11	89.36	97.6			
	ADA	90	79.69	14.623	35.5	73.07	82.84	90.29	99.4			
	TOT	183	77.86	15.958	26.6	70.42	83.11	89.66	99.4			
FINAL/ET VALUE	PLO	93	77.45	17.410	28.7	65.30	82.27	92.77	99.6			
	ADA	90	83.49	16.982	12.4	77.54	88.14	95.91	100.0			
	TOT	183	80.42	17.419	12.4	70.23	86.82	93.45	100.0			
CHG FROM BSL	PLO	93	1.36	11.031	-30.9	-4.81	2.77	7.01	29.4			
	ADA	90	3.80	11.352	-31.3	-0.57	3.84	9.09	42.0			
	TOT	183	2.56	11.226	-31.3	-2.71	3.03	8.52	42.0			
										2.44	(-0.83, 5.70)	0.142A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.29.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: IMM USAGE AT BASELINE=YES)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL HEALTH												
BSL VALUE	PLO	52	54.33	29.172	0.0	25.00	50.00	75.00	100.0			
	ADA	56	58.04	19.718	25.0	50.00	50.00	75.00	100.0			
	TOT	108	56.25	24.677	0.0	50.00	50.00	75.00	100.0			
FINAL/ET VALUE	PLO	52	52.40	23.877	0.0	25.00	50.00	75.00	100.0			
	ADA	56	59.82	22.577	0.0	50.00	56.25	75.00	100.0			
	TOT	108	56.25	23.401	0.0	50.00	50.00	75.00	100.0			
CHG FROM BSL	PLO	52	-1.92	19.708	-50.0	-25.00	0.00	0.00	50.0			
	ADA	56	1.79	20.004	-50.0	0.00	0.00	18.75	50.0			
	TOT	108	0.00	19.856	-50.0	-12.50	0.00	6.25	50.0			
										3.71	(-3.87, 11.29)	0.334A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.29.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: IMM USAGE AT BASELINE=YES)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL VISION												
BSL VALUE	PLO	52	67.31	16.344	40.0	60.00	60.00	80.00	100.0			
	ADA	56	68.57	15.187	40.0	60.00	80.00	80.00	100.0			
	TOT	108	67.96	15.693	40.0	60.00	60.00	80.00	100.0			
FINAL/ET VALUE	PLO	52	65.38	18.199	20.0	60.00	70.00	80.00	100.0			
	ADA	56	72.68	16.786	20.0	60.00	80.00	80.00	100.0			
	TOT	108	69.17	17.780	20.0	60.00	80.00	80.00	100.0			
CHG FROM BSL	PLO	52	-1.92	14.956	-40.0	-10.00	0.00	0.00	20.0			
	ADA	56	4.11	14.495	-20.0	0.00	0.00	20.00	40.0			
	TOT	108	1.20	14.959	-40.0	0.00	0.00	15.00	40.0			
										6.03	(0.41, 11.65)	0.036A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.29.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: IMM USAGE AT BASELINE=YES)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
OCULAR PAIN												
BSL VALUE	PLO	52	76.68	22.826	12.5	62.50	87.50	100.00	100.0			
	ADA	56	78.57	18.109	37.5	62.50	75.00	100.00	100.0			
	TOT	108	77.66	20.440	12.5	62.50	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	52	75.96	24.360	25.0	50.00	75.00	100.00	100.0			
	ADA	56	82.14	19.635	37.5	62.50	87.50	100.00	100.0			
	TOT	108	79.17	22.151	25.0	62.50	81.25	100.00	100.0			
CHG FROM BSL	PLO	52	-0.72	18.756	-50.0	-12.50	0.00	12.50	50.0			
	ADA	56	3.57	20.045	-50.0	0.00	0.00	12.50	62.5			
	TOT	108	1.50	19.464	-50.0	-6.25	0.00	12.50	62.5			
										4.29	(-3.13, 11.71)	0.254A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.29.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: IMM USAGE AT BASELINE=YES)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
NEAR VISION												
BSL VALUE	PLO	52	73.24	20.634	25.0	58.33	75.00	91.67	100.0			
	ADA	56	74.63	24.442	8.3	58.33	79.17	95.83	100.0			
	TOT	108	73.96	22.594	8.3	58.33	75.00	91.67	100.0			
FINAL/ET VALUE	PLO	52	76.52	20.956	25.0	58.33	79.17	100.00	100.0			
	ADA	56	79.61	24.717	0.0	75.00	83.33	100.00	100.0			
	TOT	108	78.13	22.929	0.0	66.67	83.33	100.00	100.0			
CHG FROM BSL	PLO	52	3.29	14.814	-33.3	-8.33	0.00	16.67	50.0			
	ADA	56	4.99	17.488	-41.7	-2.08	0.00	16.67	50.0			
	TOT	108	4.17	16.203	-41.7	-8.33	0.00	16.67	50.0			
										1.70	(-4.51, 7.91)	0.588A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.29.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: IMM USAGE AT BASELINE=YES)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DISTANCE VISION												
BSL VALUE	PLO	52	75.96	21.047	25.0	66.67	83.33	91.67	100.0			
	ADA	56	71.58	23.221	8.3	58.33	79.17	91.67	100.0			
	TOT	108	73.69	22.207	8.3	58.33	83.33	91.67	100.0			
FINAL/ET VALUE	PLO	52	75.88	21.474	25.0	66.67	75.00	100.00	100.0			
	ADA	56	76.34	26.342	0.0	58.33	83.33	100.00	100.0			
	TOT	108	76.12	24.011	0.0	60.42	79.17	100.00	100.0			
CHG FROM BSL	PLO	52	-0.08	15.181	-41.7	-8.33	0.00	8.33	41.7			
	ADA	56	4.76	17.951	-41.7	-2.08	4.17	14.58	75.0			
	TOT	108	2.43	16.775	-41.7	-8.33	0.00	8.33	75.0			
										4.84	(-1.52, 11.21)	0.135A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.29.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: IMM USAGE AT BASELINE=YES)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
SOCIAL FUNCTIONING												
BSL VALUE	PLO	52	90.63	15.434	37.5	75.00	100.00	100.00	100.0			
	ADA	56	84.15	21.518	0.0	75.00	87.50	100.00	100.0			
	TOT	108	87.27	19.029	0.0	75.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	52	87.74	15.703	50.0	75.00	96.88	100.00	100.0			
	ADA	56	87.61	21.068	12.5	81.25	100.00	100.00	100.0			
	TOT	108	87.67	18.593	12.5	75.00	100.00	100.00	100.0			
CHG FROM BSL	PLO	52	-2.88	11.965	-37.5	-12.50	0.00	0.00	37.5			
	ADA	56	3.46	16.075	-50.0	0.00	0.00	12.50	50.0			
	TOT	108	0.41	14.533	-50.0	0.00	0.00	0.00	50.0			
										6.34	(0.90, 11.78)	0.023A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.29.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: IMM USAGE AT BASELINE=YES)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
MENTAL HEALTH												
BSL VALUE	PLO	52	65.38	24.300	0.0	50.00	75.00	81.25	100.0			
	ADA	56	59.67	25.535	0.0	37.50	68.75	81.25	93.8			
	TOT	108	62.42	24.997	0.0	43.75	68.75	81.25	100.0			
FINAL/ET VALUE	PLO	52	69.71	25.557	6.3	50.00	75.00	93.75	100.0			
	ADA	56	72.99	26.944	0.0	56.25	81.25	93.75	100.0			
	TOT	108	71.41	26.215	0.0	56.25	78.13	93.75	100.0			
CHG FROM BSL	PLO	52	4.33	19.394	-37.5	-6.25	3.13	12.50	68.8			
	ADA	56	13.32	19.715	-31.3	0.00	12.50	25.00	62.5			
	TOT	108	8.99	19.986	-37.5	0.00	6.25	18.75	68.8			
										8.99	(1.52, 16.46)	0.019A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.29.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: IMM USAGE AT BASELINE=YES)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
ROLE DIFFICULTIES												
BSL VALUE	PLO	52	69.95	25.756	25.0	50.00	75.00	100.00	100.0			
	ADA	56	66.07	29.360	0.0	37.50	75.00	87.50	100.0			
	TOT	108	67.94	27.624	0.0	50.00	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	52	72.36	29.428	12.5	50.00	87.50	100.00	100.0			
	ADA	56	77.46	26.695	0.0	62.50	87.50	100.00	100.0			
	TOT	108	75.00	28.029	0.0	50.00	87.50	100.00	100.0			
CHG FROM BSL	PLO	52	2.40	24.384	-62.5	-12.50	0.00	18.75	62.5			
	ADA	56	11.38	23.267	-37.5	0.00	6.25	25.00	75.0			
	TOT	108	7.06	24.124	-62.5	0.00	0.00	25.00	75.0			
										8.98	(-0.11, 18.07)	0.053A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.29.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: IMM USAGE AT BASELINE=YES)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DEPENDENCY												
BSL VALUE	PLO	52	81.17	26.034	0.0	66.67	93.75	100.00	100.0			
	ADA	56	80.36	27.590	8.3	70.83	91.67	100.00	100.0			
	TOT	108	80.75	26.730	0.0	66.67	91.67	100.00	100.0			
FINAL/ET VALUE	PLO	52	83.17	25.216	0.0	75.00	95.83	100.00	100.0			
	ADA	56	85.42	24.987	8.3	83.33	100.00	100.00	100.0			
	TOT	108	84.34	25.006	0.0	79.17	100.00	100.00	100.0			
CHG FROM BSL	PLO	52	2.00	18.011	-41.7	-8.33	0.00	4.17	75.0			
	ADA	56	5.06	17.744	-33.3	0.00	0.00	8.33	58.3			
	TOT	108	3.59	17.855	-41.7	0.00	0.00	8.33	75.0			
										3.06	(-3.77, 9.88)	0.377A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.29.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: IMM USAGE AT BASELINE=YES)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DRIVING												
BSL VALUE	PLO	47	71.28	28.008	0.0	58.33	83.33	91.67	100.0			
	ADA	46	63.22	34.853	0.0	41.67	75.00	91.67	100.0			
	TOT	93	67.29	31.667	0.0	50.00	83.33	91.67	100.0			
FINAL/ET VALUE	PLO	47	69.59	28.044	0.0	58.33	75.00	91.67	100.0			
	ADA	46	68.12	33.359	0.0	58.33	81.25	100.00	100.0			
	TOT	93	68.86	30.628	0.0	58.33	75.00	91.67	100.0			
CHG FROM BSL	PLO	47	-1.68	15.870	-41.7	-8.33	0.00	0.00	66.7			
	ADA	46	4.89	26.195	-41.7	-8.33	0.00	8.33	100.0			
	TOT	93	1.57	21.737	-41.7	-8.33	0.00	8.33	100.0			
										6.58	(-2.32, 15.48)	0.146A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.29.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: IMM USAGE AT BASELINE=YES)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
COLOR VISION												
BSL VALUE	PLO	52	91.83	16.210	50.0	100.00	100.00	100.00	100.0			
	ADA	56	91.07	18.109	25.0	100.00	100.00	100.00	100.0			
	TOT	108	91.44	17.145	25.0	100.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	52	91.11	15.525	50.0	75.00	100.00	100.00	100.0			
	ADA	56	90.63	22.645	0.0	100.00	100.00	100.00	100.0			
	TOT	108	90.86	19.456	0.0	100.00	100.00	100.00	100.0			
CHG FROM BSL	PLO	52	-0.72	13.651	-25.0	0.00	0.00	0.00	50.0			
	ADA	56	-0.45	14.687	-50.0	0.00	0.00	0.00	50.0			
	TOT	108	-0.58	14.132	-50.0	0.00	0.00	0.00	50.0			
										0.27	(-5.15, 5.70)	0.920A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.29.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: IMM USAGE AT BASELINE=YES)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
PERIPHERAL VISION												
BSL VALUE	PLO	51	75.98	25.476	0.0	50.00	75.00	100.00	100.0			
	ADA	54	76.85	25.165	0.0	50.00	75.00	100.00	100.0			
	TOT	105	76.43	25.198	0.0	50.00	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	51	81.86	21.112	25.0	75.00	87.50	100.00	100.0			
	ADA	54	81.94	24.961	25.0	75.00	100.00	100.00	100.0			
	TOT	105	81.90	23.061	25.0	75.00	100.00	100.00	100.0			
CHG FROM BSL	PLO	51	5.88	18.933	-25.0	0.00	0.00	25.00	50.0			
	ADA	54	5.09	23.979	-75.0	0.00	0.00	25.00	50.0			
	TOT	105	5.48	21.576	-75.0	0.00	0.00	25.00	50.0			
										-0.79	(-9.18, 7.60)	0.852A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.29.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: IMM USAGE AT BASELINE=YES)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
TOTAL SCORE												
BSL VALUE	PLO	52	76.32	16.809	35.2	66.00	82.69	89.72	97.6			
	ADA	56	74.11	17.841	15.4	61.58	78.23	87.99	98.9			
	TOT	108	75.17	17.307	15.4	64.92	78.77	88.37	98.9			
FINAL/ET VALUE	PLO	52	77.02	18.163	31.7	64.92	80.04	93.16	98.2			
	ADA	56	79.37	19.831	20.4	68.90	85.72	94.11	100.0			
	TOT	108	78.23	18.994	20.4	65.74	84.63	93.45	100.0			
CHG FROM BSL	PLO	52	0.70	10.554	-30.9	-5.08	2.59	6.24	25.0			
	ADA	56	5.25	13.085	-30.8	-0.66	6.09	11.63	42.0			
	TOT	108	3.06	12.096	-30.9	-2.37	3.13	9.43	42.0			
										4.55	(0.00, 9.11)	0.050A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.30.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: IMM USAGE AT BASELINE=NO)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL HEALTH												
BSL VALUE	PLO	73	51.37	22.396	0.0	25.00	50.00	75.00	100.0			
	ADA	75	55.67	22.725	0.0	50.00	50.00	75.00	100.0			
	TOT	148	53.55	22.590	0.0	50.00	50.00	75.00	100.0			
FINAL/ET VALUE	PLO	73	50.86	23.230	0.0	50.00	50.00	75.00	100.0			
	ADA	75	53.33	24.774	0.0	50.00	50.00	75.00	100.0			
	TOT	148	52.11	23.975	0.0	50.00	50.00	75.00	100.0			
CHG FROM BSL	PLO	73	-0.51	18.685	-75.0	0.00	0.00	0.00	25.0			
	ADA	75	-2.33	20.621	-50.0	-25.00	0.00	0.00	50.0			
	TOT	148	-1.44	19.644	-75.0	0.00	0.00	0.00	50.0			
										-1.82	(-8.22, 4.58)	0.575A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.30.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: IMM USAGE AT BASELINE=NO)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL VISION												
BSL VALUE	PLO	73	68.36	17.079	20.0	60.00	80.00	80.00	100.0			
	ADA	74	66.76	15.972	40.0	60.00	60.00	80.00	100.0			
	TOT	147	67.55	16.494	20.0	60.00	60.00	80.00	100.0			
FINAL/ET VALUE	PLO	73	63.29	19.153	20.0	60.00	60.00	80.00	100.0			
	ADA	74	67.57	20.595	20.0	60.00	80.00	80.00	100.0			
	TOT	147	65.44	19.939	20.0	60.00	60.00	80.00	100.0			
CHG FROM BSL	PLO	73	-5.07	16.425	-40.0	-20.00	0.00	0.00	40.0			
	ADA	74	0.81	17.022	-40.0	0.00	0.00	20.00	40.0			
	TOT	147	-2.11	16.930	-40.0	-20.00	0.00	0.00	40.0			
										5.88	(0.43, 11.33)	0.035A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.30.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: IMM USAGE AT BASELINE=NO)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
OCULAR PAIN												
BSL VALUE	PLO	73	75.51	22.768	25.0	62.50	75.00	100.00	100.0			
	ADA	75	78.58	22.374	25.0	62.50	87.50	100.00	100.0			
	TOT	148	77.07	22.545	25.0	62.50	78.13	100.00	100.0			
FINAL/ET VALUE	PLO	73	80.48	17.553	37.5	75.00	75.00	100.00	100.0			
	ADA	75	79.67	20.934	12.5	75.00	75.00	100.00	100.0			
	TOT	148	80.07	19.279	12.5	75.00	75.00	100.00	100.0			
CHG FROM BSL	PLO	73	4.97	15.967	-25.0	0.00	0.00	12.50	62.5			
	ADA	75	1.08	22.915	-62.5	-12.50	0.00	12.50	62.5			
	TOT	148	3.00	19.824	-62.5	0.00	0.00	12.50	62.5			
										-3.88	(-10.31, 2.55)	0.235A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.30.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: IMM USAGE AT BASELINE=NO)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#		P-VALUE@
NEAR VISION													
BSL VALUE	PLO	73	70.26	27.051	0.0	58.33	75.00	91.67	100.0				
	ADA	75	76.50	18.350	33.3	66.67	75.00	91.67	100.0				
	TOT	148	73.42	23.188	0.0	58.33	75.00	91.67	100.0				
FINAL/ET VALUE	PLO	73	74.32	23.147	16.7	58.33	75.00	91.67	100.0				
	ADA	75	77.83	24.518	0.0	66.67	83.33	100.00	100.0				
	TOT	148	76.10	23.836	0.0	66.67	83.33	100.00	100.0				
CHG FROM BSL	PLO	73	4.05	18.763	-33.3	-8.33	0.00	8.33	75.0				
	ADA	75	1.33	22.482	-75.0	-8.33	0.00	16.67	41.7				
	TOT	148	2.67	20.705	-75.0	-8.33	0.00	16.67	75.0				
										-2.72	(-9.46,	4.02)	0.426A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.30.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: IMM USAGE AT BASELINE=NO)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DISTANCE VISION												
BSL VALUE	PLO	73	72.72	25.087	8.3	50.00	83.33	100.00	100.0			
	ADA	75	78.67	18.200	41.7	66.67	83.33	91.67	100.0			
	TOT	148	75.73	21.998	8.3	58.33	83.33	97.92	100.0			
FINAL/ET VALUE	PLO	73	73.80	23.809	8.3	58.33	75.00	91.67	100.0			
	ADA	75	80.28	21.228	0.0	66.67	83.33	100.00	100.0			
	TOT	148	77.08	22.695	0.0	62.50	83.33	100.00	100.0			
CHG FROM BSL	PLO	73	1.08	16.609	-33.3	-8.33	0.00	8.33	50.0			
	ADA	75	1.61	16.467	-50.0	-8.33	0.00	8.33	41.7			
	TOT	148	1.35	16.483	-50.0	-8.33	0.00	8.33	50.0			
										0.53	(-4.85, 5.90)	0.847A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.30.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: IMM USAGE AT BASELINE=NO)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
SOCIAL FUNCTIONING												
BSL VALUE	PLO	73	85.27	20.555	25.0	75.00	100.00	100.00	100.0			
	ADA	75	90.67	15.930	25.0	87.50	100.00	100.00	100.0			
	TOT	148	88.01	18.493	25.0	75.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	73	85.70	21.385	6.3	75.00	100.00	100.00	100.0			
	ADA	75	89.33	16.782	25.0	75.00	100.00	100.00	100.0			
	TOT	148	87.54	19.212	6.3	75.00	100.00	100.00	100.0			
CHG FROM BSL	PLO	73	0.43	13.832	-43.8	0.00	0.00	0.00	37.5			
	ADA	75	-1.33	12.927	-50.0	0.00	0.00	0.00	25.0			
	TOT	148	-0.46	13.365	-50.0	0.00	0.00	0.00	37.5			
										-1.76	(-6.11, 2.59)	0.425A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.30.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: IMM USAGE AT BASELINE=NO)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
MENTAL HEALTH												
BSL VALUE	PLO	73	63.24	24.430	6.3	50.00	68.75	81.25	100.0			
	ADA	75	70.19	19.956	0.0	56.25	75.00	87.50	100.0			
	TOT	148	66.77	22.471	0.0	50.00	75.00	87.50	100.0			
FINAL/ET VALUE	PLO	73	67.64	27.110	0.0	50.00	75.00	87.50	100.0			
	ADA	75	76.67	21.537	12.5	68.75	81.25	93.75	100.0			
	TOT	148	72.21	24.779	0.0	56.25	81.25	93.75	100.0			
CHG FROM BSL	PLO	73	4.39	17.269	-56.3	0.00	6.25	12.50	43.8			
	ADA	75	6.47	16.034	-37.5	0.00	6.25	12.50	37.5			
	TOT	148	5.45	16.630	-56.3	0.00	6.25	12.50	43.8			
										2.08	(-3.33, 7.49)	0.449A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.30.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: IMM USAGE AT BASELINE=NO)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
ROLE DIFFICULTIES												
BSL VALUE	PLO	73	66.61	26.765	0.0	50.00	75.00	87.50	100.0			
	ADA	75	73.00	23.344	12.5	50.00	75.00	100.00	100.0			
	TOT	148	69.85	25.209	0.0	50.00	75.00	87.50	100.0			
FINAL/ET VALUE	PLO	73	68.66	27.093	0.0	50.00	75.00	100.00	100.0			
	ADA	75	76.67	23.818	25.0	62.50	75.00	100.00	100.0			
	TOT	148	72.72	25.714	0.0	50.00	75.00	100.00	100.0			
CHG FROM BSL	PLO	73	2.05	18.982	-50.0	0.00	0.00	12.50	62.5			
	ADA	75	3.67	18.809	-50.0	0.00	0.00	12.50	62.5			
	TOT	148	2.87	18.847	-50.0	0.00	0.00	12.50	62.5			
										1.61	(-4.53, 7.75)	0.605A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.30.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: IMM USAGE AT BASELINE=NO)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DEPENDENCY												
BSL VALUE	PLO	72	82.75	26.586	0.0	75.00	100.00	100.00	100.0			
	ADA	75	89.44	16.629	33.3	83.33	100.00	100.00	100.0			
	TOT	147	86.17	22.252	0.0	83.33	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	72	82.06	27.395	0.0	70.83	100.00	100.00	100.0			
	ADA	75	88.00	19.579	16.7	83.33	100.00	100.00	100.0			
	TOT	147	85.09	23.836	0.0	75.00	100.00	100.00	100.0			
CHG FROM BSL	PLO	72	-0.69	16.652	-83.3	0.00	0.00	0.00	25.0			
	ADA	75	-1.44	15.462	-50.0	0.00	0.00	0.00	58.3			
	TOT	147	-1.08	16.005	-83.3	0.00	0.00	0.00	58.3			
										-0.75	(-5.99, 4.49)	0.777A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.30.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: IMM USAGE AT BASELINE=NO)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DRIVING												
BSL VALUE	PLO	57	68.57	28.577	0.0	58.33	75.00	91.67	100.0			
	ADA	54	73.77	30.657	0.0	58.33	83.33	100.00	100.0			
	TOT	111	71.10	29.587	0.0	58.33	83.33	91.67	100.0			
FINAL/ET VALUE	PLO	57	64.04	27.880	0.0	50.00	75.00	83.33	100.0			
	ADA	54	71.76	30.562	0.0	66.67	83.33	91.67	100.0			
	TOT	111	67.79	29.339	0.0	50.00	75.00	83.33	100.0			
CHG FROM BSL	PLO	57	-4.53	15.029	-41.7	-16.67	0.00	0.00	25.0			
	ADA	54	-2.01	15.330	-58.3	-8.33	0.00	0.00	25.0			
	TOT	111	-3.30	15.160	-58.3	-8.33	0.00	0.00	25.0			
										2.53	(-3.19, 8.24)	0.383A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.30.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: IMM USAGE AT BASELINE=NO)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
COLOR VISION												
BSL VALUE	PLO	71	88.38	19.744	25.0	75.00	100.00	100.00	100.0			
	ADA	74	96.96	10.096	50.0	100.00	100.00	100.00	100.0			
	TOT	145	92.76	16.115	25.0	100.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	71	90.14	17.154	25.0	75.00	100.00	100.00	100.0			
	ADA	74	96.11	10.736	50.0	100.00	100.00	100.00	100.0			
	TOT	145	93.19	14.507	25.0	100.00	100.00	100.00	100.0			
CHG FROM BSL	PLO	71	1.76	12.903	-50.0	0.00	0.00	0.00	25.0			
	ADA	74	-0.84	10.206	-25.0	0.00	0.00	0.00	50.0			
	TOT	145	0.43	11.638	-50.0	0.00	0.00	0.00	50.0			
										-2.61	(-6.42, 1.21)	0.179A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.30.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: IMM USAGE AT BASELINE=NO)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
PERIPHERAL VISION												
BSL VALUE	PLO	72	75.69	24.456	25.0	50.00	75.00	100.00	100.0			
	ADA	75	81.33	20.994	25.0	75.00	75.00	100.00	100.0			
	TOT	147	78.57	22.853	25.0	50.00	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	72	78.99	22.481	25.0	75.00	75.00	100.00	100.0			
	ADA	75	82.67	22.123	0.0	75.00	100.00	100.00	100.0			
	TOT	147	80.87	22.299	0.0	75.00	75.00	100.00	100.0			
CHG FROM BSL	PLO	72	3.30	18.997	-50.0	0.00	0.00	25.00	50.0			
	ADA	75	1.33	15.861	-25.0	0.00	0.00	0.00	25.0			
	TOT	147	2.30	17.435	-50.0	0.00	0.00	0.00	50.0			
										-1.97	(-7.66, 3.73)	0.496A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.30.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: IMM USAGE AT BASELINE=NO)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
TOTAL SCORE												
BSL VALUE	PLO	73	74.13	18.924	25.3	60.98	82.65	89.36	95.9			
	ADA	75	79.62	12.884	43.7	71.82	81.70	89.09	99.4			
	TOT	148	76.91	16.327	25.3	67.90	81.92	89.22	99.4			
FINAL/ET VALUE	PLO	73	75.33	18.531	27.9	62.04	82.27	89.09	100.0			
	ADA	75	80.56	17.513	12.4	71.55	86.55	92.77	100.0			
	TOT	148	77.98	18.151	12.4	67.02	84.47	91.78	100.0			
CHG FROM BSL	PLO	73	1.21	10.053	-28.3	-4.81	1.89	6.04	29.4			
	ADA	75	0.95	10.883	-33.6	-3.03	2.27	6.74	24.4			
	TOT	148	1.08	10.447	-33.6	-3.32	2.27	6.25	29.4			
										-0.26	(-3.67, 3.14)	0.879A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.31.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: ORAL PREDNISONE USAGE AT BASELINE >20 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL HEALTH												
BSL VALUE	PLO	24	50.00	20.851	0.0	50.00	50.00	50.00	100.0			
	ADA	23	59.78	24.702	0.0	50.00	50.00	75.00	100.0			
	TOT	47	54.79	23.101	0.0	50.00	50.00	75.00	100.0			
FINAL/ET VALUE	PLO	24	44.79	19.476	0.0	37.50	50.00	50.00	75.0			
	ADA	23	59.24	22.046	0.0	50.00	50.00	75.00	100.0			
	TOT	47	51.86	21.804	0.0	50.00	50.00	75.00	100.0			
CHG FROM BSL	PLO	24	-5.21	16.450	-50.0	-12.50	0.00	0.00	25.0			
	ADA	23	-0.54	16.201	-25.0	0.00	0.00	0.00	25.0			
	TOT	47	-2.93	16.321	-50.0	0.00	0.00	0.00	25.0			
										4.66	(-4.93, 14.26)	0.333A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.31.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: ORAL PREDNISONE USAGE AT BASELINE >20 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL VISION												
BSL VALUE	PLO	24	62.50	15.948	40.0	50.00	60.00	80.00	80.0			
	ADA	22	74.55	11.010	60.0	60.00	80.00	80.00	100.0			
	TOT	46	68.26	14.952	40.0	60.00	80.00	80.00	100.0			
FINAL/ET VALUE	PLO	24	61.67	16.594	40.0	50.00	60.00	80.00	100.0			
	ADA	22	70.00	22.039	20.0	60.00	80.00	80.00	100.0			
	TOT	46	65.65	19.624	20.0	60.00	60.00	80.00	100.0			
CHG FROM BSL	PLO	24	-0.83	17.173	-40.0	-10.00	0.00	0.00	40.0			
	ADA	22	-4.55	20.407	-40.0	-20.00	0.00	0.00	40.0			
	TOT	46	-2.61	18.671	-40.0	-20.00	0.00	0.00	40.0			
										-3.71	(-14.89, 7.46)	0.507A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.31.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: ORAL PREDNISONE USAGE AT BASELINE >20 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
OCULAR PAIN												
BSL VALUE	PLO	24	63.02	26.956	12.5	43.75	62.50	87.50	100.0			
	ADA	23	83.15	20.159	25.0	75.00	87.50	100.00	100.0			
	TOT	47	72.87	25.713	12.5	50.00	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	24	72.40	21.168	25.0	62.50	75.00	93.75	100.0			
	ADA	23	77.72	25.826	12.5	62.50	87.50	100.00	100.0			
	TOT	47	75.00	23.458	12.5	62.50	75.00	100.00	100.0			
CHG FROM BSL	PLO	24	9.38	20.606	-25.0	0.00	0.00	18.75	62.5			
	ADA	23	-5.43	15.913	-37.5	-25.00	0.00	0.00	25.0			
	TOT	47	2.13	19.733	-37.5	-12.50	0.00	12.50	62.5			
										-14.81	(-25.66, -3.96)	0.009A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.31.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: ORAL PREDNISONE USAGE AT BASELINE >20 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
NEAR VISION												
BSL VALUE	PLO	24	59.72	24.533	16.7	45.83	66.67	75.00	100.0			
	ADA	23	89.13	12.163	66.7	75.00	91.67	100.00	100.0			
	TOT	47	74.11	24.341	16.7	66.67	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	24	65.97	20.548	25.0	50.00	66.67	79.17	100.0			
	ADA	23	81.88	26.430	0.0	66.67	91.67	100.00	100.0			
	TOT	47	73.76	24.695	0.0	58.33	75.00	100.00	100.0			
CHG FROM BSL	PLO	24	6.25	20.596	-25.0	-8.33	0.00	16.67	75.0			
	ADA	23	-7.25	21.659	-75.0	-16.67	0.00	0.00	25.0			
	TOT	47	-0.35	21.976	-75.0	-8.33	0.00	16.67	75.0			
										-13.50	(-25.91, -1.08)	0.034A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.31.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: ORAL PREDNISONE USAGE AT BASELINE >20 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DISTANCE VISION												
BSL VALUE	PLO	24	63.19	26.343	16.7	45.83	62.50	87.50	100.0			
	ADA	23	86.05	15.160	50.0	75.00	91.67	100.00	100.0			
	TOT	47	74.38	24.295	16.7	58.33	83.33	100.00	100.0			
FINAL/ET VALUE	PLO	24	67.88	20.095	29.2	54.17	66.67	83.33	100.0			
	ADA	23	82.61	25.240	0.0	66.67	91.67	100.00	100.0			
	TOT	47	75.09	23.706	0.0	58.33	75.00	100.00	100.0			
CHG FROM BSL	PLO	24	4.69	18.848	-25.0	-8.33	0.00	16.67	50.0			
	ADA	23	-3.44	21.711	-50.0	-16.67	0.00	16.67	25.0			
	TOT	47	0.71	20.492	-50.0	-8.33	0.00	16.67	50.0			
										-8.13	(-20.06, 3.80)	0.177A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.31.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: ORAL PREDNISONE USAGE AT BASELINE >20 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
SOCIAL FUNCTIONING												
BSL VALUE	PLO	24	78.65	22.263	25.0	62.50	81.25	100.00	100.0			
	ADA	23	94.57	15.913	25.0	100.00	100.00	100.00	100.0			
	TOT	47	86.44	20.824	25.0	75.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	24	77.34	24.368	6.3	62.50	81.25	100.00	100.0			
	ADA	23	88.86	19.580	25.0	87.50	100.00	100.00	100.0			
	TOT	47	82.98	22.674	6.3	75.00	93.75	100.00	100.0			
CHG FROM BSL	PLO	24	-1.30	16.275	-43.8	-12.50	0.00	0.00	37.5			
	ADA	23	-5.71	13.708	-50.0	-12.50	0.00	0.00	12.5			
	TOT	47	-3.46	15.075	-50.0	-12.50	0.00	0.00	37.5			
										-4.40	(-13.26, 4.46)	0.322A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.31.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: ORAL PREDNISONE USAGE AT BASELINE >20 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
MENTAL HEALTH												
BSL VALUE	PLO	24	46.88	27.890	0.0	28.13	46.88	71.88	87.5			
	ADA	23	75.27	16.372	31.3	62.50	81.25	87.50	100.0			
	TOT	47	60.77	26.889	0.0	43.75	68.75	87.50	100.0			
FINAL/ET VALUE	PLO	24	53.65	30.503	0.0	25.00	53.13	81.25	93.8			
	ADA	23	78.26	25.343	12.5	68.75	87.50	100.00	100.0			
	TOT	47	65.69	30.448	0.0	50.00	75.00	93.75	100.0			
CHG FROM BSL	PLO	24	6.77	12.890	-12.5	0.00	6.25	12.50	43.8			
	ADA	23	2.99	16.522	-31.3	-12.50	6.25	12.50	31.3			
	TOT	47	4.92	14.741	-31.3	-6.25	6.25	12.50	43.8			
										-3.78	(-12.47, 4.90)	0.385A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.31.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: ORAL PREDNISONE USAGE AT BASELINE >20 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
ROLE DIFFICULTIES												
BSL VALUE	PLO	24	54.17	26.237	12.5	37.50	50.00	68.75	100.0			
	ADA	23	73.37	25.368	25.0	50.00	75.00	100.00	100.0			
	TOT	47	63.56	27.315	12.5	37.50	50.00	87.50	100.0			
FINAL/ET VALUE	PLO	24	56.77	27.579	12.5	31.25	50.00	75.00	100.0			
	ADA	23	82.61	26.580	25.0	75.00	100.00	100.00	100.0			
	TOT	47	69.41	29.810	12.5	50.00	75.00	100.00	100.0			
CHG FROM BSL	PLO	24	2.60	26.830	-62.5	-12.50	0.00	18.75	50.0			
	ADA	23	9.24	23.602	-25.0	0.00	0.00	25.00	75.0			
	TOT	47	5.85	25.250	-62.5	-12.50	0.00	25.00	75.0			
										6.63	(-8.24, 21.51)	0.374A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.31.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: ORAL PREDNISONE USAGE AT BASELINE >20 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DEPENDENCY												
BSL VALUE	PLO	24	64.24	33.195	0.0	41.67	75.00	95.83	100.0			
	ADA	23	88.04	18.262	33.3	75.00	100.00	100.00	100.0			
	TOT	47	75.89	29.243	0.0	58.33	83.33	100.00	100.0			
FINAL/ET VALUE	PLO	24	68.75	33.626	0.0	45.83	79.17	100.00	100.0			
	ADA	23	86.59	26.441	16.7	91.67	100.00	100.00	100.0			
	TOT	47	77.48	31.321	0.0	58.33	100.00	100.00	100.0			
CHG FROM BSL	PLO	24	4.51	10.984	-16.7	0.00	0.00	16.67	25.0			
	ADA	23	-1.45	17.705	-41.7	-8.33	0.00	8.33	25.0			
	TOT	47	1.60	14.809	-41.7	0.00	0.00	8.33	25.0			
										-5.96	(-14.58, 2.65)	0.170A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.31.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: ORAL PREDNISONE USAGE AT BASELINE >20 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DRIVING												
BSL VALUE	PLO	16	59.90	35.253	0.0	33.33	70.83	87.50	100.0			
	ADA	19	79.17	31.150	0.0	66.67	91.67	100.00	100.0			
	TOT	35	70.36	34.012	0.0	58.33	83.33	100.00	100.0			
FINAL/ET VALUE	PLO	16	58.59	31.420	0.0	41.67	54.17	83.33	100.0			
	ADA	19	78.51	24.425	0.0	66.67	83.33	100.00	100.0			
	TOT	35	69.40	29.201	0.0	50.00	75.00	91.67	100.0			
CHG FROM BSL	PLO	16	-1.30	16.081	-33.3	-8.33	0.00	8.33	25.0			
	ADA	19	-0.66	27.367	-33.3	-16.67	0.00	0.00	100.0			
	TOT	35	-0.95	22.599	-33.3	-16.67	0.00	0.00	100.0			
										0.64	(-15.19, 16.48)	0.935A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.31.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: ORAL PREDNISONE USAGE AT BASELINE >20 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
COLOR VISION												
BSL VALUE	PLO	22	80.68	18.791	50.0	75.00	75.00	100.00	100.0			
	ADA	22	98.86	5.330	75.0	100.00	100.00	100.00	100.0			
	TOT	44	89.77	16.458	50.0	75.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	22	85.23	16.653	50.0	75.00	87.50	100.00	100.0			
	ADA	22	98.86	5.330	75.0	100.00	100.00	100.00	100.0			
	TOT	44	92.05	14.031	50.0	75.00	100.00	100.00	100.0			
CHG FROM BSL	PLO	22	4.55	16.612	-25.0	0.00	0.00	25.00	25.0			
	ADA	22	0.00	7.715	-25.0	0.00	0.00	0.00	25.0			
	TOT	44	2.27	13.005	-25.0	0.00	0.00	0.00	25.0			
										-4.55	(-12.43, 3.34)	0.251A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.31.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: ORAL PREDNISONE USAGE AT BASELINE >20 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
PERIPHERAL VISION												
BSL VALUE	PLO	24	66.67	25.181	0.0	50.00	75.00	75.00	100.0			
	ADA	23	85.87	21.087	25.0	75.00	100.00	100.00	100.0			
	TOT	47	76.06	24.977	0.0	50.00	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	24	68.23	23.013	25.0	50.00	75.00	87.50	100.0			
	ADA	23	81.52	29.404	0.0	75.00	100.00	100.00	100.0			
	TOT	47	74.73	26.897	0.0	50.00	75.00	100.00	100.0			
CHG FROM BSL	PLO	24	1.56	16.613	-25.0	0.00	0.00	0.00	50.0			
	ADA	23	-4.35	27.851	-75.0	-25.00	0.00	25.00	50.0			
	TOT	47	-1.33	22.757	-75.0	-12.50	0.00	0.00	50.0			
										-5.91	(-19.32, 7.50)	0.379A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.31.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: ORAL PREDNISONE USAGE AT BASELINE >20 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
TOTAL SCORE												
BSL VALUE	PLO	24	63.40	18.381	35.2	46.24	63.04	77.80	93.3			
	ADA	23	84.29	12.484	43.7	78.29	87.58	94.58	98.9			
	TOT	47	73.63	18.838	35.2	59.05	78.29	88.52	98.9			
FINAL/ET VALUE	PLO	24	66.60	17.633	40.4	49.92	65.49	83.14	97.6			
	ADA	23	81.84	21.565	12.4	74.88	89.09	96.48	100.0			
	TOT	47	74.06	20.907	12.4	59.13	75.04	90.68	100.0			
CHG FROM BSL	PLO	24	3.20	10.633	-14.7	-6.21	3.37	7.29	29.4			
	ADA	23	-2.46	14.452	-31.3	-6.44	1.14	6.48	22.2			
	TOT	47	0.43	12.829	-31.3	-6.44	1.52	6.48	29.4			
										-5.66	(-13.09, 1.78)	0.132A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.32.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: ORAL PREDNISONE USAGE AT BASELINE <=20 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL HEALTH												
BSL VALUE	PLO	101	53.22	26.378	0.0	25.00	50.00	75.00	100.0			
	ADA	108	56.02	20.754	25.0	50.00	50.00	75.00	100.0			
	TOT	209	54.67	23.623	0.0	50.00	50.00	75.00	100.0			
FINAL/ET VALUE	PLO	101	53.09	24.071	0.0	25.00	50.00	75.00	100.0			
	ADA	108	55.44	24.425	0.0	50.00	50.00	75.00	100.0			
	TOT	209	54.31	24.225	0.0	50.00	50.00	75.00	100.0			
CHG FROM BSL	PLO	101	-0.12	19.565	-75.0	0.00	0.00	0.00	50.0			
	ADA	108	-0.58	21.234	-50.0	-25.00	0.00	18.75	50.0			
	TOT	209	-0.36	20.397	-75.0	0.00	0.00	12.50	50.0			
										-0.45	(-6.03, 5.12)	0.872A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.32.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: ORAL PREDNISONE USAGE AT BASELINE <=20 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL VISION												
BSL VALUE	PLO	101	69.21	16.714	20.0	60.00	80.00	80.00	100.0			
	ADA	108	66.11	16.051	40.0	60.00	60.00	80.00	100.0			
	TOT	209	67.61	16.409	20.0	60.00	60.00	80.00	100.0			
FINAL/ET VALUE	PLO	101	64.75	19.214	20.0	60.00	60.00	80.00	100.0			
	ADA	108	69.72	18.619	20.0	60.00	80.00	80.00	100.0			
	TOT	209	67.32	19.027	20.0	60.00	80.00	80.00	100.0			
CHG FROM BSL	PLO	101	-4.46	15.523	-40.0	-20.00	0.00	0.00	20.0			
	ADA	108	3.61	14.690	-40.0	0.00	0.00	20.00	40.0			
	TOT	209	-0.29	15.594	-40.0	0.00	0.00	0.00	40.0			
										8.07	(3.95, 12.19)	<0.001A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.32.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: ORAL PREDNISONE USAGE AT BASELINE <=20 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
OCULAR PAIN												
BSL VALUE	PLO	101	79.08	20.548	25.0	62.50	87.50	100.00	100.0			
	ADA	108	77.60	20.634	25.0	62.50	75.00	100.00	100.0			
	TOT	209	78.32	20.556	25.0	62.50	81.25	100.00	100.0			
FINAL/ET VALUE	PLO	101	80.07	20.401	25.0	62.50	87.50	100.00	100.0			
	ADA	108	81.37	19.068	37.5	75.00	87.50	100.00	100.0			
	TOT	209	80.74	19.686	25.0	75.00	87.50	100.00	100.0			
CHG FROM BSL	PLO	101	0.99	16.171	-50.0	0.00	0.00	12.50	62.5			
	ADA	108	3.76	22.461	-62.5	0.00	0.00	12.50	62.5			
	TOT	209	2.42	19.677	-62.5	0.00	0.00	12.50	62.5			
										2.77	(-2.60, 8.14)	0.310A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.32.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: ORAL PREDNISONE USAGE AT BASELINE <=20 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
NEAR VISION												
BSL VALUE	PLO	101	74.30	23.813	0.0	58.33	75.00	91.67	100.0			
	ADA	108	72.84	21.530	8.3	58.33	75.00	91.67	100.0			
	TOT	209	73.54	22.619	0.0	58.33	75.00	91.67	100.0			
FINAL/ET VALUE	PLO	101	77.43	22.105	16.7	66.67	83.33	100.00	100.0			
	ADA	108	77.89	24.171	0.0	75.00	83.33	100.00	100.0			
	TOT	209	77.67	23.142	0.0	66.67	83.33	100.00	100.0			
CHG FROM BSL	PLO	101	3.14	16.313	-33.3	-8.33	0.00	8.33	62.5			
	ADA	108	5.05	19.684	-66.7	-2.08	6.25	16.67	50.0			
	TOT	209	4.13	18.116	-66.7	-4.17	0.00	16.67	62.5			
										1.92	(-3.03, 6.87)	0.446A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.32.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: ORAL PREDNISONE USAGE AT BASELINE <=20 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DISTANCE VISION												
BSL VALUE	PLO	101	76.65	22.080	8.3	66.67	83.33	91.67	100.0			
	ADA	108	73.42	21.114	8.3	58.33	75.00	91.67	100.0			
	TOT	209	74.98	21.595	8.3	58.33	83.33	91.67	100.0			
FINAL/ET VALUE	PLO	101	76.28	23.197	8.3	58.33	83.33	100.00	100.0			
	ADA	108	77.74	23.190	0.0	66.67	83.33	100.00	100.0			
	TOT	209	77.03	23.149	0.0	62.50	83.33	100.00	100.0			
CHG FROM BSL	PLO	101	-0.37	15.162	-41.7	-8.33	0.00	8.33	50.0			
	ADA	108	4.32	15.765	-25.0	0.00	0.00	8.33	75.0			
	TOT	209	2.05	15.618	-41.7	-8.33	0.00	8.33	75.0			
										4.69	(0.47, 8.92)	0.030A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.32.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: ORAL PREDNISONE USAGE AT BASELINE <=20 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
SOCIAL FUNCTIONING												
BSL VALUE	PLO	101	89.60	17.236	37.5	75.00	100.00	100.00	100.0			
	ADA	108	86.46	19.040	0.0	75.00	100.00	100.00	100.0			
	TOT	209	87.98	18.215	0.0	75.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	101	88.74	17.162	25.0	75.00	100.00	100.00	100.0			
	ADA	108	88.54	18.574	12.5	75.00	100.00	100.00	100.0			
	TOT	209	88.64	17.863	12.5	75.00	100.00	100.00	100.0			
CHG FROM BSL	PLO	101	-0.87	12.375	-37.5	0.00	0.00	0.00	37.5			
	ADA	108	2.08	14.349	-50.0	0.00	0.00	12.50	50.0			
	TOT	209	0.66	13.481	-50.0	0.00	0.00	0.00	50.0			
										2.95	(-0.72, 6.62)	0.114A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.32.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: ORAL PREDNISONE USAGE AT BASELINE <=20 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
MENTAL HEALTH												
BSL VALUE	PLO	101	68.23	21.561	12.5	56.25	75.00	87.50	100.0			
	ADA	108	63.66	23.764	0.0	46.88	68.75	81.25	100.0			
	TOT	209	65.87	22.788	0.0	50.00	75.00	81.25	100.0			
FINAL/ET VALUE	PLO	101	72.03	24.167	0.0	56.25	81.25	93.75	100.0			
	ADA	108	74.42	23.735	0.0	62.50	81.25	93.75	100.0			
	TOT	209	73.27	23.917	0.0	62.50	81.25	93.75	100.0			
CHG FROM BSL	PLO	101	3.80	19.147	-56.3	0.00	6.25	12.50	68.8			
	ADA	108	10.76	18.022	-37.5	0.00	12.50	18.75	62.5			
	TOT	209	7.40	18.855	-56.3	0.00	6.25	18.75	68.8			
										6.97	(1.90, 12.04)	0.007A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.32.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: ORAL PREDNISONE USAGE AT BASELINE <=20 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
ROLE DIFFICULTIES												
BSL VALUE	PLO	101	71.29	25.344	0.0	50.00	75.00	100.00	100.0			
	ADA	108	69.33	26.441	0.0	50.00	75.00	87.50	100.0			
	TOT	209	70.28	25.873	0.0	50.00	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	101	73.39	27.310	0.0	50.00	75.00	100.00	100.0			
	ADA	108	75.81	24.604	0.0	62.50	75.00	100.00	100.0			
	TOT	209	74.64	25.912	0.0	50.00	75.00	100.00	100.0			
CHG FROM BSL	PLO	101	2.10	19.927	-50.0	0.00	0.00	12.50	62.5			
	ADA	108	6.48	20.613	-50.0	0.00	0.00	12.50	62.5			
	TOT	209	4.37	20.354	-50.0	0.00	0.00	12.50	62.5			
										4.38	(-1.16, 9.91)	0.121A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.32.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: ORAL PREDNISONE USAGE AT BASELINE <=20 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DEPENDENCY												
BSL VALUE	PLO	100	86.38	22.472	0.0	83.33	100.00	100.00	100.0			
	ADA	108	85.03	23.175	8.3	79.17	100.00	100.00	100.0			
	TOT	208	85.68	22.795	0.0	83.33	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	100	85.83	23.376	0.0	83.33	100.00	100.00	100.0			
	ADA	108	86.96	21.078	8.3	79.17	100.00	100.00	100.0			
	TOT	208	86.42	22.166	0.0	83.33	100.00	100.00	100.0			
CHG FROM BSL	PLO	100	-0.54	18.308	-83.3	0.00	0.00	0.00	75.0			
	ADA	108	1.93	16.534	-50.0	0.00	0.00	4.17	58.3			
	TOT	208	0.74	17.411	-83.3	0.00	0.00	0.00	75.0			
										2.47	(-2.29, 7.23)	0.308A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.32.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: ORAL PREDNISONE USAGE AT BASELINE <=20 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DRIVING												
BSL VALUE	PLO	88	71.59	26.590	0.0	58.33	83.33	91.67	100.0			
	ADA	81	66.51	33.035	0.0	50.00	83.33	91.67	100.0			
	TOT	169	69.16	29.871	0.0	58.33	83.33	91.67	100.0			
FINAL/ET VALUE	PLO	88	67.99	27.228	0.0	58.33	75.00	85.42	100.0			
	ADA	81	68.11	33.073	0.0	58.33	83.33	91.67	100.0			
	TOT	169	68.05	30.080	0.0	58.33	75.00	91.67	100.0			
CHG FROM BSL	PLO	88	-3.60	15.347	-41.7	-8.33	0.00	0.00	66.7			
	ADA	81	1.59	19.671	-58.3	0.00	0.00	8.33	100.0			
	TOT	169	-1.11	17.692	-58.3	-8.33	0.00	4.17	100.0			
										5.19	(-0.14, 10.53)	0.056A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.32.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: ORAL PREDNISONE USAGE AT BASELINE <=20 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
COLOR VISION												
BSL VALUE	PLO	101	91.83	17.716	25.0	100.00	100.00	100.00	100.0			
	ADA	108	93.52	15.426	25.0	100.00	100.00	100.00	100.0			
	TOT	209	92.70	16.554	25.0	100.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	101	91.71	16.229	25.0	100.00	100.00	100.00	100.0			
	ADA	108	92.71	18.416	0.0	100.00	100.00	100.00	100.0			
	TOT	209	92.22	17.359	0.0	100.00	100.00	100.00	100.0			
CHG FROM BSL	PLO	101	-0.12	12.310	-50.0	0.00	0.00	0.00	50.0			
	ADA	108	-0.81	13.046	-50.0	0.00	0.00	0.00	50.0			
	TOT	209	-0.48	12.670	-50.0	0.00	0.00	0.00	50.0			
										-0.69	(-4.15, 2.78)	0.696A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.32.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: ORAL PREDNISONE USAGE AT BASELINE <=20 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
PERIPHERAL VISION												
BSL VALUE	PLO	99	78.03	24.294	25.0	50.00	75.00	100.00	100.0			
	ADA	106	78.07	23.069	0.0	50.00	75.00	100.00	100.0			
	TOT	205	78.05	23.610	0.0	50.00	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	99	83.08	20.695	25.0	75.00	87.50	100.00	100.0			
	ADA	106	82.55	21.868	25.0	75.00	100.00	100.00	100.0			
	TOT	205	82.80	21.259	25.0	75.00	100.00	100.00	100.0			
CHG FROM BSL	PLO	99	5.05	19.473	-50.0	0.00	0.00	25.00	50.0			
	ADA	106	4.48	17.182	-25.0	0.00	0.00	25.00	50.0			
	TOT	205	4.76	18.281	-50.0	0.00	0.00	25.00	50.0			
										-0.57	(-5.62, 4.48)	0.824A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.32.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: ORAL PREDNISONE USAGE AT BASELINE <=20 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
TOTAL SCORE												
BSL VALUE	PLO	101	77.80	16.897	25.3	67.46	83.86	90.30	97.6			
	ADA	108	75.77	15.575	15.4	69.01	79.25	87.71	99.4			
	TOT	209	76.75	16.220	15.4	68.14	81.70	89.09	99.4			
FINAL/ET VALUE	PLO	101	78.28	17.844	27.9	69.73	84.17	92.88	100.0			
	ADA	108	79.67	17.840	20.4	70.64	85.61	92.41	100.0			
	TOT	209	79.00	17.813	20.4	70.11	84.92	92.88	100.0			
CHG FROM BSL	PLO	101	0.47	10.110	-30.9	-4.47	1.89	5.19	25.0			
	ADA	108	3.90	11.197	-33.6	-0.66	3.94	10.08	42.0			
	TOT	209	2.25	10.797	-33.6	-2.27	2.84	8.33	42.0			
										3.43	(0.51, 6.35)	0.021A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.33.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TOPICAL STEROIDS AT BASELINE=YES)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL HEALTH												
BSL VALUE	PLO	42	44.05	25.188	0.0	25.00	50.00	50.00	100.0			
	ADA	32	51.56	17.890	25.0	50.00	50.00	75.00	75.0			
	TOT	74	47.30	22.501	0.0	25.00	50.00	50.00	100.0			
FINAL/ET VALUE	PLO	42	44.64	26.787	0.0	25.00	50.00	75.00	100.0			
	ADA	32	50.00	21.997	0.0	37.50	50.00	75.00	75.0			
	TOT	74	46.96	24.812	0.0	25.00	50.00	75.00	100.0			
CHG FROM BSL	PLO	42	0.60	20.279	-75.0	0.00	0.00	25.00	25.0			
	ADA	32	-1.56	18.984	-50.0	-12.50	0.00	0.00	25.0			
	TOT	74	-0.34	19.625	-75.0	0.00	0.00	0.00	25.0			
										-2.16	(-11.39, 7.07)	0.643A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.33.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TOPICAL STEROIDS AT BASELINE=YES)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL VISION												
BSL VALUE	PLO	42	63.81	17.800	40.0	60.00	60.00	80.00	100.0			
	ADA	32	63.13	15.332	40.0	60.00	60.00	80.00	80.0			
	TOT	74	63.51	16.670	40.0	60.00	60.00	80.00	100.0			
FINAL/ET VALUE	PLO	42	58.57	22.693	20.0	40.00	60.00	80.00	100.0			
	ADA	32	62.50	20.791	20.0	40.00	60.00	80.00	100.0			
	TOT	74	60.27	21.832	20.0	40.00	60.00	80.00	100.0			
CHG FROM BSL	PLO	42	-5.24	15.963	-40.0	-20.00	0.00	0.00	40.0			
	ADA	32	-0.63	16.449	-40.0	0.00	0.00	0.00	40.0			
	TOT	74	-3.24	16.227	-40.0	-20.00	0.00	0.00	40.0			
										4.61	(-2.95, 12.18)	0.228A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.33.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TOPICAL STEROIDS AT BASELINE=YES)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#		P-VALUE@
OCULAR PAIN													
BSL VALUE	PLO	42	69.64	21.232	25.0	50.00	75.00	87.50	100.0				
	ADA	32	75.39	20.450	25.0	62.50	81.25	87.50	100.0				
	TOT	74	72.13	20.952	25.0	50.00	75.00	87.50	100.0				
FINAL/ET VALUE	PLO	42	74.11	22.495	25.0	50.00	75.00	100.00	100.0				
	ADA	32	75.78	20.561	37.5	62.50	75.00	100.00	100.0				
	TOT	74	74.83	21.551	25.0	62.50	75.00	100.00	100.0				
CHG FROM BSL	PLO	42	4.46	20.627	-50.0	0.00	0.00	12.50	62.5				
	ADA	32	0.39	24.488	-50.0	-12.50	0.00	12.50	62.5				
	TOT	74	2.70	22.310	-50.0	-12.50	0.00	12.50	62.5				
										-4.07	(-14.54,	6.39)	0.440A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.33.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TOPICAL STEROIDS AT BASELINE=YES)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
NEAR VISION												
BSL VALUE	PLO	42	61.21	27.214	0.0	41.67	62.50	83.33	100.0			
	ADA	32	71.09	19.627	33.3	54.17	75.00	83.33	100.0			
	TOT	74	65.48	24.573	0.0	50.00	66.67	83.33	100.0			
FINAL/ET VALUE	PLO	42	68.65	23.913	16.7	50.00	66.67	91.67	100.0			
	ADA	32	73.44	25.526	0.0	62.50	79.17	91.67	100.0			
	TOT	74	70.72	24.568	0.0	50.00	75.00	91.67	100.0			
CHG FROM BSL	PLO	42	7.44	20.935	-33.3	0.00	0.00	16.67	75.0			
	ADA	32	2.34	26.794	-66.7	-8.33	0.00	20.83	50.0			
	TOT	74	5.24	23.611	-66.7	-8.33	0.00	16.67	75.0			
										-5.10	(-16.15, 5.96)	0.361A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.33.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TOPICAL STEROIDS AT BASELINE=YES)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DISTANCE VISION												
BSL VALUE	PLO	42	64.68	25.490	8.3	41.67	58.33	83.33	100.0			
	ADA	32	67.84	21.040	25.0	54.17	66.67	83.33	100.0			
	TOT	74	66.05	23.567	8.3	50.00	66.67	83.33	100.0			
FINAL/ET VALUE	PLO	42	66.47	26.303	8.3	50.00	66.67	91.67	100.0			
	ADA	32	72.14	23.723	25.0	50.00	75.00	91.67	100.0			
	TOT	74	68.92	25.210	8.3	50.00	66.67	91.67	100.0			
CHG FROM BSL	PLO	42	1.79	15.863	-41.7	0.00	0.00	8.33	50.0			
	ADA	32	4.30	15.608	-25.0	-6.25	0.00	12.50	41.7			
	TOT	74	2.87	15.696	-41.7	-4.17	0.00	8.33	50.0			
										2.51	(-4.86, 9.88)	0.499A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.33.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TOPICAL STEROIDS AT BASELINE=YES)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
SOCIAL FUNCTIONING												
BSL VALUE	PLO	42	78.57	19.577	37.5	62.50	75.00	100.00	100.0			
	ADA	32	83.20	18.946	50.0	68.75	87.50	100.00	100.0			
	TOT	74	80.57	19.314	37.5	62.50	87.50	100.00	100.0			
FINAL/ET VALUE	PLO	42	78.72	23.469	6.3	62.50	87.50	100.00	100.0			
	ADA	32	84.38	19.828	50.0	68.75	100.00	100.00	100.0			
	TOT	74	81.17	22.006	6.3	62.50	87.50	100.00	100.0			
CHG FROM BSL	PLO	42	0.15	15.889	-43.8	-12.50	0.00	12.50	37.5			
	ADA	32	1.17	15.345	-50.0	0.00	0.00	12.50	37.5			
	TOT	74	0.59	15.558	-50.0	0.00	0.00	12.50	37.5			
										1.02	(-6.30, 8.35)	0.781A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.33.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TOPICAL STEROIDS AT BASELINE=YES)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#		P-VALUE@
MENTAL HEALTH													
BSL VALUE	PLO	42	55.51	27.163	6.3	31.25	53.13	81.25	100.0				
	ADA	32	64.84	20.805	25.0	46.88	68.75	84.38	93.8				
	TOT	74	59.54	24.898	6.3	43.75	62.50	81.25	100.0				
FINAL/ET VALUE	PLO	42	63.69	28.264	12.5	37.50	65.63	93.75	100.0				
	ADA	32	71.68	24.387	12.5	56.25	75.00	93.75	100.0				
	TOT	74	67.15	26.779	12.5	50.00	75.00	93.75	100.0				
CHG FROM BSL	PLO	42	8.18	19.102	-37.5	0.00	6.25	18.75	68.8				
	ADA	32	6.84	20.103	-37.5	-6.25	9.38	21.88	37.5				
	TOT	74	7.60	19.417	-37.5	-6.25	6.25	18.75	68.8				
										-1.35	(-10.49,	7.79)	0.769A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.33.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TOPICAL STEROIDS AT BASELINE=YES)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
ROLE DIFFICULTIES												
BSL VALUE	PLO	42	58.63	27.675	12.5	37.50	50.00	87.50	100.0			
	ADA	32	71.88	22.225	37.5	50.00	75.00	87.50	100.0			
	TOT	74	64.36	26.145	12.5	50.00	56.25	87.50	100.0			
FINAL/ET VALUE	PLO	42	65.48	28.930	12.5	37.50	68.75	100.00	100.0			
	ADA	32	76.17	21.850	25.0	62.50	75.00	100.00	100.0			
	TOT	74	70.10	26.482	12.5	50.00	75.00	100.00	100.0			
CHG FROM BSL	PLO	42	6.85	22.632	-50.0	0.00	0.00	25.00	62.5			
	ADA	32	4.30	23.029	-37.5	-12.50	0.00	12.50	62.5			
	TOT	74	5.74	22.683	-50.0	-12.50	0.00	12.50	62.5			
										-2.55	(-13.22, 8.12)	0.635A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.33.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TOPICAL STEROIDS AT BASELINE=YES)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DEPENDENCY												
BSL VALUE	PLO	42	71.23	30.919	0.0	50.00	83.33	100.00	100.0			
	ADA	32	81.77	20.240	16.7	70.83	83.33	100.00	100.0			
	TOT	74	75.79	27.176	0.0	58.33	83.33	100.00	100.0			
FINAL/ET VALUE	PLO	42	74.21	31.116	0.0	58.33	87.50	100.00	100.0			
	ADA	32	85.16	17.927	41.7	70.83	91.67	100.00	100.0			
	TOT	74	78.94	26.648	0.0	66.67	91.67	100.00	100.0			
CHG FROM BSL	PLO	42	2.98	18.933	-50.0	0.00	0.00	8.33	75.0			
	ADA	32	3.39	21.467	-50.0	0.00	0.00	8.33	58.3			
	TOT	74	3.15	19.927	-50.0	0.00	0.00	8.33	75.0			
										0.41	(-8.98, 9.79)	0.931A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.33.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TOPICAL STEROIDS AT BASELINE=YES)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#		P-VALUE@
DRIVING													
BSL VALUE	PLO	30	56.94	33.625	0.0	33.33	62.50	83.33	100.0				
	ADA	25	57.33	39.258	0.0	0.00	75.00	83.33	100.0				
	TOT	55	57.12	35.948	0.0	25.00	66.67	83.33	100.0				
FINAL/ET VALUE	PLO	30	57.92	31.359	0.0	33.33	66.67	83.33	100.0				
	ADA	25	54.67	39.826	0.0	0.00	66.67	91.67	100.0				
	TOT	55	56.44	35.153	0.0	25.00	66.67	83.33	100.0				
CHG FROM BSL	PLO	30	0.97	18.135	-33.3	-8.33	0.00	8.33	66.7				
	ADA	25	-2.67	20.087	-58.3	0.00	0.00	0.00	41.7				
	TOT	55	-0.68	18.955	-58.3	-8.33	0.00	8.33	66.7				
										-3.64	(-13.98,	6.70)	0.484A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.33.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TOPICAL STEROIDS AT BASELINE=YES)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
COLOR VISION												
BSL VALUE	PLO	41	85.37	21.633	25.0	75.00	100.00	100.00	100.0			
	ADA	32	88.28	17.943	50.0	75.00	100.00	100.00	100.0			
	TOT	73	86.64	20.018	25.0	75.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	41	87.20	19.463	25.0	75.00	100.00	100.00	100.0			
	ADA	32	90.63	20.820	0.0	87.50	100.00	100.00	100.0			
	TOT	73	88.70	20.000	0.0	75.00	100.00	100.00	100.0			
CHG FROM BSL	PLO	41	1.83	14.131	-25.0	0.00	0.00	0.00	25.0			
	ADA	32	2.34	18.360	-50.0	0.00	0.00	0.00	50.0			
	TOT	73	2.05	16.004	-50.0	0.00	0.00	0.00	50.0			
										0.51	(-7.06, 8.09)	0.893A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.33.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TOPICAL STEROIDS AT BASELINE=YES)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
PERIPHERAL VISION												
BSL VALUE	PLO	41	68.29	26.824	0.0	50.00	75.00	100.00	100.0			
	ADA	31	75.81	20.900	50.0	50.00	75.00	100.00	100.0			
	TOT	72	71.53	24.576	0.0	50.00	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	41	75.91	24.747	25.0	50.00	75.00	100.00	100.0			
	ADA	31	80.65	22.089	25.0	75.00	75.00	100.00	100.0			
	TOT	72	77.95	23.595	25.0	50.00	75.00	100.00	100.0			
CHG FROM BSL	PLO	41	7.62	18.303	-25.0	0.00	0.00	25.00	50.0			
	ADA	31	4.84	18.730	-25.0	0.00	0.00	25.00	50.0			
	TOT	72	6.42	18.409	-25.0	0.00	0.00	25.00	50.0			
										-2.78	(-11.56, 5.99)	0.529A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.33.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TOPICAL STEROIDS AT BASELINE=YES)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
TOTAL SCORE												
BSL VALUE	PLO	42	66.76	19.616	25.3	50.61	67.55	85.64	95.9			
	ADA	32	72.90	14.773	47.5	60.00	71.89	84.87	95.9			
	TOT	74	69.42	17.838	25.3	55.27	70.87	85.64	95.9			
FINAL/ET VALUE	PLO	42	69.98	20.291	27.9	52.25	72.90	87.65	100.0			
	ADA	32	75.53	18.568	33.1	58.21	80.67	92.54	100.0			
	TOT	74	72.38	19.629	27.9	54.77	74.87	89.09	100.0			
CHG FROM BSL	PLO	42	3.23	10.715	-30.9	-1.38	3.41	7.01	29.4			
	ADA	32	2.62	13.468	-33.6	-2.37	3.86	9.85	37.0			
	TOT	74	2.97	11.900	-33.6	-1.52	3.86	9.09	37.0			
										-0.61	(-6.21, 5.00)	0.830A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.34.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TOPICAL STEROIDS AT BASELINE=NO)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL HEALTH												
BSL VALUE	PLO	83	56.93	24.480	0.0	50.00	50.00	75.00	100.0			
	ADA	99	58.33	22.304	0.0	50.00	50.00	75.00	100.0			
	TOT	182	57.69	23.267	0.0	50.00	50.00	75.00	100.0			
FINAL/ET VALUE	PLO	83	54.97	20.838	0.0	50.00	50.00	75.00	100.0			
	ADA	99	58.08	24.374	0.0	50.00	50.00	75.00	100.0			
	TOT	182	56.66	22.821	0.0	50.00	50.00	75.00	100.0			
CHG FROM BSL	PLO	83	-1.96	18.467	-50.0	-25.00	0.00	0.00	50.0			
	ADA	99	-0.25	20.900	-50.0	-25.00	0.00	12.50	50.0			
	TOT	182	-1.03	19.792	-50.0	-25.00	0.00	0.00	50.0			
										1.71	(-4.12, 7.53)	0.564A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.34.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TOPICAL STEROIDS AT BASELINE=NO)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL VISION												
BSL VALUE	PLO	83	70.00	15.850	20.0	60.00	80.00	80.00	100.0			
	ADA	98	68.98	15.498	40.0	60.00	70.00	80.00	100.0			
	TOT	181	69.45	15.625	20.0	60.00	80.00	80.00	100.0			
FINAL/ET VALUE	PLO	83	66.99	15.752	20.0	60.00	60.00	80.00	100.0			
	ADA	98	72.14	18.063	20.0	60.00	80.00	80.00	100.0			
	TOT	181	69.78	17.190	20.0	60.00	80.00	80.00	100.0			
CHG FROM BSL	PLO	83	-3.01	15.829	-40.0	-20.00	0.00	0.00	20.0			
	ADA	98	3.16	15.834	-40.0	0.00	0.00	20.00	40.0			
	TOT	181	0.33	16.087	-40.0	0.00	0.00	20.00	40.0			
										6.18	(1.51, 10.84)	0.010A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.34.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TOPICAL STEROIDS AT BASELINE=NO)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
OCULAR PAIN												
BSL VALUE	PLO	83	79.22	22.873	12.5	62.50	87.50	100.00	100.0			
	ADA	99	79.61	20.625	25.0	75.00	87.50	100.00	100.0			
	TOT	182	79.43	21.619	12.5	62.50	87.50	100.00	100.0			
FINAL/ET VALUE	PLO	83	80.87	19.457	25.0	62.50	75.00	100.00	100.0			
	ADA	99	82.32	20.125	12.5	75.00	87.50	100.00	100.0			
	TOT	182	81.66	19.782	12.5	75.00	87.50	100.00	100.0			
CHG FROM BSL	PLO	83	1.66	15.467	-25.0	0.00	0.00	12.50	62.5			
	ADA	99	2.71	20.809	-62.5	0.00	0.00	12.50	62.5			
	TOT	182	2.23	18.523	-62.5	0.00	0.00	12.50	62.5			
										1.06	(-4.39, 6.51)	0.702A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.34.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TOPICAL STEROIDS AT BASELINE=NO)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
NEAR VISION												
BSL VALUE	PLO	83	76.71	21.415	16.7	66.67	75.00	91.67	100.0			
	ADA	99	77.19	21.440	8.3	66.67	83.33	91.67	100.0			
	TOT	182	76.97	21.371	8.3	66.67	83.33	91.67	100.0			
FINAL/ET VALUE	PLO	83	78.56	20.641	25.0	58.33	83.33	100.00	100.0			
	ADA	99	80.26	24.088	0.0	75.00	83.33	100.00	100.0			
	TOT	182	79.49	22.536	0.0	66.67	83.33	100.00	100.0			
CHG FROM BSL	PLO	83	1.86	14.699	-33.3	-8.33	0.00	8.33	41.7			
	ADA	99	3.07	18.178	-75.0	-4.17	0.00	16.67	41.7			
	TOT	182	2.52	16.648	-75.0	-8.33	0.00	16.67	41.7			
										1.21	(-3.68, 6.11)	0.625A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.34.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TOPICAL STEROIDS AT BASELINE=NO)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DISTANCE VISION												
BSL VALUE	PLO	83	78.82	20.957	16.7	66.67	83.33	91.67	100.0			
	ADA	99	78.16	20.072	8.3	66.67	83.33	91.67	100.0			
	TOT	182	78.46	20.426	8.3	66.67	83.33	91.67	100.0			
FINAL/ET VALUE	PLO	83	78.82	19.707	16.7	66.67	83.33	100.00	100.0			
	ADA	99	80.68	23.210	0.0	75.00	91.67	100.00	100.0			
	TOT	182	79.83	21.645	0.0	66.67	83.33	100.00	100.0			
CHG FROM BSL	PLO	83	0.00	16.098	-33.3	-8.33	0.00	8.33	50.0			
	ADA	99	2.53	17.636	-50.0	-4.17	0.00	8.33	75.0			
	TOT	182	1.37	16.953	-50.0	-8.33	0.00	8.33	75.0			
										2.53	(-2.45, 7.50)	0.318A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.34.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TOPICAL STEROIDS AT BASELINE=NO)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
SOCIAL FUNCTIONING												
BSL VALUE	PLO	83	92.02	16.631	25.0	87.50	100.00	100.00	100.0			
	ADA	99	89.39	18.503	0.0	87.50	100.00	100.00	100.0			
	TOT	182	90.59	17.675	0.0	87.50	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	83	90.51	15.289	25.0	87.50	100.00	100.00	100.0			
	ADA	99	89.96	18.185	12.5	87.50	100.00	100.00	100.0			
	TOT	182	90.21	16.883	12.5	87.50	100.00	100.00	100.0			
CHG FROM BSL	PLO	83	-1.51	11.574	-37.5	0.00	0.00	0.00	37.5			
	ADA	99	0.57	14.288	-50.0	0.00	0.00	0.00	50.0			
	TOT	182	-0.38	13.126	-50.0	0.00	0.00	0.00	50.0			
										2.07	(-1.78, 5.93)	0.290A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.34.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TOPICAL STEROIDS AT BASELINE=NO)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
MENTAL HEALTH												
BSL VALUE	PLO	83	68.50	21.603	0.0	56.25	75.00	81.25	93.8			
	ADA	99	65.97	23.783	0.0	56.25	75.00	81.25	100.0			
	TOT	182	67.12	22.788	0.0	56.25	75.00	81.25	100.0			
FINAL/ET VALUE	PLO	83	70.93	25.217	0.0	56.25	81.25	87.50	100.0			
	ADA	99	76.20	23.852	0.0	62.50	81.25	93.75	100.0			
	TOT	182	73.80	24.557	0.0	62.50	81.25	93.75	100.0			
CHG FROM BSL	PLO	83	2.43	17.381	-56.3	-6.25	6.25	12.50	43.8			
	ADA	99	10.23	17.231	-31.3	0.00	12.50	18.75	62.5			
	TOT	182	6.67	17.685	-56.3	0.00	6.25	12.50	62.5			
										7.79	(2.71, 12.87)	0.003A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.34.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TOPICAL STEROIDS AT BASELINE=NO)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
ROLE DIFFICULTIES												
BSL VALUE	PLO	83	72.74	24.394	0.0	50.00	75.00	100.00	100.0			
	ADA	99	69.44	27.446	0.0	50.00	75.00	100.00	100.0			
	TOT	182	70.95	26.079	0.0	50.00	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	83	72.59	27.432	0.0	50.00	75.00	100.00	100.0			
	ADA	99	77.27	26.023	0.0	62.50	87.50	100.00	100.0			
	TOT	182	75.14	26.703	0.0	50.00	81.25	100.00	100.0			
CHG FROM BSL	PLO	83	-0.15	20.334	-62.5	-12.50	0.00	12.50	62.5			
	ADA	99	7.83	20.484	-50.0	0.00	0.00	12.50	75.0			
	TOT	182	4.19	20.746	-62.5	0.00	0.00	12.50	75.0			
										7.98	(1.98, 13.97)	0.009A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.34.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TOPICAL STEROIDS AT BASELINE=NO)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DEPENDENCY												
BSL VALUE	PLO	82	87.65	21.700	0.0	83.33	100.00	100.00	100.0			
	ADA	99	86.78	22.961	8.3	83.33	100.00	100.00	100.0			
	TOT	181	87.18	22.341	0.0	83.33	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	82	86.79	22.679	8.3	83.33	100.00	100.00	100.0			
	ADA	99	87.46	23.218	8.3	83.33	100.00	100.00	100.0			
	TOT	181	87.15	22.914	8.3	83.33	100.00	100.00	100.0			
CHG FROM BSL	PLO	82	-0.86	16.233	-83.3	0.00	0.00	0.00	41.7			
	ADA	99	0.67	14.949	-50.0	0.00	0.00	0.00	58.3			
	TOT	181	-0.02	15.519	-83.3	0.00	0.00	0.00	58.3			
										1.54	(-3.04, 6.12)	0.509A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.34.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TOPICAL STEROIDS AT BASELINE=NO)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DRIVING												
BSL VALUE	PLO	74	75.00	24.060	0.0	58.33	83.33	91.67	100.0			
	ADA	75	72.78	29.814	0.0	58.33	83.33	100.00	100.0			
	TOT	149	73.88	27.041	0.0	58.33	83.33	91.67	100.0			
FINAL/ET VALUE	PLO	74	70.05	25.867	0.0	58.33	75.00	91.67	100.0			
	ADA	75	75.22	26.993	0.0	66.67	83.33	100.00	100.0			
	TOT	149	72.65	26.478	0.0	58.33	83.33	91.67	100.0			
CHG FROM BSL	PLO	74	-4.95	13.925	-41.7	-8.33	0.00	0.00	25.0			
	ADA	75	2.44	21.543	-41.7	-8.33	0.00	8.33	100.0			
	TOT	149	-1.23	18.479	-41.7	-8.33	0.00	0.00	100.0			
										7.40	(1.52, 13.28)	0.014A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.34.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TOPICAL STEROIDS AT BASELINE=NO)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
COLOR VISION												
BSL VALUE	PLO	82	92.07	16.139	50.0	100.00	100.00	100.00	100.0			
	ADA	98	96.43	12.435	25.0	100.00	100.00	100.00	100.0			
	TOT	180	94.44	14.366	25.0	100.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	82	92.23	14.519	50.0	87.50	100.00	100.00	100.0			
	ADA	98	94.77	15.640	25.0	100.00	100.00	100.00	100.0			
	TOT	180	93.61	15.151	25.0	100.00	100.00	100.00	100.0			
CHG FROM BSL	PLO	82	0.15	12.804	-50.0	0.00	0.00	0.00	50.0			
	ADA	98	-1.66	9.436	-50.0	0.00	0.00	0.00	25.0			
	TOT	180	-0.83	11.102	-50.0	0.00	0.00	0.00	50.0			
										-1.81	(-5.09, 1.47)	0.277A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.34.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TOPICAL STEROIDS AT BASELINE=NO)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
PERIPHERAL VISION												
BSL VALUE	PLO	82	79.57	22.949	25.0	75.00	75.00	100.00	100.0			
	ADA	98	80.61	23.411	0.0	75.00	87.50	100.00	100.0			
	TOT	180	80.14	23.143	0.0	75.00	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	82	82.32	20.122	25.0	75.00	75.00	100.00	100.0			
	ADA	98	82.91	23.703	0.0	75.00	100.00	100.00	100.0			
	TOT	180	82.64	22.085	0.0	75.00	100.00	100.00	100.0			
CHG FROM BSL	PLO	82	2.74	19.147	-50.0	0.00	0.00	25.00	50.0			
	ADA	98	2.30	20.015	-75.0	0.00	0.00	0.00	50.0			
	TOT	180	2.50	19.571	-75.0	0.00	0.00	25.00	50.0			
										-0.45	(-6.24, 5.35)	0.879A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.34.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TOPICAL STEROIDS AT BASELINE=NO)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
TOTAL SCORE												
BSL VALUE	PLO	83	79.23	15.706	26.6	70.98	85.87	91.10	97.6			
	ADA	99	78.67	15.384	15.4	73.37	81.40	89.09	99.4			
	TOT	182	78.93	15.491	15.4	71.48	83.50	90.29	99.4			
FINAL/ET VALUE	PLO	83	79.10	16.542	28.7	66.44	84.51	92.88	98.2			
	ADA	99	81.51	18.300	12.4	74.88	87.20	94.58	100.0			
	TOT	182	80.41	17.514	12.4	70.80	86.42	92.95	100.0			
CHG FROM BSL	PLO	83	-0.13	9.842	-28.3	-6.06	1.67	5.19	21.5			
	ADA	99	2.84	11.585	-31.3	-2.08	3.60	9.58	42.0			
	TOT	182	1.49	10.897	-31.3	-3.79	2.56	8.07	42.0			
										2.97	(-0.21, 6.15)	0.067A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.35.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PROTOCOL DEVIATION 'WRONG TREATMENT/INCORRECT DOSE REGARDING PREDNISONE'=YES)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
GENERAL HEALTH									
BSL VALUE	PLO	1	50.00		50.0	50.00	50.00	50.00	50.0
	ADA	3	66.67	28.868	50.0	50.00	50.00	100.00	100.0
	TOT	4	62.50	25.000	50.0	50.00	50.00	75.00	100.0
FINAL/ET VALUE	PLO	1	50.00		50.0	50.00	50.00	50.00	50.0
	ADA	3	66.67	28.868	50.0	50.00	50.00	100.00	100.0
	TOT	4	62.50	25.000	50.0	50.00	50.00	75.00	100.0
CHG FROM BSL	PLO	1	0.00		0.0	0.00	0.00	0.00	0.0
	ADA	3	0.00	0.000	0.0	0.00	0.00	0.00	0.0
	TOT	4	0.00	0.000	0.0	0.00	0.00	0.00	0.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.35.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PROTOCOL DEVIATION 'WRONG TREATMENT/INCORRECT DOSE REGARDING PREDNISONE'=YES)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
GENERAL VISION									
BSL VALUE	PLO	1	80.00		80.0	80.00	80.00	80.00	80.0
	ADA	3	80.00	20.000	60.0	60.00	80.00	100.00	100.0
	TOT	4	80.00	16.330	60.0	70.00	80.00	90.00	100.0
FINAL/ET VALUE	PLO	1	60.00		60.0	60.00	60.00	60.00	60.0
	ADA	3	86.67	11.547	80.0	80.00	80.00	100.00	100.0
	TOT	4	80.00	16.330	60.0	70.00	80.00	90.00	100.0
CHG FROM BSL	PLO	1	-20.00		-20.0	-20.00	-20.00	-20.00	-20.0
	ADA	3	6.67	11.547	0.0	0.00	0.00	20.00	20.0
	TOT	4	0.00	16.330	-20.0	-10.00	0.00	10.00	20.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.35.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PROTOCOL DEVIATION 'WRONG TREATMENT/INCORRECT DOSE REGARDING PREDNISONE'=YES)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
OCULAR PAIN									
BSL VALUE	PLO	1	25.00		25.0	25.00	25.00	25.00	25.0
	ADA	3	66.67	14.434	50.0	50.00	75.00	75.00	75.0
	TOT	4	56.25	23.936	25.0	37.50	62.50	75.00	75.0
FINAL/ET VALUE	PLO	1	87.50		87.5	87.50	87.50	87.50	87.5
	ADA	3	87.50	21.651	62.5	62.50	100.00	100.00	100.0
	TOT	4	87.50	17.678	62.5	75.00	93.75	100.00	100.0
CHG FROM BSL	PLO	1	62.50		62.5	62.50	62.50	62.50	62.5
	ADA	3	20.83	7.217	12.5	12.50	25.00	25.00	25.0
	TOT	4	31.25	21.651	12.5	18.75	25.00	43.75	62.5

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.35.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PROTOCOL DEVIATION 'WRONG TREATMENT/INCORRECT DOSE REGARDING PREDNISONE'=YES)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
NEAR VISION									
BSL VALUE	PLO	1	58.33		58.3	58.33	58.33	58.33	58.3
	ADA	3	91.67	14.434	75.0	75.00	100.00	100.00	100.0
	TOT	4	83.33	20.412	58.3	66.67	87.50	100.00	100.0
FINAL/ET VALUE	PLO	1	58.33		58.3	58.33	58.33	58.33	58.3
	ADA	3	97.22	4.811	91.7	91.67	100.00	100.00	100.0
	TOT	4	87.50	19.837	58.3	75.00	95.83	100.00	100.0
CHG FROM BSL	PLO	1	0.00		0.0	0.00	0.00	0.00	0.0
	ADA	3	5.56	17.347	-8.3	-8.33	0.00	25.00	25.0
	TOT	4	4.17	14.434	-8.3	-4.17	0.00	12.50	25.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.35.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PROTOCOL DEVIATION 'WRONG TREATMENT/INCORRECT DOSE REGARDING PREDNISONE'=YES)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
DISTANCE VISION									
BSL VALUE	PLO	1	91.67		91.7	91.67	91.67	91.67	91.7
	ADA	3	80.56	20.972	58.3	58.33	83.33	100.00	100.0
	TOT	4	83.33	18.002	58.3	70.83	87.50	95.83	100.0
FINAL/ET VALUE	PLO	1	91.67		91.7	91.67	91.67	91.67	91.7
	ADA	3	88.89	12.729	75.0	75.00	91.67	100.00	100.0
	TOT	4	89.58	10.486	75.0	83.33	91.67	95.83	100.0
CHG FROM BSL	PLO	1	0.00		0.0	0.00	0.00	0.00	0.0
	ADA	3	8.33	8.333	0.0	0.00	8.33	16.67	16.7
	TOT	4	6.25	7.979	0.0	0.00	4.17	12.50	16.7

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.35.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PROTOCOL DEVIATION 'WRONG TREATMENT/INCORRECT DOSE REGARDING PREDNISONE'=YES)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
SOCIAL FUNCTIONING									
BSL VALUE	PLO	1	87.50		87.5	87.50	87.50	87.50	87.5
	ADA	3	95.83	7.217	87.5	87.50	100.00	100.00	100.0
	TOT	4	93.75	7.217	87.5	87.50	93.75	100.00	100.0
FINAL/ET VALUE	PLO	1	100.00		100.0	100.00	100.00	100.00	100.0
	ADA	3	95.83	7.217	87.5	87.50	100.00	100.00	100.0
	TOT	4	96.88	6.250	87.5	93.75	100.00	100.00	100.0
CHG FROM BSL	PLO	1	12.50		12.5	12.50	12.50	12.50	12.5
	ADA	3	0.00	0.000	0.0	0.00	0.00	0.00	0.0
	TOT	4	3.13	6.250	0.0	0.00	0.00	6.25	12.5

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.35.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PROTOCOL DEVIATION 'WRONG TREATMENT/INCORRECT DOSE REGARDING PREDNISONE'=YES)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
MENTAL HEALTH									
BSL VALUE	PLO	1	43.75		43.8	43.75	43.75	43.75	43.8
	ADA	3	81.25	12.500	68.8	68.75	81.25	93.75	93.8
	TOT	4	71.88	21.348	43.8	56.25	75.00	87.50	93.8
FINAL/ET VALUE	PLO	1	87.50		87.5	87.50	87.50	87.50	87.5
	ADA	3	93.75	10.825	81.3	81.25	100.00	100.00	100.0
	TOT	4	92.19	9.375	81.3	84.38	93.75	100.00	100.0
CHG FROM BSL	PLO	1	43.75		43.8	43.75	43.75	43.75	43.8
	ADA	3	12.50	6.250	6.3	6.25	12.50	18.75	18.8
	TOT	4	20.31	16.437	6.3	9.38	15.63	31.25	43.8

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.35.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PROTOCOL DEVIATION 'WRONG TREATMENT/INCORRECT DOSE REGARDING PREDNISONE'=YES)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
ROLE DIFFICULTIES									
BSL VALUE	PLO	1	37.50		37.5	37.50	37.50	37.50	37.5
	ADA	3	87.50	12.500	75.0	75.00	87.50	100.00	100.0
	TOT	4	75.00	27.003	37.5	56.25	81.25	93.75	100.0
FINAL/ET VALUE	PLO	1	87.50		87.5	87.50	87.50	87.50	87.5
	ADA	3	100.00	0.000	100.0	100.00	100.00	100.00	100.0
	TOT	4	96.88	6.250	87.5	93.75	100.00	100.00	100.0
CHG FROM BSL	PLO	1	50.00		50.0	50.00	50.00	50.00	50.0
	ADA	3	12.50	12.500	0.0	0.00	12.50	25.00	25.0
	TOT	4	21.88	21.348	0.0	6.25	18.75	37.50	50.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.35.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PROTOCOL DEVIATION 'WRONG TREATMENT/INCORRECT DOSE REGARDING PREDNISONE'=YES)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
DEPENDENCY									
BSL VALUE	PLO	1	83.33		83.3	83.33	83.33	83.33	83.3
	ADA	3	88.89	19.245	66.7	66.67	100.00	100.00	100.0
	TOT	4	87.50	15.957	66.7	75.00	91.67	100.00	100.0
FINAL/ET VALUE	PLO	1	100.00		100.0	100.00	100.00	100.00	100.0
	ADA	3	97.22	4.811	91.7	91.67	100.00	100.00	100.0
	TOT	4	97.92	4.167	91.7	95.83	100.00	100.00	100.0
CHG FROM BSL	PLO	1	16.67		16.7	16.67	16.67	16.67	16.7
	ADA	3	8.33	14.434	0.0	0.00	0.00	25.00	25.0
	TOT	4	10.42	12.500	0.0	0.00	8.33	20.83	25.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.35.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PROTOCOL DEVIATION 'WRONG TREATMENT/INCORRECT DOSE REGARDING PREDNISONE'=YES)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
DRIVING									
BSL VALUE	PLO	0							
	ADA	3	75.00	22.048	58.3	58.33	66.67	100.00	100.0
	TOT	3	75.00	22.048	58.3	58.33	66.67	100.00	100.0
FINAL/ET VALUE	PLO	0							
	ADA	3	80.56	26.788	50.0	50.00	91.67	100.00	100.0
	TOT	3	80.56	26.788	50.0	50.00	91.67	100.00	100.0
CHG FROM BSL	PLO	0							
	ADA	3	5.56	17.347	-8.3	-8.33	0.00	25.00	25.0
	TOT	3	5.56	17.347	-8.3	-8.33	0.00	25.00	25.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.35.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PROTOCOL DEVIATION 'WRONG TREATMENT/INCORRECT DOSE REGARDING PREDNISONE'=YES)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
COLOR VISION									
BSL VALUE	PLO	1	75.00		75.0	75.00	75.00	75.00	75.0
	ADA	3	100.00	0.000	100.0	100.00	100.00	100.00	100.0
	TOT	4	93.75	12.500	75.0	87.50	100.00	100.00	100.0
FINAL/ET VALUE	PLO	1	100.00		100.0	100.00	100.00	100.00	100.0
	ADA	3	100.00	0.000	100.0	100.00	100.00	100.00	100.0
	TOT	4	100.00	0.000	100.0	100.00	100.00	100.00	100.0
CHG FROM BSL	PLO	1	25.00		25.0	25.00	25.00	25.00	25.0
	ADA	3	0.00	0.000	0.0	0.00	0.00	0.00	0.0
	TOT	4	6.25	12.500	0.0	0.00	0.00	12.50	25.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.35.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PROTOCOL DEVIATION 'WRONG TREATMENT/INCORRECT DOSE REGARDING PREDNISONE'=YES)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
PERIPHERAL VISION									
BSL VALUE	PLO	1	75.00		75.0	75.00	75.00	75.00	75.0
	ADA	3	75.00	25.000	50.0	50.00	75.00	100.00	100.0
	TOT	4	75.00	20.412	50.0	62.50	75.00	87.50	100.0
FINAL/ET VALUE	PLO	1	100.00		100.0	100.00	100.00	100.00	100.0
	ADA	3	100.00	0.000	100.0	100.00	100.00	100.00	100.0
	TOT	4	100.00	0.000	100.0	100.00	100.00	100.00	100.0
CHG FROM BSL	PLO	1	25.00		25.0	25.00	25.00	25.00	25.0
	ADA	3	25.00	25.000	0.0	0.00	25.00	50.00	50.0
	TOT	4	25.00	20.412	0.0	12.50	25.00	37.50	50.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.35.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PROTOCOL DEVIATION 'WRONG TREATMENT/INCORRECT DOSE REGARDING PREDNISONE'=YES)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
TOTAL SCORE									
BSL VALUE	PLO	1	65.71		65.7	65.71	65.71	65.71	65.7
	ADA	3	83.85	13.372	70.4	70.42	83.98	97.16	97.2
	TOT	4	79.32	14.195	65.7	68.06	77.20	90.57	97.2
FINAL/ET VALUE	PLO	1	87.25		87.3	87.25	87.25	87.25	87.3
	ADA	3	93.42	6.169	87.8	87.77	92.50	100.00	100.0
	TOT	4	91.88	5.907	87.3	87.51	90.13	96.25	100.0
CHG FROM BSL	PLO	1	21.54		21.5	21.54	21.54	21.54	21.5
	ADA	3	9.57	7.310	2.8	2.84	8.52	17.35	17.3
	TOT	4	12.56	8.453	2.8	5.68	12.94	19.45	21.5

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.36.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PROTOCOL DEVIATION 'WRONG TREATMENT/INCORRECT DOSE REGARDING PREDNISONE'=NO)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL HEALTH												
BSL VALUE	PLO	124	52.62	25.467	0.0	25.00	50.00	75.00	100.0			
	ADA	128	56.45	21.335	0.0	50.00	50.00	75.00	100.0			
	TOT	252	54.56	23.490	0.0	50.00	50.00	75.00	100.0			
FINAL/ET VALUE	PLO	124	51.51	23.512	0.0	25.00	50.00	75.00	100.0			
	ADA	128	55.86	23.941	0.0	50.00	50.00	75.00	100.0			
	TOT	252	53.72	23.784	0.0	50.00	50.00	75.00	100.0			
CHG FROM BSL	PLO	124	-1.11	19.128	-75.0	0.00	0.00	0.00	50.0			
	ADA	128	-0.59	20.624	-50.0	-25.00	0.00	12.50	50.0			
	TOT	252	-0.84	19.864	-75.0	-12.50	0.00	0.00	50.0			
										0.52	(-4.42, 5.46)	0.835A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.36.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PROTOCOL DEVIATION 'WRONG TREATMENT/INCORRECT DOSE REGARDING PREDNISONE'=NO)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL VISION												
BSL VALUE	PLO	124	67.82	16.751	20.0	60.00	60.00	80.00	100.0			
	ADA	127	67.24	15.465	40.0	60.00	60.00	80.00	100.0			
	TOT	251	67.53	16.083	20.0	60.00	60.00	80.00	100.0			
FINAL/ET VALUE	PLO	124	64.19	18.788	20.0	60.00	60.00	80.00	100.0			
	ADA	127	69.37	19.138	20.0	60.00	80.00	80.00	100.0			
	TOT	251	66.81	19.105	20.0	60.00	60.00	80.00	100.0			
CHG FROM BSL	PLO	124	-3.63	15.841	-40.0	-20.00	0.00	0.00	40.0			
	ADA	127	2.13	16.116	-40.0	0.00	0.00	20.00	40.0			
	TOT	251	-0.72	16.208	-40.0	0.00	0.00	0.00	40.0			
										5.76	(1.78, 9.73)	0.005A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.36.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PROTOCOL DEVIATION 'WRONG TREATMENT/INCORRECT DOSE REGARDING PREDNISONE'=NO)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
OCULAR PAIN												
BSL VALUE	PLO	124	76.41	22.327	12.5	62.50	75.00	100.00	100.0			
	ADA	128	78.86	20.664	25.0	62.50	87.50	100.00	100.0			
	TOT	252	77.65	21.490	12.5	62.50	84.38	100.00	100.0			
FINAL/ET VALUE	PLO	124	78.53	20.756	25.0	62.50	75.00	100.00	100.0			
	ADA	128	80.57	20.381	12.5	68.75	87.50	100.00	100.0			
	TOT	252	79.56	20.550	12.5	62.50	75.00	100.00	100.0			
CHG FROM BSL	PLO	124	2.12	16.543	-50.0	0.00	0.00	12.50	62.5			
	ADA	128	1.71	21.732	-62.5	-12.50	0.00	12.50	62.5			
	TOT	252	1.91	19.316	-62.5	0.00	0.00	12.50	62.5			
										-0.41	(-5.21, 4.39)	0.867A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.36.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PROTOCOL DEVIATION 'WRONG TREATMENT/INCORRECT DOSE REGARDING PREDNISONE'=NO)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
NEAR VISION												
BSL VALUE	PLO	124	71.61	24.609	0.0	58.33	75.00	91.67	100.0			
	ADA	128	75.33	21.127	8.3	58.33	75.00	91.67	100.0			
	TOT	252	73.50	22.937	0.0	58.33	75.00	91.67	100.0			
FINAL/ET VALUE	PLO	124	75.37	22.239	16.7	58.33	79.17	100.00	100.0			
	ADA	128	78.16	24.635	0.0	70.83	83.33	100.00	100.0			
	TOT	252	76.79	23.482	0.0	66.67	83.33	100.00	100.0			
CHG FROM BSL	PLO	124	3.76	17.236	-33.3	-8.33	0.00	16.67	75.0			
	ADA	128	2.83	20.625	-75.0	-8.33	0.00	16.67	50.0			
	TOT	252	3.29	19.001	-75.0	-8.33	0.00	16.67	75.0			
										-0.93	(-5.65, 3.79)	0.698A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.36.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PROTOCOL DEVIATION 'WRONG TREATMENT/INCORRECT DOSE REGARDING PREDNISONE'=NO)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DISTANCE VISION												
BSL VALUE	PLO	124	73.92	23.497	8.3	58.33	83.33	91.67	100.0			
	ADA	128	75.52	20.777	8.3	62.50	83.33	91.67	100.0			
	TOT	252	74.74	22.128	8.3	58.33	83.33	91.67	100.0			
FINAL/ET VALUE	PLO	124	74.53	22.842	8.3	58.33	75.00	100.00	100.0			
	ADA	128	78.35	23.704	0.0	66.67	83.33	100.00	100.0			
	TOT	252	76.47	23.316	0.0	58.33	83.33	100.00	100.0			
CHG FROM BSL	PLO	124	0.60	16.043	-41.7	-8.33	0.00	8.33	50.0			
	ADA	128	2.83	17.270	-50.0	-6.25	0.00	8.33	75.0			
	TOT	252	1.74	16.682	-50.0	-8.33	0.00	8.33	75.0			
										2.23	(-1.91, 6.37)	0.290A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.36.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PROTOCOL DEVIATION 'WRONG TREATMENT/INCORRECT DOSE REGARDING PREDNISONE'=NO)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
SOCIAL FUNCTIONING												
BSL VALUE	PLO	124	87.50	18.792	25.0	75.00	100.00	100.00	100.0			
	ADA	128	87.70	18.888	0.0	75.00	100.00	100.00	100.0			
	TOT	252	87.60	18.804	0.0	75.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	124	86.44	19.222	6.3	75.00	100.00	100.00	100.0			
	ADA	128	88.43	18.841	12.5	75.00	100.00	100.00	100.0			
	TOT	252	87.45	19.018	6.3	75.00	100.00	100.00	100.0			
CHG FROM BSL	PLO	124	-1.06	13.137	-43.8	-3.13	0.00	0.00	37.5			
	ADA	128	0.73	14.665	-50.0	0.00	0.00	9.38	50.0			
	TOT	252	-0.15	13.936	-50.0	0.00	0.00	0.00	50.0			
										1.79	(-1.67, 5.25)	0.309A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.36.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PROTOCOL DEVIATION 'WRONG TREATMENT/INCORRECT DOSE REGARDING PREDNISONE'=NO)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
MENTAL HEALTH												
BSL VALUE	PLO	124	64.30	24.330	0.0	50.00	68.75	81.25	100.0			
	ADA	128	65.33	23.110	0.0	50.00	68.75	81.25	100.0			
	TOT	252	64.82	23.676	0.0	50.00	68.75	81.25	100.0			
FINAL/ET VALUE	PLO	124	68.35	26.441	0.0	50.00	75.00	90.63	100.0			
	ADA	128	74.66	24.038	0.0	62.50	81.25	93.75	100.0			
	TOT	252	71.55	25.396	0.0	56.25	78.13	93.75	100.0			
CHG FROM BSL	PLO	124	4.05	17.827	-56.3	0.00	6.25	12.50	68.8			
	ADA	128	9.33	18.141	-37.5	0.00	12.50	18.75	62.5			
	TOT	252	6.73	18.145	-56.3	0.00	6.25	18.75	68.8			
										5.28	(0.81, 9.74)	0.021A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.36.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PROTOCOL DEVIATION 'WRONG TREATMENT/INCORRECT DOSE REGARDING PREDNISONE'=NO)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
ROLE DIFFICULTIES												
BSL VALUE	PLO	124	68.25	26.259	0.0	50.00	75.00	100.00	100.0			
	ADA	128	69.63	26.327	0.0	50.00	75.00	87.50	100.0			
	TOT	252	68.95	26.250	0.0	50.00	75.00	93.75	100.0			
FINAL/ET VALUE	PLO	124	70.06	28.101	0.0	50.00	75.00	100.00	100.0			
	ADA	128	76.46	25.031	0.0	62.50	75.00	100.00	100.0			
	TOT	252	73.31	26.726	0.0	50.00	75.00	100.00	100.0			
CHG FROM BSL	PLO	124	1.81	20.946	-62.5	-12.50	0.00	12.50	62.5			
	ADA	128	6.84	21.270	-50.0	0.00	0.00	12.50	75.0			
	TOT	252	4.37	21.219	-62.5	0.00	0.00	12.50	75.0			
										5.02	(-0.22, 10.26)	0.060A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.36.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PROTOCOL DEVIATION 'WRONG TREATMENT/INCORRECT DOSE REGARDING PREDNISONE'=NO)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DEPENDENCY												
BSL VALUE	PLO	123	82.08	26.368	0.0	75.00	100.00	100.00	100.0			
	ADA	128	85.48	22.484	8.3	79.17	100.00	100.00	100.0			
	TOT	251	83.81	24.475	0.0	75.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	123	82.38	26.464	0.0	75.00	100.00	100.00	100.0			
	ADA	128	86.65	22.192	8.3	83.33	100.00	100.00	100.0			
	TOT	251	84.56	24.424	0.0	75.00	100.00	100.00	100.0			
CHG FROM BSL	PLO	123	0.30	17.222	-83.3	0.00	0.00	0.00	75.0			
	ADA	128	1.17	16.789	-50.0	0.00	0.00	8.33	58.3			
	TOT	251	0.75	16.974	-83.3	0.00	0.00	0.00	75.0			
										0.87	(-3.36, 5.10)	0.687A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.36.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PROTOCOL DEVIATION 'WRONG TREATMENT/INCORRECT DOSE REGARDING PREDNISONE'=NO)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DRIVING												
BSL VALUE	PLO	104	69.79	28.216	0.0	58.33	83.33	91.67	100.0			
	ADA	97	68.73	33.253	0.0	58.33	83.33	91.67	100.0			
	TOT	201	69.28	30.677	0.0	58.33	83.33	91.67	100.0			
FINAL/ET VALUE	PLO	104	66.55	27.957	0.0	50.00	75.00	83.33	100.0			
	ADA	97	69.76	31.972	0.0	58.33	83.33	100.00	100.0			
	TOT	201	68.10	29.929	0.0	58.33	75.00	91.67	100.0			
CHG FROM BSL	PLO	104	-3.25	15.405	-41.7	-8.33	0.00	0.00	66.7			
	ADA	97	1.03	21.373	-58.3	-8.33	0.00	8.33	100.0			
	TOT	201	-1.18	18.603	-58.3	-8.33	0.00	0.00	100.0			
										4.28	(-0.88, 9.43)	0.104A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.36.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PROTOCOL DEVIATION 'WRONG TREATMENT/INCORRECT DOSE REGARDING PREDNISONE'=NO)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
COLOR VISION												
BSL VALUE	PLO	122	89.96	18.368	25.0	75.00	100.00	100.00	100.0			
	ADA	127	94.29	14.499	25.0	100.00	100.00	100.00	100.0			
	TOT	249	92.17	16.617	25.0	100.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	122	90.47	16.472	25.0	75.00	100.00	100.00	100.0			
	ADA	127	93.60	17.242	0.0	100.00	100.00	100.00	100.0			
	TOT	249	92.07	16.908	0.0	100.00	100.00	100.00	100.0			
CHG FROM BSL	PLO	122	0.51	13.095	-50.0	0.00	0.00	0.00	50.0			
	ADA	127	-0.69	12.431	-50.0	0.00	0.00	0.00	50.0			
	TOT	249	-0.10	12.749	-50.0	0.00	0.00	0.00	50.0			
										-1.20	(-4.39, 1.98)	0.458A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.36.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PROTOCOL DEVIATION 'WRONG TREATMENT/INCORRECT DOSE REGARDING PREDNISONE'=NO)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
PERIPHERAL VISION												
BSL VALUE	PLO	122	75.82	24.883	0.0	50.00	75.00	100.00	100.0			
	ADA	126	79.56	22.891	0.0	75.00	75.00	100.00	100.0			
	TOT	248	77.72	23.917	0.0	50.00	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	122	80.02	21.897	25.0	75.00	75.00	100.00	100.0			
	ADA	126	81.94	23.375	0.0	75.00	100.00	100.00	100.0			
	TOT	248	81.00	22.635	0.0	75.00	75.00	100.00	100.0			
CHG FROM BSL	PLO	122	4.20	18.920	-50.0	0.00	0.00	25.00	50.0			
	ADA	126	2.38	19.346	-75.0	0.00	0.00	25.00	50.0			
	TOT	248	3.28	19.121	-75.0	0.00	0.00	25.00	50.0			
										-1.82	(-6.61, 2.97)	0.455A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.36.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PROTOCOL DEVIATION 'WRONG TREATMENT/INCORRECT DOSE REGARDING PREDNISONE'=NO)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
TOTAL SCORE												
BSL VALUE	PLO	124	75.11	18.090	25.3	62.97	82.69	89.72	97.6			
	ADA	128	77.11	15.439	15.4	70.76	80.17	88.52	99.4			
	TOT	252	76.13	16.792	15.4	67.55	81.27	89.09	99.4			
FINAL/ET VALUE	PLO	124	75.94	18.370	27.9	63.64	81.48	91.95	100.0			
	ADA	128	79.74	18.560	12.4	70.64	85.87	92.82	100.0			
	TOT	252	77.87	18.528	12.4	66.43	84.33	92.63	100.0			
CHG FROM BSL	PLO	124	0.83	10.097	-30.9	-5.15	1.99	5.76	29.4			
	ADA	128	2.63	12.079	-33.6	-2.18	3.66	9.62	42.0			
	TOT	252	1.74	11.162	-33.6	-3.13	2.59	7.80	42.0			
										1.80	(-0.97, 4.56)	0.202A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.37.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: GEOGRAPHIC REGION=NORTH AMERICA)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL HEALTH												
BSL VALUE	PLO	36	56.94	23.612	0.0	50.00	50.00	75.00	100.0			
	ADA	33	65.91	18.560	25.0	50.00	75.00	75.00	100.0			
	TOT	69	61.23	21.666	0.0	50.00	50.00	75.00	100.0			
FINAL/ET VALUE	PLO	36	56.94	22.048	0.0	50.00	50.00	75.00	100.0			
	ADA	33	65.53	17.408	25.0	50.00	75.00	75.00	100.0			
	TOT	69	61.05	20.285	0.0	50.00	62.50	75.00	100.0			
CHG FROM BSL	PLO	36	0.00	17.928	-50.0	0.00	0.00	0.00	50.0			
	ADA	33	-0.38	16.082	-25.0	0.00	0.00	0.00	25.0			
	TOT	69	-0.18	16.947	-50.0	0.00	0.00	0.00	50.0			
										-0.38	(-8.59, 7.83)	0.927A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.37.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: GEOGRAPHIC REGION=NORTH AMERICA)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL VISION												
BSL VALUE	PLO	36	72.78	17.339	40.0	60.00	80.00	80.00	100.0			
	ADA	33	70.30	16.674	40.0	60.00	80.00	80.00	100.0			
	TOT	69	71.59	16.945	40.0	60.00	80.00	80.00	100.0			
FINAL/ET VALUE	PLO	36	68.89	17.530	20.0	60.00	80.00	80.00	100.0			
	ADA	33	72.73	17.189	20.0	60.00	80.00	80.00	100.0			
	TOT	69	70.72	17.348	20.0	60.00	80.00	80.00	100.0			
CHG FROM BSL	PLO	36	-3.89	13.369	-40.0	-20.00	0.00	0.00	20.0			
	ADA	33	2.42	14.797	-40.0	0.00	0.00	0.00	40.0			
	TOT	69	-0.87	14.322	-40.0	0.00	0.00	0.00	40.0			
										6.31	(-0.45, 13.08)	0.067A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.37.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: GEOGRAPHIC REGION=NORTH AMERICA)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
OCULAR PAIN												
BSL VALUE	PLO	36	81.25	17.803	37.5	75.00	87.50	100.00	100.0			
	ADA	33	79.55	20.208	37.5	62.50	87.50	100.00	100.0			
	TOT	69	80.43	18.870	37.5	75.00	87.50	100.00	100.0			
FINAL/ET VALUE	PLO	36	81.60	19.477	50.0	68.75	87.50	100.00	100.0			
	ADA	33	84.47	18.230	50.0	75.00	100.00	100.00	100.0			
	TOT	69	82.97	18.808	50.0	75.00	87.50	100.00	100.0			
CHG FROM BSL	PLO	36	0.35	11.759	-25.0	0.00	0.00	6.25	25.0			
	ADA	33	4.92	20.238	-50.0	0.00	0.00	12.50	50.0			
	TOT	69	2.54	16.408	-50.0	0.00	0.00	12.50	50.0			
										4.58	(-3.30, 12.45)	0.250A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.37.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: GEOGRAPHIC REGION=NORTH AMERICA)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
NEAR VISION												
BSL VALUE	PLO	36	74.07	23.719	16.7	58.33	75.00	91.67	100.0			
	ADA	33	78.03	23.806	12.5	66.67	83.33	100.00	100.0			
	TOT	69	75.97	23.669	12.5	66.67	83.33	95.83	100.0			
FINAL/ET VALUE	PLO	36	77.43	21.739	16.7	66.67	83.33	95.83	100.0			
	ADA	33	83.08	21.799	8.3	75.00	83.33	100.00	100.0			
	TOT	69	80.13	21.793	8.3	66.67	83.33	100.00	100.0			
CHG FROM BSL	PLO	36	3.36	15.392	-33.3	0.00	0.00	12.50	41.7			
	ADA	33	5.05	15.194	-33.3	0.00	0.00	16.67	41.7			
	TOT	69	4.17	15.209	-33.3	0.00	0.00	16.67	41.7			
										1.69	(-5.66, 9.05)	0.647A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.37.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: GEOGRAPHIC REGION=NORTH AMERICA)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DISTANCE VISION												
BSL VALUE	PLO	36	75.00	24.560	8.3	58.33	83.33	91.67	100.0			
	ADA	33	78.54	21.578	8.3	75.00	83.33	91.67	100.0			
	TOT	69	76.69	23.081	8.3	66.67	83.33	91.67	100.0			
FINAL/ET VALUE	PLO	36	75.81	23.355	8.3	64.58	83.33	91.67	100.0			
	ADA	33	80.81	24.250	8.3	75.00	91.67	100.00	100.0			
	TOT	69	78.20	23.744	8.3	66.67	83.33	100.00	100.0			
CHG FROM BSL	PLO	36	0.81	12.826	-25.0	-8.33	0.00	8.33	33.3			
	ADA	33	2.27	12.417	-25.0	-8.33	0.00	8.33	25.0			
	TOT	69	1.51	12.561	-25.0	-8.33	0.00	8.33	33.3			
										1.46	(-4.61, 7.54)	0.632A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.37.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: GEOGRAPHIC REGION=NORTH AMERICA)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
SOCIAL FUNCTIONING												
BSL VALUE	PLO	36	89.24	19.629	37.5	81.25	100.00	100.00	100.0			
	ADA	33	87.88	22.854	0.0	87.50	100.00	100.00	100.0			
	TOT	69	88.59	21.085	0.0	87.50	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	36	92.19	15.553	25.0	87.50	100.00	100.00	100.0			
	ADA	33	89.96	21.534	12.5	87.50	100.00	100.00	100.0			
	TOT	69	91.12	18.547	12.5	87.50	100.00	100.00	100.0			
CHG FROM BSL	PLO	36	2.95	10.616	-12.5	0.00	0.00	0.00	37.5			
	ADA	33	2.08	10.443	-25.0	0.00	0.00	0.00	25.0			
	TOT	69	2.54	10.465	-25.0	0.00	0.00	0.00	37.5			
										-0.87	(-5.94, 4.20)	0.733A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.37.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: GEOGRAPHIC REGION=NORTH AMERICA)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
MENTAL HEALTH												
BSL VALUE	PLO	36	66.49	23.393	12.5	50.00	71.88	87.50	100.0			
	ADA	33	65.21	26.406	0.0	50.00	75.00	87.50	93.8			
	TOT	69	65.88	24.702	0.0	50.00	75.00	87.50	100.0			
FINAL/ET VALUE	PLO	36	72.22	26.366	0.0	56.25	81.25	93.75	100.0			
	ADA	33	76.89	29.707	0.0	62.50	93.75	100.00	100.0			
	TOT	69	74.46	27.904	0.0	62.50	87.50	93.75	100.0			
CHG FROM BSL	PLO	36	5.73	22.329	-56.3	0.00	6.25	12.50	68.8			
	ADA	33	11.68	14.914	-25.0	6.25	12.50	18.75	41.7			
	TOT	69	8.57	19.242	-56.3	0.00	12.50	18.75	68.8			
										5.95	(-3.26, 15.16)	0.202A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.37.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: GEOGRAPHIC REGION=NORTH AMERICA)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
ROLE DIFFICULTIES												
BSL VALUE	PLO	36	72.22	29.141	0.0	50.00	75.00	100.00	100.0			
	ADA	33	74.62	30.053	0.0	50.00	87.50	100.00	100.0			
	TOT	69	73.37	29.387	0.0	50.00	87.50	100.00	100.0			
FINAL/ET VALUE	PLO	36	76.74	26.752	0.0	56.25	81.25	100.00	100.0			
	ADA	33	81.82	27.080	0.0	75.00	100.00	100.00	100.0			
	TOT	69	79.17	26.832	0.0	75.00	87.50	100.00	100.0			
CHG FROM BSL	PLO	36	4.51	19.629	-37.5	0.00	0.00	12.50	62.5			
	ADA	33	7.20	19.772	-25.0	0.00	0.00	12.50	75.0			
	TOT	69	5.80	19.598	-37.5	0.00	0.00	12.50	75.0			
										2.68	(-6.79, 12.16)	0.574A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.37.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: GEOGRAPHIC REGION=NORTH AMERICA)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DEPENDENCY												
BSL VALUE	PLO	36	83.33	27.241	0.0	75.00	100.00	100.00	100.0			
	ADA	33	84.09	25.800	8.3	75.00	100.00	100.00	100.0			
	TOT	69	83.70	26.369	0.0	75.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	36	85.19	27.394	0.0	83.33	100.00	100.00	100.0			
	ADA	33	87.12	24.034	8.3	83.33	100.00	100.00	100.0			
	TOT	69	86.11	25.672	0.0	83.33	100.00	100.00	100.0			
CHG FROM BSL	PLO	36	1.85	24.730	-83.3	0.00	0.00	4.17	75.0			
	ADA	33	3.03	16.247	-33.3	0.00	0.00	8.33	50.0			
	TOT	69	2.42	20.960	-83.3	0.00	0.00	8.33	75.0			
										1.18	(-8.98, 11.33)	0.818A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.37.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: GEOGRAPHIC REGION=NORTH AMERICA)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DRIVING												
BSL VALUE	PLO	35	72.38	23.113	0.0	58.33	83.33	83.33	100.0			
	ADA	30	75.56	29.921	0.0	66.67	83.33	100.00	100.0			
	TOT	65	73.85	26.306	0.0	66.67	83.33	91.67	100.0			
FINAL/ET VALUE	PLO	35	70.00	24.996	0.0	58.33	75.00	83.33	100.0			
	ADA	30	78.75	25.576	0.0	66.67	83.33	100.00	100.0			
	TOT	65	74.04	25.449	0.0	66.67	83.33	91.67	100.0			
CHG FROM BSL	PLO	35	-2.38	10.564	-33.3	-8.33	0.00	0.00	16.7			
	ADA	30	3.19	25.654	-41.7	-8.33	0.00	8.33	100.0			
	TOT	65	0.19	19.114	-41.7	-8.33	0.00	8.33	100.0			
										5.58	(-3.90, 15.05)	0.244A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.37.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: GEOGRAPHIC REGION=NORTH AMERICA)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
COLOR VISION												
BSL VALUE	PLO	35	91.43	18.132	25.0	100.00	100.00	100.00	100.0			
	ADA	33	93.18	17.976	25.0	100.00	100.00	100.00	100.0			
	TOT	68	92.28	17.943	25.0	100.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	35	93.21	15.262	25.0	100.00	100.00	100.00	100.0			
	ADA	33	92.42	24.594	0.0	100.00	100.00	100.00	100.0			
	TOT	68	92.83	20.181	0.0	100.00	100.00	100.00	100.0			
CHG FROM BSL	PLO	35	1.79	7.514	-12.5	0.00	0.00	0.00	25.0			
	ADA	33	-0.76	11.667	-50.0	0.00	0.00	0.00	25.0			
	TOT	68	0.55	9.763	-50.0	0.00	0.00	0.00	25.0			
										-2.54	(-7.27, 2.18)	0.286A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.37.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: GEOGRAPHIC REGION=NORTH AMERICA)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
PERIPHERAL VISION												
BSL VALUE	PLO	35	72.86	29.933	0.0	50.00	75.00	100.00	100.0			
	ADA	32	87.50	21.997	0.0	75.00	100.00	100.00	100.0			
	TOT	67	79.85	27.261	0.0	75.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	35	81.07	25.068	25.0	75.00	100.00	100.00	100.0			
	ADA	32	89.06	22.840	25.0	87.50	100.00	100.00	100.0			
	TOT	67	84.89	24.185	25.0	75.00	100.00	100.00	100.0			
CHG FROM BSL	PLO	35	8.21	18.427	-25.0	0.00	0.00	25.00	50.0			
	ADA	32	1.56	21.001	-75.0	0.00	0.00	0.00	50.0			
	TOT	67	5.04	19.831	-75.0	0.00	0.00	25.00	50.0			
										-6.65	(-16.27, 2.97)	0.172A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.37.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: GEOGRAPHIC REGION=NORTH AMERICA)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
TOTAL SCORE												
BSL VALUE	PLO	36	77.33	18.234	25.3	67.90	84.68	90.70	97.6			
	ADA	33	79.31	17.992	15.4	78.26	83.86	89.09	98.9			
	TOT	69	78.28	18.013	15.4	70.87	83.86	90.23	98.9			
FINAL/ET VALUE	PLO	36	79.31	18.110	27.9	71.78	83.77	92.82	98.2			
	ADA	33	82.96	19.885	20.4	75.80	89.28	97.05	100.0			
	TOT	69	81.06	18.928	20.4	74.70	87.39	93.83	100.0			
CHG FROM BSL	PLO	36	1.98	7.228	-20.6	-0.38	2.59	5.25	19.3			
	ADA	33	3.66	9.412	-22.2	1.52	3.98	8.52	22.7			
	TOT	69	2.78	8.324	-22.2	0.03	3.03	7.12	22.7			
										1.67	(-2.34, 5.69)	0.408A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.38.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: GEOGRAPHIC REGION=WESTERN AND EASTERN EUROPE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL HEALTH												
BSL VALUE	PLO	54	52.78	27.757	0.0	25.00	50.00	75.00	100.0			
	ADA	64	57.81	20.352	25.0	50.00	50.00	75.00	100.0			
	TOT	118	55.51	24.049	0.0	50.00	50.00	75.00	100.0			
FINAL/ET VALUE	PLO	54	49.77	21.513	25.0	25.00	50.00	62.50	100.0			
	ADA	64	57.23	23.338	0.0	50.00	50.00	75.00	100.0			
	TOT	118	53.81	22.734	0.0	50.00	50.00	75.00	100.0			
CHG FROM BSL	PLO	54	-3.01	17.667	-50.0	-25.00	0.00	0.00	25.0			
	ADA	64	-0.59	20.465	-50.0	-25.00	0.00	25.00	50.0			
	TOT	118	-1.69	19.193	-50.0	-25.00	0.00	0.00	50.0			
										2.42	(-4.62, 9.46)	0.497A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.38.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: GEOGRAPHIC REGION=WESTERN AND EASTERN EUROPE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL VISION												
BSL VALUE	PLO	54	67.22	16.301	20.0	60.00	60.00	80.00	100.0			
	ADA	64	70.00	14.254	40.0	60.00	70.00	80.00	100.0			
	TOT	118	68.73	15.222	20.0	60.00	60.00	80.00	100.0			
FINAL/ET VALUE	PLO	54	63.33	17.698	20.0	60.00	60.00	80.00	80.0			
	ADA	64	73.91	16.961	20.0	60.00	80.00	80.00	100.0			
	TOT	118	69.07	18.021	20.0	60.00	80.00	80.00	100.0			
CHG FROM BSL	PLO	54	-3.89	18.058	-40.0	-20.00	0.00	0.00	20.0			
	ADA	64	3.91	16.678	-40.0	0.00	0.00	20.00	40.0			
	TOT	118	0.34	17.683	-40.0	0.00	0.00	20.00	40.0			
										7.80	(1.46, 14.13)	0.016A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.38.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: GEOGRAPHIC REGION=WESTERN AND EASTERN EUROPE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
OCULAR PAIN												
BSL VALUE	PLO	54	77.55	21.905	25.0	62.50	75.00	100.00	100.0			
	ADA	64	79.98	19.486	25.0	68.75	84.38	100.00	100.0			
	TOT	118	78.87	20.574	25.0	62.50	78.13	100.00	100.0			
FINAL/ET VALUE	PLO	54	78.70	20.977	25.0	62.50	75.00	100.00	100.0			
	ADA	64	82.03	18.882	37.5	75.00	87.50	100.00	100.0			
	TOT	118	80.51	19.851	25.0	75.00	81.25	100.00	100.0			
CHG FROM BSL	PLO	54	1.16	15.216	-50.0	0.00	0.00	12.50	50.0			
	ADA	64	2.05	21.335	-62.5	-12.50	0.00	12.50	62.5			
	TOT	118	1.64	18.713	-62.5	0.00	0.00	12.50	62.5			
										0.89	(-5.98, 7.77)	0.797A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.38.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: GEOGRAPHIC REGION=WESTERN AND EASTERN EUROPE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
NEAR VISION												
BSL VALUE	PLO	54	76.08	22.608	16.7	58.33	75.00	91.67	100.0			
	ADA	64	77.60	20.243	8.3	66.67	83.33	91.67	100.0			
	TOT	118	76.91	21.278	8.3	66.67	83.33	91.67	100.0			
FINAL/ET VALUE	PLO	54	77.01	22.427	25.0	58.33	83.33	100.00	100.0			
	ADA	64	81.71	21.460	0.0	75.00	83.33	100.00	100.0			
	TOT	118	79.56	21.940	0.0	66.67	83.33	100.00	100.0			
CHG FROM BSL	PLO	54	0.93	13.118	-33.3	-8.33	0.00	8.33	25.0			
	ADA	64	4.10	16.290	-41.7	0.00	0.00	12.50	50.0			
	TOT	118	2.65	14.946	-41.7	-8.33	0.00	8.33	50.0			
										3.18	(-2.29, 8.64)	0.252A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.38.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: GEOGRAPHIC REGION=WESTERN AND EASTERN EUROPE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DISTANCE VISION												
BSL VALUE	PLO	54	78.09	20.938	16.7	66.67	83.33	100.00	100.0			
	ADA	64	79.23	19.996	25.0	66.67	83.33	91.67	100.0			
	TOT	118	78.71	20.353	16.7	66.67	83.33	91.67	100.0			
FINAL/ET VALUE	PLO	54	75.77	21.492	25.0	58.33	75.00	100.00	100.0			
	ADA	64	82.62	20.940	0.0	75.00	91.67	100.00	100.0			
	TOT	118	79.48	21.379	0.0	66.67	83.33	100.00	100.0			
CHG FROM BSL	PLO	54	-2.31	16.542	-41.7	-8.33	0.00	0.00	50.0			
	ADA	64	3.39	16.764	-41.7	0.00	0.00	8.33	75.0			
	TOT	118	0.78	16.835	-41.7	-8.33	0.00	8.33	75.0			
										5.70	(-0.40, 11.80)	0.067A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.38.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: GEOGRAPHIC REGION=WESTERN AND EASTERN EUROPE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
SOCIAL FUNCTIONING												
BSL VALUE	PLO	54	90.05	17.235	25.0	75.00	100.00	100.00	100.0			
	ADA	64	90.63	14.773	50.0	81.25	100.00	100.00	100.0			
	TOT	118	90.36	15.880	25.0	75.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	54	86.46	16.900	50.0	75.00	100.00	100.00	100.0			
	ADA	64	91.60	14.783	37.5	87.50	100.00	100.00	100.0			
	TOT	118	89.25	15.927	37.5	75.00	100.00	100.00	100.0			
CHG FROM BSL	PLO	54	-3.59	13.822	-37.5	-12.50	0.00	0.00	37.5			
	ADA	64	0.98	14.824	-50.0	0.00	0.00	0.00	50.0			
	TOT	118	-1.11	14.494	-50.0	0.00	0.00	0.00	50.0			
										4.56	(-0.70, 9.83)	0.088A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.38.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: GEOGRAPHIC REGION=WESTERN AND EASTERN EUROPE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
MENTAL HEALTH												
BSL VALUE	PLO	54	67.32	19.986	6.3	50.00	75.00	81.25	93.8			
	ADA	64	64.91	22.750	6.3	50.00	68.75	81.25	100.0			
	TOT	118	66.01	21.473	6.3	50.00	75.00	81.25	100.0			
FINAL/ET VALUE	PLO	54	69.44	23.595	0.0	56.25	75.00	87.50	100.0			
	ADA	64	76.17	21.242	12.5	62.50	81.25	93.75	100.0			
	TOT	118	73.09	22.505	0.0	62.50	78.13	93.75	100.0			
CHG FROM BSL	PLO	54	2.12	17.139	-37.5	-6.25	6.25	12.50	37.5			
	ADA	64	11.26	17.882	-31.3	0.00	6.25	18.75	62.5			
	TOT	118	7.08	18.060	-37.5	0.00	6.25	18.75	62.5			
										9.14	(2.72, 15.56)	0.006A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.38.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: GEOGRAPHIC REGION=WESTERN AND EASTERN EUROPE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
ROLE DIFFICULTIES												
BSL VALUE	PLO	54	66.90	22.276	12.5	50.00	62.50	75.00	100.0			
	ADA	64	66.41	24.688	12.5	50.00	75.00	87.50	100.0			
	TOT	118	66.63	23.517	12.5	50.00	68.75	87.50	100.0			
FINAL/ET VALUE	PLO	54	68.52	27.011	25.0	50.00	75.00	100.00	100.0			
	ADA	64	75.59	24.339	25.0	62.50	75.00	100.00	100.0			
	TOT	118	72.35	25.729	25.0	50.00	75.00	100.00	100.0			
CHG FROM BSL	PLO	54	1.62	18.972	-37.5	-12.50	0.00	12.50	50.0			
	ADA	64	9.18	21.849	-50.0	0.00	6.25	25.00	62.5			
	TOT	118	5.72	20.843	-50.0	0.00	0.00	12.50	62.5			
										7.56	(0.03, 15.09)	0.049A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.38.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: GEOGRAPHIC REGION=WESTERN AND EASTERN EUROPE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DEPENDENCY												
BSL VALUE	PLO	53	86.24	21.458	0.0	83.33	100.00	100.00	100.0			
	ADA	64	86.07	23.005	8.3	83.33	100.00	100.00	100.0			
	TOT	117	86.15	22.223	0.0	83.33	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	53	84.59	20.955	16.7	75.00	100.00	100.00	100.0			
	ADA	64	88.67	20.432	8.3	83.33	100.00	100.00	100.0			
	TOT	117	86.82	20.682	8.3	75.00	100.00	100.00	100.0			
CHG FROM BSL	PLO	53	-1.65	13.185	-41.7	0.00	0.00	0.00	41.7			
	ADA	64	2.60	14.076	-33.3	0.00	0.00	4.17	58.3			
	TOT	117	0.68	13.786	-41.7	0.00	0.00	0.00	58.3			
										4.26	(-0.78, 9.29)	0.097A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.38.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: GEOGRAPHIC REGION=WESTERN AND EASTERN EUROPE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DRIVING												
BSL VALUE	PLO	49	72.96	27.836	0.0	58.33	83.33	91.67	100.0			
	ADA	49	70.83	30.548	0.0	58.33	83.33	91.67	100.0			
	TOT	98	71.90	29.092	0.0	58.33	83.33	91.67	100.0			
FINAL/ET VALUE	PLO	49	67.35	28.303	0.0	50.00	75.00	91.67	100.0			
	ADA	49	72.87	28.994	0.0	66.67	83.33	100.00	100.0			
	TOT	98	70.11	28.637	0.0	58.33	75.00	91.67	100.0			
CHG FROM BSL	PLO	49	-5.61	15.649	-41.7	-16.67	0.00	0.00	25.0			
	ADA	49	2.04	19.416	-33.3	-8.33	0.00	4.17	100.0			
	TOT	98	-1.79	17.959	-41.7	-8.33	0.00	0.00	100.0			
										7.65	(0.58, 14.72)	0.034A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.38.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: GEOGRAPHIC REGION=WESTERN AND EASTERN EUROPE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
COLOR VISION												
BSL VALUE	PLO	54	91.20	17.616	50.0	100.00	100.00	100.00	100.0			
	ADA	64	96.88	10.446	50.0	100.00	100.00	100.00	100.0			
	TOT	118	94.28	14.401	50.0	100.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	54	91.67	15.357	50.0	75.00	100.00	100.00	100.0			
	ADA	64	96.29	11.718	50.0	100.00	100.00	100.00	100.0			
	TOT	118	94.17	13.642	50.0	100.00	100.00	100.00	100.0			
CHG FROM BSL	PLO	54	0.46	14.961	-50.0	0.00	0.00	0.00	50.0			
	ADA	64	-0.59	11.450	-50.0	0.00	0.00	0.00	50.0			
	TOT	118	-0.11	13.125	-50.0	0.00	0.00	0.00	50.0			
										-1.05	(-5.87, 3.77)	0.667A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.38.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: GEOGRAPHIC REGION=WESTERN AND EASTERN EUROPE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
PERIPHERAL VISION												
BSL VALUE	PLO	54	79.63	22.294	25.0	75.00	75.00	100.00	100.0			
	ADA	63	78.17	22.671	25.0	50.00	75.00	100.00	100.0			
	TOT	117	78.85	22.413	25.0	75.00	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	54	81.71	19.534	25.0	75.00	75.00	100.00	100.0			
	ADA	63	82.94	20.977	25.0	75.00	100.00	100.00	100.0			
	TOT	117	82.37	20.246	25.0	75.00	75.00	100.00	100.0			
CHG FROM BSL	PLO	54	2.08	20.853	-50.0	0.00	0.00	25.00	50.0			
	ADA	63	4.76	19.498	-50.0	0.00	0.00	25.00	50.0			
	TOT	117	3.53	20.092	-50.0	0.00	0.00	25.00	50.0			
										2.68	(-4.72, 10.07)	0.475A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.38.I


CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: GEOGRAPHIC REGION=WESTERN AND EASTERN EUROPE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
TOTAL SCORE												
BSL VALUE	PLO	54	77.54	16.212	26.6	68.90	83.48	89.36	95.5			
	ADA	64	78.30	14.248	42.7	71.08	80.31	88.88	99.4			
	TOT	118	77.95	15.117	26.6	70.79	81.92	89.09	99.4			
FINAL/ET VALUE	PLO	54	76.72	17.412	35.9	62.04	80.27	92.95	98.2			
	ADA	64	82.19	15.653	35.1	74.99	86.27	92.97	100.0			
	TOT	118	79.69	16.636	35.1	69.85	85.30	92.95	100.0			
CHG FROM BSL	PLO	54	-0.81	11.187	-30.9	-6.74	2.14	6.17	20.8			
	ADA	64	3.89	11.903	-30.8	-0.70	3.45	9.47	42.0			
	TOT	118	1.74	11.770	-30.9	-3.22	2.71	7.01	42.0			
										4.71	(0.47, 8.95)	0.030A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.


Program Source Code: [redacted]

FIGURE 14.2__2000.1.1.4.1.I
KAPLAN-MEIER CURVE TIME TO TREATMENT FAILURE ON OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: GENDER=MALE)




NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
Program Source Code: [redacted]

FIGURE 14.2__2000.1.1.4.2.I
KAPLAN-MEIER CURVE TIME TO TREATMENT FAILURE ON OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: GENDER=FEMALE)




NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
Program Source Code: [redacted]

FIGURE 14.2__2000.1.1.4.3.I
KAPLAN-MEIER CURVE TIME TO TREATMENT FAILURE ON OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: AGE < 30 YEARS)




NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
Program Source Code: [redacted]

FIGURE 14.2__2000.1.1.4.4.I
KAPLAN-MEIER CURVE TIME TO TREATMENT FAILURE ON OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: AGE >= 30 TO < 50 YEARS)




NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
Program Source Code: [redacted]

FIGURE 14.2__2000.1.1.4.5.I
KAPLAN-MEIER CURVE TIME TO TREATMENT FAILURE ON OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: AGE >= 50 YEARS)




NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
Program Source Code: [redacted]

FIGURE 14.2__2000.1.1.4.6.I
KAPLAN-MEIER CURVE TIME TO TREATMENT FAILURE ON OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=WHITE)




NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
Program Source Code: [redacted]

FIGURE 14.2__2000.1.1.4.7.1.I
KAPLAN-MEIER CURVE TIME TO TREATMENT FAILURE ON OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=NON-WHITE)




NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
Program Source Code: [redacted]

FIGURE 14.2__2000.1.1.4.7.2.I
KAPLAN-MEIER CURVE TIME TO TREATMENT FAILURE ON OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=BLACK)




NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
Program Source Code: [redacted]

FIGURE 14.2__2000.1.1.4.7.3.I
KAPLAN-MEIER CURVE TIME TO TREATMENT FAILURE ON OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=ASIAN)



NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
Program Source Code: [redacted]

FIGURE 14.2__2000.1.1.4.7.4.I
KAPLAN-MEIER CURVE TIME TO TREATMENT FAILURE ON OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=AMERICAN INDIAN/ALASKA NATIVE)




NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
Program Source Code: [redacted]

FIGURE 14.2__2000.1.1.4.7.5.I
KAPLAN-MEIER CURVE TIME TO TREATMENT FAILURE ON OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER)


** NO DATA IN THIS SEGMENT OR PART OF THIS FIGURE. **

FIGURE 14.2__2000.1.1.4.7.6.I
KAPLAN-MEIER CURVE TIME TO TREATMENT FAILURE ON OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=OTHER)




NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
Program Source Code: [redacted]

FIGURE 14.2__2000.1.1.4.7.7.I
KAPLAN-MEIER CURVE TIME TO TREATMENT FAILURE ON OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=MULTI RACE)




NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
Program Source Code: [redacted]

FIGURE 14.2__2000.1.1.4.8.I
KAPLAN-MEIER CURVE TIME TO TREATMENT FAILURE ON OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF UVEITIS < 1 YEAR)



NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
Program Source Code: [redacted]


FIGURE 14.2__2000.1.1.4.9.I
KAPLAN-MEIER CURVE TIME TO TREATMENT FAILURE ON OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF UVEITIS >= 1 YEAR)



NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
Program Source Code: [redacted]

[redacted]
ADALIMUMAB (UVEITIS)
CLINICAL SUMMARY OF EFFICACY (JAPAN)
R&D/15/0714- CLINICAL/STATISTICAL
FIGURE PAGE 1 OF 1


FIGURE 14.2__2000.1.1.4.10.I
KAPLAN-MEIER CURVE TIME TO TREATMENT FAILURE ON OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=INTERMEDIATE)



NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
NOTE: 3 SUBJECTS HAD INTERMEDIATE AND POSTERIOR UVEITIS.
Program Source Code: [redacted]

[redacted]
ADALIMUMAB (UVEITIS)
CLINICAL SUMMARY OF EFFICACY (JAPAN)
R&D/15/0714- CLINICAL/STATISTICAL
FIGURE PAGE 1 OF 1


FIGURE 14.2__2000.1.1.4.11.I
KAPLAN-MEIER CURVE TIME TO TREATMENT FAILURE ON OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=POSTERIOR)



NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
NOTE: 3 SUBJECTS HAD INTERMEDIATE AND POSTERIOR UVEITIS.
Program Source Code: [redacted]


[redacted]
ADALIMUMAB (UVEITIS)
CLINICAL SUMMARY OF EFFICACY (JAPAN)
R&D/15/0714- CLINICAL/STATISTICAL
FIGURE PAGE 1 OF 1

FIGURE 14.2__2000.1.1.4.12.I
KAPLAN-MEIER CURVE TIME TO TREATMENT FAILURE ON OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=PANUVEITIS)




NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
NOTE: 3 SUBJECTS HAD INTERMEDIATE AND POSTERIOR UVEITIS.
Program Source Code: [redacted]

FIGURE 14.2__2000.1.1.4.13.I
KAPLAN-MEIER CURVE TIME TO TREATMENT FAILURE ON OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=IDIOPATHIC/OTHER)




NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
Program Source Code: [redacted]

FIGURE 14.2__2000.1.1.4.14.I
KAPLAN-MEIER CURVE TIME TO TREATMENT FAILURE ON OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=BIRDSHOT CHOROIDOPATHY)




NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
Program Source Code: [redacted]

FIGURE 14.2__2000.1.1.4.15.I
KAPLAN-MEIER CURVE TIME TO TREATMENT FAILURE ON OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=MULTIFOCAL CHOROIDITIS AND PANUVEITIS)




NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
Program Source Code: [redacted]

FIGURE 14.2__2000.1.1.4.16.I
KAPLAN-MEIER CURVE TIME TO TREATMENT FAILURE ON OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=VOGT KOYANAGI HARADA)




NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
Program Source Code: [redacted]

FIGURE 14.2__2000.1.1.4.17.I
KAPLAN-MEIER CURVE TIME TO TREATMENT FAILURE ON OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=SARCOID)




NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
Program Source Code: [redacted]

FIGURE 14.2__2000.1.1.4.18.I
KAPLAN-MEIER CURVE TIME TO TREATMENT FAILURE ON OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=BEHCET'S)




NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
Program Source Code: [redacted]

FIGURE 14.2__2000.1.1.4.19.I
KAPLAN-MEIER CURVE TIME TO TREATMENT FAILURE ON OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS=0-1)




NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
Program Source Code: [redacted]

FIGURE 14.2__2000.1.1.4.20.I
KAPLAN-MEIER CURVE TIME TO TREATMENT FAILURE ON OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS=2)




NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
Program Source Code: [redacted]

FIGURE 14.2__2000.1.1.4.21.I
KAPLAN-MEIER CURVE TIME TO TREATMENT FAILURE ON OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS>=3)




NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
Program Source Code: [redacted]

FIGURE 14.2__2000.1.1.4.22.I
KAPLAN-MEIER CURVE TIME TO TREATMENT FAILURE ON OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TIME SINCE LAST FLARE < 6 MONTHS AT BASELINE)




NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
Program Source Code: [redacted]

FIGURE 14.2__2000.1.1.4.23.I
KAPLAN-MEIER CURVE TIME TO TREATMENT FAILURE ON OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TIME SINCE LAST FLARE >= 6 MONTHS AT BASELINE)




NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
Program Source Code: [redacted]

FIGURE 14.2__2000.1.1.4.24.I
KAPLAN-MEIER CURVE TIME TO TREATMENT FAILURE ON OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE < 15 MG/DAY)




NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
Program Source Code: [redacted]

FIGURE 14.2__2000.1.1.4.25.I
KAPLAN-MEIER CURVE TIME TO TREATMENT FAILURE ON OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE >= 15 to < 30 MG/DAY)




NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
Program Source Code: [redacted]

FIGURE 14.2__2000.1.1.4.26.I
KAPLAN-MEIER CURVE TIME TO TREATMENT FAILURE ON OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE >= 30 MG/DAY)




NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
Program Source Code: [redacted]

FIGURE 14.2__2000.1.1.4.27.I
KAPLAN-MEIER CURVE TIME TO TREATMENT FAILURE ON OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: OCT EVIDENCE OF MACULAR EDEMA BASED ON CRT AT BASELINE=YES)




NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
Program Source Code: [redacted]

FIGURE 14.2__2000.1.1.4.28.I
KAPLAN-MEIER CURVE TIME TO TREATMENT FAILURE ON OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: OCT EVIDENCE OF MACULAR EDEMA BASED ON CRT AT BASELINE=NO)




NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
Program Source Code: [redacted]

FIGURE 14.2__2000.1.1.4.29.I
KAPLAN-MEIER CURVE TIME TO TREATMENT FAILURE ON OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: IMM USAGE AT BASELINE=YES)




NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
Program Source Code: [redacted]

FIGURE 14.2__2000.1.1.4.30.I
KAPLAN-MEIER CURVE TIME TO TREATMENT FAILURE ON OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: IMM USAGE AT BASELINE=NO)




NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
Program Source Code: [redacted]

FIGURE 14.2__2000.1.1.4.31.I
KAPLAN-MEIER CURVE TIME TO TREATMENT FAILURE ON OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: ORAL PREDNISONE USAGE AT BASELINE >20 MG/DAY)




NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
Program Source Code: [redacted]

FIGURE 14.2__2000.1.1.4.32.I
KAPLAN-MEIER CURVE TIME TO TREATMENT FAILURE ON OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: ORAL PREDNISONE USAGE AT BASELINE <=20 MG/DAY)



NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
Program Source Code: [redacted]


FIGURE 14.2__2000.1.1.4.33.I
KAPLAN-MEIER CURVE TIME TO TREATMENT FAILURE ON OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TOPICAL STEROIDS AT BASELINE=YES)



NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
Program Source Code: [redacted]


[redacted]
ADALIMUMAB (UVEITIS)
CLINICAL SUMMARY OF EFFICACY (JAPAN)
R&D/15/0714- CLINICAL/STATISTICAL
FIGURE PAGE 1 OF 1

FIGURE 14.2__2000.1.1.4.34.I
KAPLAN-MEIER CURVE TIME TO TREATMENT FAILURE ON OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TOPICAL STEROIDS AT BASELINE=NO)




NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
Program Source Code: [redacted]

FIGURE 14.2__2000.1.1.4.35.I
KAPLAN-MEIER CURVE TIME TO TREATMENT FAILURE ON OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PROTOCOL DEVIATION 'WRONG TREATMENT/INCORRECT DOSE REGARDING PREDNISONE'=YES)




NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
Program Source Code: [redacted]

FIGURE 14.2__2000.1.1.4.36.I
KAPLAN-MEIER CURVE TIME TO TREATMENT FAILURE ON OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PROTOCOL DEVIATION 'WRONG TREATMENT/INCORRECT DOSE REGARDING PREDNISONE'=NO)




NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
Program Source Code: [redacted]

FIGURE 14.2__2000.1.1.4.37.I
KAPLAN-MEIER CURVE TIME TO TREATMENT FAILURE ON OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: GEOGRAPHIC REGION=NORTH AMERICA)




NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
Program Source Code: [redacted]

FIGURE 14.2__2000.1.1.4.38.I
KAPLAN-MEIER CURVE TIME TO TREATMENT FAILURE ON OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: GEOGRAPHIC REGION=WESTERN AND EASTERN EUROPE)




NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
Program Source Code: [redacted]

FIGURE 14.2__2000.3.1.2.1.I
KAPLAN-MEIER CURVE TIME TO OCT EVIDENCE OF MACULAR EDEMA BASED ON CRT AT OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: GENDER=MALE)




NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
Program Source Code: [redacted]

FIGURE 14.2__2000.3.1.2.2.I
KAPLAN-MEIER CURVE TIME TO OCT EVIDENCE OF MACULAR EDEMA BASED ON CRT AT OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: GENDER=FEMALE)




NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
Program Source Code: [redacted]

FIGURE 14.2__2000.3.1.2.3.I
KAPLAN-MEIER CURVE TIME TO OCT EVIDENCE OF MACULAR EDEMA BASED ON CRT AT OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: AGE < 30 YEARS)




NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
Program Source Code: [redacted]

FIGURE 14.2__2000.3.1.2.4.I
KAPLAN-MEIER CURVE TIME TO OCT EVIDENCE OF MACULAR EDEMA BASED ON CRT AT OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: AGE >= 30 TO < 50 YEARS)




NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
Program Source Code: [redacted]

FIGURE 14.2__2000.3.1.2.5.I
KAPLAN-MEIER CURVE TIME TO OCT EVIDENCE OF MACULAR EDEMA BASED ON CRT AT OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: AGE >= 50 YEARS)




NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
Program Source Code: [redacted]

FIGURE 14.2__2000.3.1.2.6.I
KAPLAN-MEIER CURVE TIME TO OCT EVIDENCE OF MACULAR EDEMA BASED ON CRT AT OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=WHITE)




NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
Program Source Code: [redacted]

FIGURE 14.2__2000.3.1.2.7.1.I
KAPLAN-MEIER CURVE TIME TO OCT EVIDENCE OF MACULAR EDEMA BASED ON CRT AT OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=NON-WHITE)




NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
Program Source Code: [redacted]

FIGURE 14.2__2000.3.1.2.7.2.I
KAPLAN-MEIER CURVE TIME TO OCT EVIDENCE OF MACULAR EDEMA BASED ON CRT AT OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=BLACK)




NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
Program Source Code: [redacted]

FIGURE 14.2__2000.3.1.2.7.3.I
KAPLAN-MEIER CURVE TIME TO OCT EVIDENCE OF MACULAR EDEMA BASED ON CRT AT OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=ASIAN)



NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
Program Source Code: [redacted]

FIGURE 14.2__2000.3.1.2.7.4.I
KAPLAN-MEIER CURVE TIME TO OCT EVIDENCE OF MACULAR EDEMA BASED ON CRT AT OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=AMERICAN INDIAN/ALASKA NATIVE)




NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
Program Source Code: [redacted]

FIGURE 14.2__2000.3.1.2.7.5.I
KAPLAN-MEIER CURVE TIME TO OCT EVIDENCE OF MACULAR EDEMA BASED ON CRT AT OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER)


** NO DATA IN THIS SEGMENT OR PART OF THIS FIGURE. **

FIGURE 14.2__2000.3.1.2.7.6.I
KAPLAN-MEIER CURVE TIME TO OCT EVIDENCE OF MACULAR EDEMA BASED ON CRT AT OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=OTHER)




NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
Program Source Code: [redacted]

FIGURE 14.2__2000.3.1.2.7.7.I
KAPLAN-MEIER CURVE TIME TO OCT EVIDENCE OF MACULAR EDEMA BASED ON CRT AT OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=MULTI RACE)




NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
Program Source Code: [redacted]

FIGURE 14.2__2000.3.1.2.8.I
KAPLAN-MEIER CURVE TIME TO OCT EVIDENCE OF MACULAR EDEMA BASED ON CRT AT OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF UVEITIS < 1 YEAR)




NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
Program Source Code: [redacted]

FIGURE 14.2__2000.3.1.2.9.I
KAPLAN-MEIER CURVE TIME TO OCT EVIDENCE OF MACULAR EDEMA BASED ON CRT AT OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF UVEITIS >= 1 YEAR)



NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
Program Source Code: [redacted]


FIGURE 14.2__2000.3.1.2.10.I
KAPLAN-MEIER CURVE TIME TO OCT EVIDENCE OF MACULAR EDEMA BASED ON CRT AT OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=INTERMEDIATE)



NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
NOTE: 3 SUBJECTS HAD INTERMEDIATE AND POSTERIOR UVEITIS.
Program Source Code: [redacted]

[redacted]
ADALIMUMAB (UVEITIS)
CLINICAL SUMMARY OF EFFICACY (JAPAN)
R&D/15/0714- CLINICAL/STATISTICAL
FIGURE PAGE 1 OF 1


FIGURE 14.2__2000.3.1.2.11.I
KAPLAN-MEIER CURVE TIME TO OCT EVIDENCE OF MACULAR EDEMA BASED ON CRT AT OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=POSTERIOR)



NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
NOTE: 3 SUBJECTS HAD INTERMEDIATE AND POSTERIOR UVEITIS.
Program Source Code: [redacted]


FIGURE 14.2__2000.3.1.2.12.I

KAPLAN-MEIER CURVE TIME TO OCT EVIDENCE OF MACULAR EDEMA BASED ON CRT AT OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=PANUVEITIS)




NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
NOTE: 3 SUBJECTS HAD INTERMEDIATE AND POSTERIOR UVEITIS.
Program Source Code: [redacted]

FIGURE 14.2__2000.3.1.2.13.I
KAPLAN-MEIER CURVE TIME TO OCT EVIDENCE OF MACULAR EDEMA BASED ON CRT AT OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=IDIOPATHIC/OTHER)




NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
Program Source Code: [redacted]

FIGURE 14.2__2000.3.1.2.14.I
KAPLAN-MEIER CURVE TIME TO OCT EVIDENCE OF MACULAR EDEMA BASED ON CRT AT OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=BIRDSHOT CHOROIDOPATHY)




NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
Program Source Code: [redacted]

FIGURE 14.2__2000.3.1.2.15.I
KAPLAN-MEIER CURVE TIME TO OCT EVIDENCE OF MACULAR EDEMA BASED ON CRT AT OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=MULTIFOCAL CHOROIDITIS AND PANUVEITIS)




NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
Program Source Code: [redacted]

FIGURE 14.2__2000.3.1.2.16.I
KAPLAN-MEIER CURVE TIME TO OCT EVIDENCE OF MACULAR EDEMA BASED ON CRT AT OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=VOGT KOYANAGI HARADA)




NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
Program Source Code: [redacted]

FIGURE 14.2__2000.3.1.2.17.I
KAPLAN-MEIER CURVE TIME TO OCT EVIDENCE OF MACULAR EDEMA BASED ON CRT AT OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=SARCOID)




NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
Program Source Code: [redacted]

FIGURE 14.2__2000.3.1.2.18.I
KAPLAN-MEIER CURVE TIME TO OCT EVIDENCE OF MACULAR EDEMA BASED ON CRT AT OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=BEHCET'S)




NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
Program Source Code: [redacted]

FIGURE 14.2__2000.3.1.2.19.I
KAPLAN-MEIER CURVE TIME TO OCT EVIDENCE OF MACULAR EDEMA BASED ON CRT AT OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS=0-1)




NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
Program Source Code: [redacted]

FIGURE 14.2__2000.3.1.2.20.I
KAPLAN-MEIER CURVE TIME TO OCT EVIDENCE OF MACULAR EDEMA BASED ON CRT AT OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS=2)




NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
Program Source Code: [redacted]

FIGURE 14.2__2000.3.1.2.21.I
KAPLAN-MEIER CURVE TIME TO OCT EVIDENCE OF MACULAR EDEMA BASED ON CRT AT OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS>=3)




NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
Program Source Code: [redacted]

FIGURE 14.2__2000.3.1.2.22.I
KAPLAN-MEIER CURVE TIME TO OCT EVIDENCE OF MACULAR EDEMA BASED ON CRT AT OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TIME SINCE LAST FLARE < 6 MONTHS AT BASELINE)




NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
Program Source Code: [redacted]

FIGURE 14.2__2000.3.1.2.23.I
KAPLAN-MEIER CURVE TIME TO OCT EVIDENCE OF MACULAR EDEMA BASED ON CRT AT OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TIME SINCE LAST FLARE >= 6 MONTHS AT BASELINE)




NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
Program Source Code: [redacted]

FIGURE 14.2__2000.3.1.2.24.I
KAPLAN-MEIER CURVE TIME TO OCT EVIDENCE OF MACULAR EDEMA BASED ON CRT AT OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE < 15 MG/DAY)




NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
Program Source Code: [redacted]

FIGURE 14.2__2000.3.1.2.25.I
KAPLAN-MEIER CURVE TIME TO OCT EVIDENCE OF MACULAR EDEMA BASED ON CRT AT OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE >= 15 to < 30 MG/DAY)



NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
Program Source Code: [redacted]

FIGURE 14.2__2000.3.1.2.26.I
KAPLAN-MEIER CURVE TIME TO OCT EVIDENCE OF MACULAR EDEMA BASED ON CRT AT OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE >= 30 MG/DAY)



NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
Program Source Code: [redacted]


FIGURE 14.2__2000.3.1.2.27.I

KAPLAN-MEIER CURVE TIME TO OCT EVIDENCE OF MACULAR EDEMA BASED ON CRT AT OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: OCT EVIDENCE OF MACULAR EDEMA BASED ON CRT AT BASELINE=YES)

** ENDPOINT IS NOT DEFINED FOR THIS SUBGROUP. **


[redacted]
ADALIMUMAB (UVEITIS)
CLINICAL SUMMARY OF EFFICACY (JAPAN)
R&D/15/0714- CLINICAL/STATISTICAL
FIGURE PAGE 1 OF 1

FIGURE 14.2__2000.3.1.2.28.I
KAPLAN-MEIER CURVE TIME TO OCT EVIDENCE OF MACULAR EDEMA BASED ON CRT AT OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: OCT EVIDENCE OF MACULAR EDEMA BASED ON CRT AT BASELINE=NO)




NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
Program Source Code: [redacted]

FIGURE 14.2__2000.3.1.2.29.I
KAPLAN-MEIER CURVE TIME TO OCT EVIDENCE OF MACULAR EDEMA BASED ON CRT AT OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: IMM USAGE AT BASELINE=YES)




NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
Program Source Code: [redacted]

FIGURE 14.2__2000.3.1.2.30.I
KAPLAN-MEIER CURVE TIME TO OCT EVIDENCE OF MACULAR EDEMA BASED ON CRT AT OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: IMM USAGE AT BASELINE=NO)




NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
Program Source Code: [redacted]

FIGURE 14.2__2000.3.1.2.31.I
KAPLAN-MEIER CURVE TIME TO OCT EVIDENCE OF MACULAR EDEMA BASED ON CRT AT OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: ORAL PREDNISONE USAGE AT BASELINE >20 MG/DAY)




NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
Program Source Code: [redacted]

FIGURE 14.2__2000.3.1.2.32.I
KAPLAN-MEIER CURVE TIME TO OCT EVIDENCE OF MACULAR EDEMA BASED ON CRT AT OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: ORAL PREDNISONE USAGE AT BASELINE <=20 MG/DAY)




NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
Program Source Code: [redacted]

FIGURE 14.2__2000.3.1.2.33.I
KAPLAN-MEIER CURVE TIME TO OCT EVIDENCE OF MACULAR EDEMA BASED ON CRT AT OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TOPICAL STEROIDS AT BASELINE=YES)




NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
Program Source Code: [redacted]

FIGURE 14.2__2000.3.1.2.34.I
KAPLAN-MEIER CURVE TIME TO OCT EVIDENCE OF MACULAR EDEMA BASED ON CRT AT OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TOPICAL STEROIDS AT BASELINE=NO)




NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
Program Source Code: [redacted]

FIGURE 14.2__2000.3.1.2.35.I
KAPLAN-MEIER CURVE TIME TO OCT EVIDENCE OF MACULAR EDEMA BASED ON CRT AT OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PROTOCOL DEVIATION 'WRONG TREATMENT/INCORRECT DOSE REGARDING PREDNISONE'=YES)




NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
Program Source Code: [redacted]

FIGURE 14.2__2000.3.1.2.36.I
KAPLAN-MEIER CURVE TIME TO OCT EVIDENCE OF MACULAR EDEMA BASED ON CRT AT OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PROTOCOL DEVIATION 'WRONG TREATMENT/INCORRECT DOSE REGARDING PREDNISONE'=NO)




NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
Program Source Code: [redacted]

FIGURE 14.2__2000.3.1.2.37.I
KAPLAN-MEIER CURVE TIME TO OCT EVIDENCE OF MACULAR EDEMA BASED ON CRT AT OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: GEOGRAPHIC REGION=NORTH AMERICA)



NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
Program Source Code: [redacted]

FIGURE 14.2__2000.3.1.2.38.I
KAPLAN-MEIER CURVE TIME TO OCT EVIDENCE OF MACULAR EDEMA BASED ON CRT AT OR AFTER WEEK 2
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: GEOGRAPHIC REGION=WESTERN AND EASTERN EUROPE)



NOTE: P# - PLACEBO (NUMBER OF EVENTS/NUMBER AT RISK), A# - ADALIMUMAB (NUMBER OF EVENTS/NUMBER AT RISK)
Program Source Code: [redacted]

2.7.3.6.3　付録 C：医薬品[redacted]相談の照会事項回答

2.7.3.6.3.1　照会事項回答（20[redacted]年[redacted]月[redacted]日付）

照会事項 1

相談資料付録 D に示された結果（図 2.5.4-3，2.5.4-4，2.5.4-5）を踏まえると，M10-877 試験において，国内症例における本剤の治療成功期間が海外症例と比べて短く，また，プラセボ群との群間差も小さくなっています。また，同様の傾向が M10-880 試験においても認められます（図 2.5.4-6，2.5.4-7）。M10-877 試験において，上記の傾向が認められた要因について，以下の点及びメイン試験に対し既に実施されている部分集団解析結果等を踏まえ，詳細に考察してください。

- 年齢等の患者背景，炎症部位，原因疾患，ベースライン時の疾患の重症度，ベースライン時のステロイド投与量，免疫抑制剤の使用等の国内外の分布の違いや日本人集団における投与群間の分布の影響
- 日本人集団における主要評価項目の個々の項目が治療不成功に与えた影響

［回答］

国内症例における本剤の治療成功期間（以下「治療不成功までの期間」）が海外症例と比べて短い理由について調査しました。その結果，汎ぶどう膜炎患者の割合が海外症例に比べて高かったことが最も妥当な説明であると考えられました。

M10-877 試験において，日本人サブ試験では 16 例中 13 例（81.3%），メイン試験では 217 例中 97 例（44.7%）が汎ぶどう炎であり，両者間で統計学的に有意な差が認められ，臨床的にも意味のある差でした（表 2.7.3-52）。

炎症を起こす複数の解剖学上の部位を含んでいる汎ぶどう膜炎は，炎症を起こすリスクが高く，治療不成功までの期間が短いことが予想されます。


日本人サブ試験では，プラセボ群に無作為割付けされた被験者における治療不成功までの期間の中央値は 2.8 ヵ月（表 2.7.3-53），投与開始 9 ヵ月時点で治療不成功の被験者は 75%でした（M10-877 試験 CSR［5.3.5.1-1］Table 14.2__1.1.3.J）。メイン試験のプラセボ群における汎ぶどう膜炎の被験者の治療不成功までの期間の中央値は 2.9 ヵ月（表 2.7.3-54），投与開始 9 ヵ月時点では 100%が治療不成功でした（M10-877 試験 CSR［5.3.5.1-1］Table 14.2__10.1.1.3.12.M）。それに対して，中間部ぶどう膜炎では，治療不成功までの期間の中央値は 2.8 ヵ月（M10-877 試験 CSR［5.3.5.1-1］Table 14.2__10.1.1.1.10.M），投与開始 9 ヵ月時点では 84%が治療不成功であり（M10-877 試験 CSR［5.3.5.1-1］Table 14.2__10.1.1.3.10.M），後部ぶどう膜炎では，治療不成功までの期間の中央値は 3.9 ヵ月（M10-877 試験 CSR［5.3.5.1-1］Table 14.2__10.1.1.1.11.M），投与開始 9 ヵ月時点では 69%が治療不成功でした（M10-877 試験 CSR［5.3.5.1-1］Table 14.2_10.1.1.3.11.M）。

この結果は，汎ぶどう膜炎の被験者の方がより早く再燃することを示しています。

なお，図 2.7.3-18 に示しますように，日本人（外れ値を除く）と非日本人の汎ぶどう膜炎患者のカプラン・マイヤー曲線は類似しており，メイン試験のサブグループ解析の汎ぶどう膜炎群

において，アダリムマブ群は，プラセボ群よりも統計学的に有意に優れていました（表 2.7.3-54, $P < 0.001$）。

図 2.7.3-18. 治療不成功までの期間のカプランマイヤー曲線（6 週以降）（汎ぶどう膜炎の非日本人と日本人（M10-877 試験，外れ値の症例番号 1400702 を除く）



相互参照：M10-877 試験 Post-hoc Analysis Report / Japan Sub-Study（5.3.5.4-1）Appendix C（C-2）

ベースライン時の患者背景及び疾患背景について日本人サブ試験とメイン試験を比較した結果，表 2.7.3-52 に示しますように，ぶどう膜炎のタイプを含むいくつかの項目において，日本人サブ試験とメイン試験で統計学的に有意な差が認められました。

病理学的に疾患の重症度に関連する網脈絡膜病変と脈絡膜病変を有した被検者の割合が日本人サブ試験でメイン試験に比べて高かったことは注目すべきことであり，このことは，日本人の方がより重症であったことを示唆しています。

その他に，原疾患がサルコイドーシスのグループ及びベースラインの炎症の継続期間が長いグループが，メイン試験に比べて日本人サブ試験で高い割合でした（表 2.7.3-52）。しかしながら，これらの因子と治療不成功までの期間との関連は不明であり，メイン試験のサブグループ解析から，これらの因子が治療不成功までの期間を短くすることに対して意味のある影響はなかったと考えられました（M10-877 試験 CSR Tables 14-2_10.1.1.1.13M–18M，27M，28M）。

以上のことから，M10-877 試験では，日本人サブ試験において，汎ぶどう膜炎患者の割合がメイン試験に比べて著しく高かったことが，日本人サブ試験の治療不成功までの期間がメイン試験より短かった主な理由と考えられました。

表 2.7.3-52. ぶどう膜炎の診断，病歴及びベースラインの疾患特性（M10-877 試験，ITT 集団）

部分集団		日本人サブ試験 n (%)	メイン試験 n (%)	*P* 値
ぶどう膜炎診断日からの期間 (年)	< 1	6 (37.50)	77 (35.48)	1.000
	≥ 1	10 (62.50)	140 (64.52)	
直近の再燃からの期間 (月)	< 6	7 (43.75)	111 (51.39)	0.6115
	≥ 6	9 (56.25)	105 (48.61)	
現在の再燃の持続期間 (日)	< 60	5 (31.25)	138 (63.59)	0.0152
	≥ 60	11 (68.75)	79 (36.41)	
直近の再燃時のプレドニゾンの投与量 (mg)	< 15	9 (56.25)	159 (73.61)	0.1953
	15 – < 30	4 (25.00)	22 (10.19)	
	≥ 30	3 (18.75)	35 (16.20)	
診断	特発性ぶどう膜炎	7 (43.75)	81 (37.33)	0.0076
	バードショット網脈絡膜症	0	44 (20.28)	
	多巣性脈絡膜炎及び汎ぶどう膜炎	0	11 (5.07)	
	VKH	1 (6.25)	25 (11.52)	
	サルコイドーシス	6 (37.50)	18 (8.29)	
	ベーチェット病	2 (12.50)	16 (7.37)	
	その他	0	22 (10.14)	
性別	男性	5 (31.25)	93 (42.86)	0.4386
	女性	11 (68.75)	124 (57.14)	
年齢 (歳)	< 30	2 (12.50)	44 (20.28)	0.0684
	30 – < 50	5 (31.25)	105 (48.39)	
	≥ 50	9 (56.25)	68 (31.34)	
ぶどう膜炎の種類	中間部ぶどう膜炎	1 (6.25)	47 (21.66)	0.0212
	後部ぶどう膜炎	2 (12.50)	73 (33.64)	
	汎ぶどう膜炎	13 (81.25)	97 (44.70)	
過去 12 ヵ月の再燃回数	1	3 (18.75)	37 (17.05)	0.4284
	2	9 (56.25)	100 (46.08)	
	≥ 3	4 (25.00)	80 (36.87)	
免疫抑制剤の併用	あり	3 (18.75)	67 (30.88)	0.4040
	なし	13 (81.25)	150 (69.12)	

部分集団			日本人サブ試験 n (%)	メイン試験 n (%)	P 値
前房内細胞のグレード	右眼	0 – 1	16 (100)	179 (82.49)	0.0813
		2 – 4	0	38 (17.51)	
	左眼	0 – 1	16 (100)	178 (82.03)	0.0809
		2 – 4	0	39 (17.97)	
硝子体混濁のグレード	右眼	0 – 1	9 (56.25)	147 (67.74)	0.4105
		2 – 4	7 (43.75)	70 (32.26)	
	左眼	0 – 1	11 (68.75)	149 (68.66)	1.0000
		2 – 4	5 (31.25)	68 (31.34)	
網脈絡膜病変	右眼	あり	11 (68.75)	86 (39.63)	0.0334
		なし	5 (31.25)	131 (60.37)	
	左眼	あり	8 (50.00)	88 (40.55)	0.5999
		なし	8 (50.00)	129 (59.45)	
網膜血管病変	右眼	あり	10 (62.50)	74 (34.10)	0.0303
		なし	6 (37.50)	143 (65.90)	
	左眼	あり	11 (68.75)	85 (39.17)	0.0325
		なし	5 (31.25)	132 (60.83)	

相互参照：M10-877 試験 Post-hoc Analysis Report / Japan Sub-Study（5.3.5.4-1）Appendix D（D-4）

表 2.7.3-53. 治療不成功までの期間：6 週以降（M10-877 試験，日本人サブ試験，ITT 集団）

投与群	N	治療不成功 n (%)	治療不成功までの期間の中央値 (月)	ハザード比 [a]	ハザード比の 95%CI
プラセボ群	8	6 (75.0)	2.8		
アダリムマブ群	8	8 (100)	2.4	1.20	0.41, 3.54

注：投与 6 週時以降の治療不成功をイベントとして集計した。治療不成功以外の理由で脱落した症例は，その時点で観察打ち切りとした。

a. 投与群を因子とした比例ハザード回帰によるハザード比（プラセボ群対アダリムマブ群）。

相互参照：M10-877 試験 CSR（5.3.5.1-1）Table 14.2__1.1.1.J

表 2.7.3-54. 治療不成功までの期間：6 週以降（M10-877 試験，メイン試験，ITT 集団及び汎ぶどう膜炎の部分集団）

解析 投与群	N	治療不成功 n (%)	治療不成功までの期間の中央値 (月)	ハザード比 [a]	ハザード比の 95% CI	*P* 値 [b]
主要解析 (ITT 集団)						
プラセボ群	107	84 (78.5)	3.0			
アダリムマブ群	110	60 (54.5)	5.6	0.50	0.36, 0.70	< 0.001
部分集団解析 (汎ぶどう膜炎)						
プラセボ群	47	41 (87.2)	2.9			
アダリムマブ群	50	33 (66.0)	3.8	0.45	0.27, 0.74	< 0.001

注：投与 6 週時以降の治療不成功をイベントとして集計した。治療不成功以外の理由で脱落した症例は，その時点で観察打ち切りとした。

a. 投与群を因子とした比例ハザード回帰によるハザード比（プラセボ群対アダリムマブ群）。

b. ログランク検定による両側 *P* 値。

相互参照：M10-877 試験 CSR（5.3.5.1-1）Table 14.2__1.1.1.M，Table 14.2__10.1.1.1.12.M

照会事項 2

M10-877 試験の日本サブ試験における全被験者の背景因子，有効性，安全性，ステロイド投与量等について，一覧表として提示し，被験者#1400702 の治療不成功までの期間が 553 日となった要因を考察してください。

［回答］

全被験者の背景因子，有効性，安全性，ステロイド投与量等についてまとめた一覧表を付録 C（2.7.3.6.3.2 項）に示します。他の被験者のデータと比較しましたが，被験者#1400702 が試験終了まで再燃を起こさなかった要因について明確にできませんでした。

この症例は，外れ値と判断された症例でした。M10-877 試験の日本人サブ試験が解釈し難い結果であったため，この症例を除外した解析を実施しました。その結果，[redacted]相談資料及び CTD M2.5 臨床に関する概括評価（案）にも記載した通り，16 例中のこの 1 例が M10-877 試験日本人サブ試験の結果に大きな影響を与えたと考えられました（M10-877 試験 Post-hoc Analysis Report / Japan Sub-Study［5.3.5.4-1］）。

2.7.3.6.3.2　M10-877 試験及び M10-880 試験の被験者一覧

M10-877試験 日本人全症例の要約

投与	被験者ID	性別	生年	年齢（歳）	体重 (kg) スクリーニング	ぶどう膜炎のタイプ	診断（原疾患）	罹患の眼	最後再燃時のプレドニゾン用量 (mg/日)	再燃の有無 Treatment Failure (TF)	再燃までの期間	再燃時のプレドニゾン用量 (mg/日)	組入れ時に該当した基準	再燃と判断した基準	備考
アダリムマブ	1400101	女性	19[redacted]	52	51	後部ぶどう膜炎	フォークト・小柳・原田病	両眼	40	はい	70	7.5	CR/RVL	CR/RVL BCVA	
アダリムマブ	1400302	女性	19[redacted]	61	56	汎ぶどう膜炎	サルコイドーシス	両眼	0	はい	140	0	CR/RVL	CR/RVL	
アダリムマブ	1400304	女性	19[redacted]	59	71	汎ぶどう膜炎	特発性	両眼	0	はい	147	0	CR/RVL	CR/RVL	
アダリムマブ	1400601	女性	19[redacted]	44	45	汎ぶどう膜炎	ベーチェット病	左眼	30	はい	147	0	VH CR/RVL	CR/RVL	
アダリムマブ	1400603	男性	19[redacted]	44	64	汎ぶどう膜炎	ベーチェット病	両眼	0	はい	77	5	VH	CR/RVL	
アダリムマブ	1400703	女性	19[redacted]	65	58	後部ぶどう膜炎	サルコイドーシス	両眼	10	はい	41	20	VH CR/RVL	VH CR/RVL	重篤な有害事象（右尿管結石）
アダリムマブ	1400705	男性	1[redacted]	41	70	汎ぶどう膜炎	特発性	両眼	15	はい	43	15	VH CR/RVL	VH CR/RVL	
アダリムマブ	1401003	女性	19[redacted]	65	38	中間部ぶどう膜炎	特発性	両眼	0	はい	43	20	CR/RVL	VH	
プラセボ	1400401	女性	19[redacted]	70	83	汎ぶどう膜炎	サルコイドーシス	両眼	20	はい	42	20	VH CR/RVL	VH CR/RVL BCVA	
プラセボ	1400602	男性	19[redacted]	28	86	汎ぶどう膜炎	サルコイドーシス	右眼	20	はい	84	4	VH CR/RVL	VH CR/RVL BCVA	
プラセボ	1400702	男性	19[redacted]	59	75	汎ぶどう膜炎	特発性	両眼	30	いいえ（治験完了）	(553)	(0)	CR/RVL	-	治療不成功なしに投与80週を完了
プラセボ	1400704	女性	19[redacted]	54	78	汎ぶどう膜炎	特発性	両眼	0	はい	42	20	VH	VH	
プラセボ	1400901	女性	19[redacted]	33	54	汎ぶどう膜炎	サルコイドーシス	両眼	3	はい	112	0	VH CR/RVL	VH	
プラセボ	1400902	女性	19[redacted]	47	48	汎ぶどう膜炎	サルコイドーシス	両眼	0	いいえ（治験完了）	(134)	(0)	CR/RVL	-	海外メイン試験の終了に伴い投与20週に試験を終了
プラセボ	1401001	女性	19[redacted]	70	67	汎ぶどう膜炎	特発性	両眼	20	はい	85	4	VH CR/RVL	VH	
プラセボ	1401004	男性	19[redacted]	22	61	汎ぶどう膜炎	特発性	両眼	0	はい	43	30	CR/RVL	VH	

AC：前房内細胞（のグレード）
VH：硝子体混濁（のグレード）
CR/RVL：（炎症性の）脈絡膜病変 / 網膜血管病変
BCVA：最高矯正視力


M10-877 試験 日本人サブ試験 個別票（16 症例）

被験者識別コード	**1400101**（性別，年齢，体重；女性，52 歳，51kg）
治験薬の投与（アダリムマブ又はプラセボ）	アダリムマブ
ぶどう膜炎のタイプ	後部ぶどう膜炎
診断（原疾患）	フォークト・小柳・原田病
罹患期間（診断からベースライン時まで）	3 ヵ月（20[redacted]年[redacted]月～）
最初の来院日（スクリーニング）	20[redacted]年[redacted]月[redacted]日
罹患の眼（右眼，左眼，又は両眼）	両眼
最後の再燃からの経過期間	3 ヵ月（20[redacted]年[redacted]月～）
現在の再燃の継続時間	25 日（20[redacted]年[redacted]月[redacted]日～）
最後の再燃時のプレドニゾン投与量	40 mg/日
最後 12 ヵ月における再燃回数	1

注；期日（月日）不明の場合，「日」不明は“1”日，「月日」不明は“1”月“1”日として期間（日数又は月数）を算出した。

有効性評価（再燃の有無）

再燃の有無（はい又はいいえ）	はい
ベースライン － 治験終了 / 中止時来院	20[redacted]年[redacted]月[redacted]日 － 20[redacted]年[redacted]月[redacted]日
再燃までの期間	70 日
再燃時のプレドニゾン投与量	7.5 mg/日
組入れ時に該当した基準	CR/RVL
再燃と判断した基準	CR/RVL, BCVA



Week (877)	SC	BL	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	18	…	20	…	24
AC-R	0	0	0			0		0		0		1+										
AC-L	0	0	0			0		0		0		1+										
VH-R	0	0	0			0		0		0		0										
VH-L	0	0	0			0		0		0		0										
CR/RVL-R	Yes	Yes	Yes			No		No		No		Yes										
CR/RVL-L	Yes	Yes	Yes			No		No		No		Yes										
BCVA-R	62	67	79			82		85		83		64										
BCVA-L	75	77	79			80		80		79		51										
												TF										

-R：右
-L：左

AC： 前房内細胞（のグレード）
VH： 硝子体混濁（のグレード）
CR/RVL：（炎症性の）脈絡網膜病変 / 網膜血管病変
BCVA： 最高矯正視力

SC：スクリーニング
BL：ベースライン
TF：再燃

有害事象（徴候・症状・疾患）


有害事象	発現日	消失日	重症度	重篤	治験責任医師の判断		備考
					アダリムマブ / プラセボ	プレドニゾン	
胃不快感	20[redacted]年[redacted]月[redacted]日	20[redacted]年[redacted]月[redacted]日	軽度	いいえ	多分関連なし	多分関連あり	
発痛	20[redacted]年[redacted]月[redacted]日	20[redacted]年[redacted]月[redacted]日 時点で継続中	軽度	いいえ	多分関連なし	多分関連あり	
ぶどう膜炎の増悪（両眼）	20[redacted]年[redacted]月[redacted]日	20[redacted]年[redacted]月[redacted]日 時点で継続中	軽度	いいえ	多分関連なし	多分関連なし	

被験者識別コード	1400302（性別，年齢，体重；女性，61 歳，56kg）
治験薬の投与（アダリムマブ又はプラセボ）	アダリムマブ
ぶどう膜炎のタイプ	汎ぶどう膜炎
診断（原疾患）	サルコイドーシス
罹患期間（診断からベースライン時まで）	32 ヵ月（20[redacted]年[redacted]月[redacted]日～）
最初の来院日（スクリーニング）	20[redacted]年[redacted]月[redacted]日
罹患の眼（右眼，左眼，又は両眼）	両眼
最後の再燃からの経過期間	7 ヵ月（20[redacted]年[redacted]月[redacted]日～）
現在の再燃の継続時間	91 日（20[redacted]年[redacted]月[redacted]日～）
最後の再燃時のプレドニゾン投与量	0 mg/日
最後 12 ヵ月における再燃回数	2

注；期日（月日）不明の場合，「日」不明は“1”日，「月日」不明は“1”月“1”日として期間（日数又は月数）を算出した。

有効性評価（再燃の有無）

再燃の有無（はい又はいいえ）	はい
ベースライン － 治験終了 / 中止時来院	20[redacted]年[redacted]月[redacted]日 － 20[redacted]年[redacted]月[redacted]日
再燃までの期間	140 日
再燃時のプレドニゾン投与量	0 mg/日
組入れ時に該当した基準	CR/RVL
再燃と判断した基準	CR/RVL



Week (877)	SC	BL	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	18	20	···	24
		60	60	50	40	30	20	15	12.5	10	7.5	5	4	3	2	1						
AC-R	1+	0.5+	0			0		0		0				0				0.5+		0.5+		
AC-L	0.5+	0.5+	0			0		0		0				0				0		0.5+		
VH-R	1+	1+	0			0		0		0				0				0.5+		1+		
VH-L	0.5+	0.5+	0			0		0		0				0				0		0		
CR/RVL-R	Yes	Yes	No			No		No		No				No				No		Yes		
CR/RVL-L	No	No	No			No		No		No				No				No		No		
BCVA-R	81	84	87			89		86		83				78				77		76		
BCVA-L	84	87	87			90		89		86				84				82		81		
																				TF		

-R：右　　AC：　前房内細胞（のグレード）　　SC：スクリーニング
-L：左　　VH：　硝子体混濁（のグレード）　　BL：ベースライン
CR/RVL：（炎症性の）脈絡網膜病変 / 網膜血管病変　　TF：再燃
BCVA：最高矯正視力

有害事象（徴候・症状・疾患）


有害事象	発現日	消失日	重症度	重篤	治験責任医師の判断		備考
					アダリムマブ / プラセボ	プレドニゾン	
胃不快感	20[redacted]年[redacted]月[redacted]日	20[redacted]年[redacted]月[redacted]日	軽度	いいえ	関連なし	多分関連あり	
不眠症	20[redacted]年[redacted]月[redacted]日	20[redacted]年[redacted]月[redacted]日	軽度	いいえ	関連なし	多分関連あり	
頭痛	20[redacted]年[redacted]月[redacted]日	20[redacted]年[redacted]月[redacted]日	軽度	いいえ	関連なし	多分関連あり	
動悸	20[redacted]年[redacted]月[redacted]日	20[redacted]年[redacted]月[redacted]日	軽度	いいえ	関連なし	関連あり	
右肘挫傷	20[redacted]年[redacted]月[redacted]日	20[redacted]年[redacted]月[redacted]日	軽度	いいえ	関連なし	関連なし	
爪周炎	20[redacted]年[redacted]月[redacted]日	20[redacted]年[redacted]月[redacted]日	軽度	いいえ	関連あり	関連あり	
満月様顔貌	20[redacted]年[redacted]月[redacted]日	20[redacted]年[redacted]月[redacted]日	軽度	いいえ	関連なし	関連あり	
右膝関節滲出液	20[redacted]年[redacted]月[redacted]日	20[redacted]年[redacted]月[redacted]日	軽度	いいえ	関連なし	多分関連あり	
右足関節捻挫症	20[redacted]年[redacted]月[redacted]日	20[redacted]年[redacted]月[redacted]日時点で継続中	軽度	いいえ	関連なし	関連なし	
鼻涙管狭窄	20[redacted]年[redacted]月[redacted]日	20[redacted]年[redacted]月[redacted]日時点で継続中	軽度	いいえ	関連なし	関連なし	
口内乾燥 / 舌不快感	20[redacted]年[redacted]月[redacted]日	20[redacted]年[redacted]月[redacted]日時点で継続中	軽度	いいえ	関連なし	多分関連あり	

被験者識別コード	**1400304**（性別，年齢，体重；女性，59 歳，71kg）
治験薬の投与（アダリムマブ又はプラセボ）	アダリムマブ
ぶどう膜炎のタイプ	汎ぶどう膜炎
診断（原疾患）	特発性ぶどう膜炎
罹患期間（診断からベースライン時まで）	5 ヵ月（20[redacted]年[redacted]月[redacted]日～）
最初の来院日（スクリーニング）	20[redacted]年[redacted]月[redacted]日
罹患の眼（右眼，左眼，又は両眼）	両眼
最後の再燃からの経過期間	5 ヵ月（20[redacted]年[redacted]月[redacted]日～）
現在の再燃の継続時間	26 日（20[redacted]年[redacted]月[redacted]日～）
最後の再燃時のプレドニゾン投与量	0 mg/日
最後 12 ヵ月における再燃回数	1

注；期日（月日）不明の場合，「日」不明は“1”日，「月日」不明は“1”月“1”日として期間（日数又は月数）を算出した。

有効性評価（再燃の有無）

再燃の有無（はい又はいいえ）	はい
ベースライン － 治験終了 / 中止時来院	20[redacted]年[redacted]月[redacted]日 － 20[redacted]年[redacted]月[redacted]日
再燃までの期間	147 日
再燃時のプレドニゾン投与量	0 mg/日
組入れ時に該当した基準	CR/RVL
再燃と判断した基準	CR/RVL



Week (877)	SC	BL	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	18	20	···	24
AC-R	0.5+	0.5+	0.5+			0		0		0				0				0		0		
AC-L	0.5+	0.5+	0.5+			0		0		0				0				0		0		
VH-R	1+	0.5+	0			0.5+		0		0				0				0		1+		
VH-L	0	0.5+	0			0		0		0				0				0		0		
CR/RVL-R	Yes	Yes	No			No		No		No				No				No		Yes		
CR/RVL-L	Yes	Yes	No			No		No		No				No				No		No		
BCVA-R	83	83	85			83		84		86				84				84		78		
BCVA-L	85	84	85			85		85		85				82				85		89		
																				TF		

-R：右
-L：左

AC： 前房内細胞（のグレード）
VH： 硝子体混濁（のグレード）
CR/RVL：（炎症性の）脈絡網膜病変 / 網膜血管病変
BCVA： 最高矯正視力

SC：スクリーニング
BL：ベースライン
TF：再燃

有害事象（徴候・症状・疾患）


有害事象	発現日	消失日	重症度	重篤	治験責任医師の判断		備考
					アダリムマブ / プラセボ	プレドニゾン	
不眠症	20[redacted]年[redacted]月[redacted]日	20[redacted]年[redacted]月[redacted]日	軽度	いいえ	関連なし	関連あり	
胃不快感	20[redacted]年[redacted]月[redacted]日	20[redacted]年[redacted]月[redacted]日	軽度	いいえ	関連なし	関連あり	
不安	20[redacted]年[redacted]月[redacted]日	20[redacted]年[redacted]月[redacted]日	軽度	いいえ	関連なし	関連あり	
糖尿病増悪	20[redacted]年[redacted]月[redacted]日	20[redacted]年[redacted]月[redacted]日	軽度	いいえ	関連なし	関連あり	
便秘	20[redacted]年[redacted]月[redacted]日	20[redacted]年[redacted]月[redacted]日	軽度	いいえ	関連なし	関連なし	
不安	20[redacted]年[redacted]月[redacted]日	20[redacted]年[redacted]月[redacted]日	軽度	いいえ	関連なし	関連なし	

被験者識別コード	**1400601**（性別，年齢，体重；女性，44 歳，45kg）
治験薬の投与（アダリムマブ又はプラセボ）	アダリムマブ
ぶどう膜炎のタイプ	汎ぶどう膜炎
診断（原疾患）	ベーチェット病
罹患期間（診断からベースライン時まで）	6 ヵ月（20[redacted] 年 [redacted] 月 [redacted] 日～）
最初の来院日（スクリーニング）	20[redacted] 年 [redacted] 月 [redacted] 日
罹患の眼（右眼，左眼，又は両眼）	左眼
最後の再燃からの経過期間	6 ヵ月（20[redacted] 年 [redacted] 月 [redacted] 日～）
現在の再燃の継続時間	35 日（20[redacted] 年 [redacted] 月 [redacted] 日～）
最後の再燃時のプレドニゾン投与量	30 mg/日
最後 12 ヵ月における再燃回数	3

注；期日（月日）不明の場合，「日」不明は“1”日，「月日」不明は“1”月“1”日として期間（日数又は月数）を算出した。

有効性評価（再燃の有無）

再燃の有無（はい又はいいえ）	はい
ベースライン － 治験終了 / 中止時来院	20[redacted] 年 [redacted] 月 [redacted] 日 － 20[redacted] 年 [redacted] 月 [redacted] 日
再燃までの期間	147 日
再燃時のプレドニゾン投与量	0 mg/日
組入れ時に該当した基準	VH, CR/RVL
再燃と判断した基準	CR/RVL



Week (877)	SC	BL	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	18	20	…	24
AC-R	0	0	0			0		0		0				0				0		0		
AC-L	0.5+	1+	0.5+			0.5+		0.5+		0				0				0		0.5+		
VH-R	0	0	0			0		0		0				0				0		0		
VH-L	2+	2+	0.5+			0		0		0				0				0		0.5+		
CR/RVL-R	No	No	No			No		No		No				No				No		No		
CR/RVL-L	Yes	Yes	No			No		No		No				No				No		Yes		
BCVA-R	88	95	95			91		94		95				94				95		95		
BCVA-L	54	65	81			85		85		87				87				87		85		
																				TF		

-R：右
-L：左

AC： 前房内細胞（のグレード）
VH： 硝子体混濁（のグレード）
CR/RVL：（炎症性の）脈絡網膜病変 / 網膜血管病変
BCVA： 最高矯正視力

SC：スクリーニング
BL：ベースライン
TF：再燃

有害事象（徴候・症状・疾患）


有害事象	発現日	消失日	重症度	重篤	治験責任医師の判断		備考
					アダリムマブ / プラセボ	プレドニゾン	
不眠症	20[redacted] 年 [redacted] 月 [redacted] 日	20[redacted] 年 [redacted] 月 [redacted] 日	軽度	いいえ	関連なし	多分関連あり	
皮脂欠乏性湿疹	20[redacted] 年 [redacted] 月 [redacted] 日	20[redacted] 年 [redacted] 月 [redacted] 日	軽度	いいえ	関連なし	関連なし	

被験者識別コード	**1400603**（性別，年齢，体重；男性，44 歳，64kg）
治験薬の投与（アダリムマブ又はプラセボ）	アダリムマブ
ぶどう膜炎のタイプ	汎ぶどう膜炎
診断（原疾患）	ベーチェット病
罹患期間（診断からベースライン時まで）	159 ヵ月（19[redacted]年[redacted]月～）
最初の来院日（スクリーニング）	20[redacted]年[redacted]月[redacted]日
罹患の眼（右眼，左眼，又は両眼）	両眼
最後の再燃からの経過期間	3 ヵ月（20[redacted]年[redacted]月[redacted]日～）
現在の再燃の継続時間	35 日（20[redacted]年[redacted]月[redacted]日～）
最後の再燃時のプレドニゾン投与量	0 mg/日
最後 12 ヵ月における再燃回数	2

注；期日（月日）不明の場合，「日」不明は“1”日，「月日」不明は“1”月“1”日として期間（日数又は月数）を算出した。

有効性評価（再燃の有無）

再燃の有無（はい又はいいえ）	はい
ベースライン ― 治験終了 / 中止時来院	20[redacted]年[redacted]月[redacted]日 ― 20[redacted]年[redacted]月[redacted]日
再燃までの期間	77 日
再燃時のプレドニゾン投与量	5 mg/日
組入れ時に該当した基準	VH
再燃と判断した基準	CR/RVL



Week (877)	SC	BL	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	⋯	20	⋯	24
AC-R	0	0	0			0		0		0.5+				1+								
AC-L	0.5+	0	0			0		0.5+		0.5+				1+								
VH-R	2+	2+	1+			0.5+		0.5+		0.5+				2+								
VH-L	0	0	0			0		0		0.5+				1+								
CR/RVL-R	No	No	No			No		No		No				Yes								
CR/RVL-L	No	No	No			No		No		No				Yes								
BCVA-R	26	27	38			47		43		38				33								
BCVA-L	30	33	34			34		35		34				29								
														TF								

-R：右
-L：左
AC： 前房内細胞（のグレード）
VH： 硝子体混濁（のグレード）
CR/RVL：（炎症性の）脈絡網膜病変 / 網膜血管病変
BCVA： 最高矯正視力
SC：スクリーニング
BL：ベースライン
TF：再燃

有害事象（徴候・症状・疾患）


有害事象	発現日	消失日	重症度	重篤	治験責任医師の判断		備考
					アダリムマブ / プラセボ	プレドニゾン	
-	-	-	-	-	-	-	-

被験者識別コード	**1400703**（性別，年齢，体重；女性，65 歳，58kg）
治験薬の投与（アダリムマブ又はプラセボ）	アダリムマブ
ぶどう膜炎のタイプ	後部ぶどう膜炎
診断（原疾患）	サルコイドーシス
罹患期間（診断からベースライン時まで）	17 ヵ月（20[redacted]年[redacted]月[redacted]日～）
最初の来院日（スクリーニング）	20[redacted]年[redacted]月[redacted]日
罹患の眼（右眼，左眼，又は両眼）	両眼
最後の再燃からの経過期間	8 ヵ月（20[redacted]年[redacted]月[redacted]日～）
現在の再燃の継続時間	77 日（20[redacted]年[redacted]月[redacted]日～）
最後の再燃時のプレドニゾン投与量	10 mg/日
最後 12 ヵ月における再燃回数	2

注；期日（月日）不明の場合，「日」不明は“1”日，「月日」不明は“1”月“1”日として期間（日数又は月数）を算出した。

有効性評価（再燃の有無）

再燃の有無（はい又はいいえ）	はい
ベースライン － 治験終了 / 中止時来院	20[redacted]年[redacted]月[redacted]日 － 20[redacted]年[redacted]月[redacted]日
再燃までの期間	41 日
再燃時のプレドニゾン投与量	20 mg/日
組入れ時に該当した基準	VH, CR/RVL
再燃と判断した基準	VH, CR/RVL



Week (877)	SC	BL	1	2	3	4		6	7	8	9	10	11	12	13	14	15	16	…	20	…	24
AC-R	1+	1+	0.5+			0		0.5+														
AC-L	0.5+	0.5+	0.5+			0.5+		0.5+														
VH-R	2+	2+	2+			1+		1+														
VH-L	1+	2+	2+			0.5+		0.5+														
CR/RVL-R	Yes	Yes	Yes			No		No														
CR/RVL-L	Yes	Yes	Yes			No		Yes														
BCVA-R	65	62	62			66		62														
BCVA-L	74	73	69			69		69														
								TF														

-R：右
-L：左

AC： 前房内細胞（のグレード）
VH： 硝子体混濁（のグレード）
CR/RVL：（炎症性の）脈絡網膜病変 / 網膜血管病変
BCVA： 最高矯正視力

SC：スクリーニング
BL：ベースライン
TF：再燃

有害事象（徴候・症状・疾患）

有害事象	発現日	消失日	重症度	重篤	治験責任医師の判断		備考
					アダリムマブ / プラセボ	プレドニゾン	
右尿管結石	20[redacted]年[redacted]月[redacted]日	20[redacted]年[redacted]月[redacted]日時点で継続中	中等度	はい	多分関連なし	多分関連なし	重篤な有害事象
小腸炎	20[redacted]年[redacted]月[redacted]日	20[redacted]年[redacted]月[redacted]日	軽度	いいえ	関連なし	関連なし	
不眠症	20[redacted]年[redacted]月[redacted]日	20[redacted]年[redacted]月[redacted]日	軽度	いいえ	関連なし	多分関連あり	